CA3042727A1

CA3042727A1 - Anti-gitr antigen-binding proteins and methods of use thereof

Info

Publication number: CA3042727A1
Application number: CA3042727A
Authority: CA
Inventors: Daniel Hicklin; Cynthia Seidel-Dugan; William Winston; Jose-Andres Salmeron-Garcia; Heather BRODKIN; Sonja KLEFFEL; Nels P. NIELSON
Original assignee: Potenza Therapeutics Inc
Current assignee: Potenza Therapeutics Inc
Priority date: 2016-11-19
Filing date: 2017-11-19
Publication date: 2018-05-24

Abstract

Provided herein are antigen-binding proteins (ABPs) that selectively bind to GITR and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.

Description

ANTI-GITR ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
FIELD
[1] Provided herein are antigen-binding proteins (ABPs) with binding specificity for glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) and compositions comprising such ABPs, including pharmaceutical compositions, diagnostic compositions, and kits. Also provided are methods of making GITR ABPs, and methods of using GITR ABPs, for example, for therapeutic purposes, diagnostic purposes, and research purposes.
BACKGROUND

[2] GITR is a member of the tumor necrosis factor receptor (TNFR) superfamily.
GITR is expressed in many cells of the innate and adaptive immune system, and membrane surface expression is increased in activated T cells. See Hanabuchib et al., Blood, 2006, 107:3617-3623; and Nocentini et al., Eur. I Immunol., 2005, 35:1016-1022; each of which is incorporated by reference in its entirety. GITR is activated by GITR ligand (GITRL).

[3] Agonism of GITR has a co-stimulatory effect on effector T cells. See Schaer et al., Curr.
Op/n. Immunol., 2012, 24:217-224, incorporated by reference in its entirety.
GITR
agonists have been proposed as therapeutic agents for cancer therapy. See Schaer et al., supra; Melero et al., Clin Cancer Res., 2013, 19:1044-1053; Cohen et al., I
Cl/n. Oncol., 2007, 25:3058; Cohen et al., PLoS One, 2010, 5:e10436; Nocentini et al., Br.
Pharmacol., 2012, 165:2089-2099; and U.S. Pat. Pub. No. 2007/0098719; each of which is incorporated by reference in its entirety.

[4] Although antibody agonists of GITR have shown promise in mouse models, it has been difficult to obtain agonizing antibodies to human GITR. Nocentini et al. (Br.
Pharmacol., 2012, 165:2089-2099) have noted that lainti-GITR mAbs have much weaker triggering potential in humans than in mice." They speculate that this may be a result of the fact that human GITR must be multimerized into stable trimers or superclusters (e.g., tetramers of trimers) in order to be robustly activated.

[5] Thus, there is a need for ABPs that can agonize human GITR more potently than known antibodies. Provided herein are ABPs that fulfill this need.

SUMMARY

[6] Provided herein are ABPs that specifically bind GITR and methods of using such ABPs.

[7] In one aspect is provided an isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), comprising the following six CDR sequences: (a) a CDR-H3 having the sequence XIX2X3X4X5RGYGDYGGHHAFDI, wherein Xi is A or V, X2 is H, D, L, or R, X3 is E or D, X4 is R, N, S, or A, and X5 is V, D
or G (SEQ ID NO:141); (b) a CDR-H2 having the sequence X1IX2X3SGX4TYYNPSLKS, wherein Xi is G, L, or S, X2 is Y, A, or V, X3 is E, Y or H, and X4 is S or K
(SEQ ID
NO:142); (c) a CDR-H1 having the sequence XISISSX2X3X4X5WX6, wherein Xi is Y
or G, X2 is G, S, or E, X3 is L, G, S, Y, or A, X4 is G, A, Y, M, or G, X5 is V, A, or is absent, and X6 is S or G (SEQ ID NO:143); (d) a CDR-L3 having the sequence QQEYX1TPPX2, wherein Xi is A or N and X2 is T or S (SEQ ID NO:144); (e) a CDR-L2 having the sequence XIAX2SLX3X4, wherein Xi is A or S, X2 is D or S, X3 is Q, D, K, or E, and X4 is S or Y (SEQ ID NO:145); and (f) a CDR-L1 having the sequence XIAS X25I
X3X4YLN, wherein Xi is G or R, X2 is Q or K, X3 is S, D, or N, and X4 is S or T (SEQ ID
NO:146).

[8] In one embodiment, the ABP of (a) comprises a VH sequence of SEQ ID NO:9 and a VL
sequence of SEQ ID NO:10; in another embodiment, the ABP of (b) comprises a VII
sequence of SEQ ID NO:19 and a VL sequence of SEQ ID NO:20; in another embodiment, the ABP of (c) comprises a VII sequence of SEQ ID NO:26 and a VL sequence of SEQ ID
NO:27; in another embodiment, the ABP of (d) comprises a VH sequence of SEQ ID

NO:26 or SEQ ID NO:34 and a VL sequence of SEQ ID NO:35; in another embodiment, the ABP of (e) comprises a VH sequence of SEQ ID NO:26 and a VL sequence of SEQ ID
NO:40; in another embodiment, the ABP of (f) comprises a VH sequence of SEQ ID
NO:44 and a VL sequence of SEQ ID NO:45; in another embodiment, the ABP of (g) comprises a VH sequence of SEQ ID NO:44 and a VL sequence of SEQ ID NO:53; in another embodiment, the ABP of (h) comprises a VII sequence of SEQ ID NO:58 and a VL
sequence of SEQ ID NO:10; in another embodiment, the ABP of (i) comprises a VH

sequence of SEQ ID NO:104 and a VL sequence of SEQ ID NO:10; and in another embodiment, the ABP of (j) comprises a VII sequence of SEQ ID NO:105 and a VL
sequence of SEQ ID NO:10.

[9] In one embodiment, the ABP of (b) comprises a heavy chain of SEQ ID NO:7 and a light chain of SEQ ID NO:8; In another embodiment, the ABP of (b) comprises a heavy chain of SEQ ID NO:17 and a light chain of SEQ ID NO:18. In another embodiment, the ABP of (c) comprises a heavy chain of SEQ ID NO:24 and a light chain of SEQ ID NO:25.
In another embodiment, the ABP of (d) comprises (i) a heavy chain of SEQ ID NO:32 and a light chain of SEQ ID NO:33, or (ii) a heavy chain of SEQ ID NO:37 and a light chain of SEQ ID NO:33. In another embodiment, the ABP of (e) comprises (i) a heavy chain of SEQ ID NO:38 and a light chain of SEQ ID NO:39. In another embodiment, the ABP
of (f) comprises a heavy chain of SEQ ID NO:42 and a light chain of SEQ ID NO:43;
in another embodiment, the ABP of (g) comprises (i) a heavy chain of SEQ ID NO:51 and a light chain of SEQ ID NO:52; In another embodiment, the ABP of (h) comprises (i) a heavy chain of SEQ ID NO:57 and a light chain of SEQ ID NO:8; In another embodiment, the ABP of (i) comprises (i) a heavy chain of SEQ ID NO:114 and a light chain of SEQ ID
NO:8, or (ii) a heavy chain of SEQ ID NO:120 and a light chain of SEQ ID NO:8;
or (iii) a heavy chain of SEQ ID NO:122 and a light chain of SEQ ID NO:8; or in another embodiment, the ABP of (j) comprises (i) a heavy chain of SEQ ID NO:115 and a light chain of SEQ ID NO:8, or (ii) a heavy chain of SEQ ID NO:121 and a light chain of SEQ
ID NO:8; or (iii) a heavy chain of SEQ ID NO:123 and a light chain of SEQ ID
NO:8.

[10] In another embodiment, the ABP comprises a heavy chain of SEQ ID NO:7 and a light chain of SEQ ID NO:8; or a heavy chain of SEQ ID NO:17 and a light chain of SEQ
ID NO:18; or a heavy chain of SEQ ID NO:24 and a light chain of SEQ ID NO:25;
a heavy chain of SEQ ID NO:32 and a light chain of SEQ ID NO:33, or (ii) a heavy chain of SEQ ID NO:37 and a light chain of SEQ ID NO:33; a heavy chain of SEQ ID NO:38 and a light chain of SEQ ID NO:39; a heavy chain of SEQ ID NO:42 and a light chain of SEQ
ID NO:43; a heavy chain of SEQ ID NO:51 and a light chain of SEQ ID NO:52; a heavy chain of SEQ ID NO:57 and a light chain of SEQ ID NO:8; a heavy chain of SEQ
ID
NO:114 and a light chain of SEQ ID NO:8, or (ii) a heavy chain of SEQ ID
NO:120 and a light chain of SEQ ID NO:8; or (iii) a heavy chain of SEQ ID NO:122 and a light chain of SEQ ID NO:8; or a heavy chain of SEQ ID NO:115 and a light chain of SEQ ID
NO:8, or (ii) a heavy chain of SEQ ID NO:121 and a light chain of SEQ ID NO:8; or (iii) a heavy chain of SEQ ID NO:123 and a light chain of SEQ ID NO:8.

[11] In another aspect is provided an isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), comprising the following six CDR sequences: (a) a CDR-H3 having the sequence set forth in SEQ ID NO:66;
(b) a CDR-H2 having the sequence set forth in SEQ ID NO:65; (c) a CDR-H1 having the sequence set forth in SEQ ID NO:64; (d) a CDR-L3 having the sequence set forth in SEQ
ID NO:69; (e) a CDR-L2 having the sequence set forth in SEQ ID NO:68; and (f) a CDR-Li having the sequence set forth in SEQ ID NO:67.

[12] In one embodiment, the ABP comprises a VII sequence of SEQ ID NO:62 and a VL
sequence of SEQ ID NO:63; a VH sequence of SEQ ID NO:70 and a VL sequence of SEQ
ID NO: 63; or a VH sequence of SEQ ID NO: 97 and a VL sequence of SEQ ID NO
:63.

[13] In another embodiment, the ABP comprises (i) a heavy chain of SEQ ID
NO:171 and a light chain of SEQ ID NO:172; a heavy chain of SEQ ID NO:173 and a light chain of SEQ ID NO:174; a heavy chain sequence of SEQ ID NO:106 and a light chain sequence of SEQ ID NO:107; or (ii) a heavy chain sequence of SEQ ID NO:116 and a light chain sequence of SEQ ID NO:107.

[14] In another aspect is provided an isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), comprising the following six CDR sequences: (a) a CDR-H3 having the sequence set forth in SEQ ID NO:75;
(b) a CDR-H2 having the sequence set forth in SEQ ID NO:74; (c) a CDR-H1 having the sequence set forth in SEQ ID NO:73; (d) a CDR-L3 having the sequence set forth in SEQ
ID NO:78; (e) a CDR-L2 having the sequence set forth in SEQ ID NO:77; and (f) a CDR-Li having the sequence set forth in SEQ ID NO:75.

[15] In one embodiment, the ABP comprises a VII sequence of SEQ ID NO:71 and a VL
sequence of SEQ ID NO:72; or a VH sequence of SEQ ID NO:98 and a VL sequence of SEQ ID NO:72.

[16] In another embodiment, the ABP comprises a heavy chain of SEQ ID
NO:173 and a light chain of SEQ ID NO:109; or the ABP comprises (i) a heavy chain of SEQ ID
NO:108 and a light chain of SEQ ID NO:109; or (ii) a heavy chain of SEQ ID NO:117 and a light chain of SEQ ID NO:109.

[17] In another aspect is provided an isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), comprising the following six CDR sequences: (a) a CDR-H3 having the sequence set forth in SEQ ID NO:83;
(b) a CDR-H2 having the sequence set forth in (i) SEQ ID NO:82, or (ii) SEQ ID
NO:100; (c) a CDR-H1 having the sequence set forth in SEQ ID NO:81; (d) a CDR-L3 having the sequence set forth in SEQ ID NO:86; (e) a CDR-L2 having the sequence set forth in SEQ
ID NO:85; and (f) a CDR-L1 having the sequence set forth in SEQ ID NO:84.

[18] In one embodiment, the ABP comprises the CDR-H2 sequence of (b)(i) of the above paragraph and a VH sequence of SEQ ID NO:79 and a VL sequence of SEQ ID NO:80.
In another embodiment, the ABP comprises the CDR-H2 sequence of (b)(i) of the above paragraph and a VH sequence of SEQ ID NO:87 and a VL sequence of SEQ ID NO:80.
In another embodiment, the ABP comprises the CDR-H2 sequence of (b)(i) of the above paragraph and a VH sequence of SEQ ID NO:88 and a VL sequence of SEQ ID NO:80.
In another embodiment, the ABP comprises the CDR-H2 sequence of (b)(ii) of the above paragraph and a VH sequence of SEQ ID NO:99 and a VL sequence of SEQ ID NO:80.

[19] In one embodiment, the ABP comprises a heavy chain of SEQ ID NO:174 and alight chain of SEQ ID NO:111; In another embodiment, the ABP comprises a heavy chain of SEQ ID NO:175 and a light chain of SEQ ID NO: iii; in another embodiment, the ABP
comprises a heavy chain of SEQ ID NO:176 and a light chain of SEQ ID NO: iii;
In another embodiment, the ABP comprises a heavy chain of SEQ ID NO:110 and a light chain of SEQ ID NO:111; or (ii) a heavy chain of SEQ ID NO:118 and a light chain of SEQ ID NO:111.

[20] In another aspect is provided an isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO:1), comprising the following six CDR sequences: (a) a CDR-H3 having the sequence set forth in SEQ ID NO:93; (b) a CDR-H2 having the sequence GIIPIFGEAQYAQX1FX2G, wherein Xi is K or R, and X2 is Q or R (SEQ ID NO:215); (c) a CDR-H1 having the sequence set forth in SEQ ID
NO:91;
(d) a CDR-L3 having the sequence set forth in SEQ ID NO:94; (d) a CDR-L2 having the sequence set forth in SEQ ID NO:85; and (e) a CDR-L1 having the sequence set forth in SEQ ID NO:84.

[21] In one embodiment, the ABP comprises: a CDR-H2 of SEQ ID NO:92; a CDR-H2 of SEQ ID NO:96; or a CDR-H2 of SEQ ID NO:102.

[22] In another embodiment, the ABP comprises a VII sequence of SEQ ID
NO:89 and a VL sequence of SEQ ID NO:90. In another embodiment, the ABP comprises a VII
sequence of SEQ ID NO:95 and a VL sequence of SEQ ID NO:90. In another embodiment, the ABP comprises a VII sequence of SEQ ID NO:101 and a VL sequence of SEQ ID
NO:90.

[23] In another embodiment, the ABP comprises a heavy chain of SEQ ID
NO:177 and a light chain of SEQ ID NO:113. In another embodiment, the ABP comprises a heavy chain of SEQ ID NO:178 and a light chain of SEQ ID NO:113. In another embodiment, the ABP
comprises a heavy chain of SEQ ID NO:112 and a light chain of SEQ ID NO:113;
or (ii) a heavy chain of SEQ ID NO:119 and a light chain of SEQ ID NO:113.

[24] In another aspect is provided an isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), comprising the following six CDR sequences: (a) a CDR-H3 having the sequence set forth in SEQ ID
NO:134; (b) a CDR-H2 having the sequence set forth in SEQ ID NO:133;a CDR-H1 having the sequence set forth in SEQ ID NO:132; (c) a CDR-L3 having the sequence set forth in SEQ
ID
NO:135; (d) a CDR-L2 having the sequence set forth in SEQ ID NO:68; and (e) a having the sequence set forth in SEQ ID NO:67.

[25] In one embodiment, the ABP comprises (i) a VH sequence of SEQ ID
NO:126 and a VL sequence of SEQ ID NO:128; or (ii) a VH sequence of SEQ ID NO:127 and a VL
sequence of SEQ ID NO:128.

[26] In one embodiment, the ABP comprises (i) a heavy chain of SEQ ID
NO:124 and a light chain of SEQ ID NO:125; or (ii) a heavy chain of SEQ ID NO:136 and a light chain of SEQ ID NO:125.

[27] In another aspect is provided an isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), comprising: (a) a having at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% identity to a CDR-H3 of a VH region selected from SEQ ID NOs:
9, 19, 26, 34, 44, 58, 62, 70, 71, 79, 87, 88, 89, 95, 97, 98, 99, 101, 104, 105, 126, and 127; (b) a CDR-H2 having at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% identity to a CDR-H2 of a VH region selected from SEQ ID
NOs: 9, 19, 26, 34, 44, 58, 62, 70, 71, 79, 87, 88, 89, 95, 97, 98, 99, 101, 104, 105, 126, and 127; (c) a CDR-H1 having at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% identity to a CDR-H1 of a VH region selected from SEQ ID NOs: 9, 19, 26, 34, 44, 58, 62, 70, 71, 79, 87, 88, 89, 95, 97, 98, 99, 101, 104, 105, 126, and 127; (d) a CDR-L3 having at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% identity to a CDR-L3 of a VL
region selected from SEQ ID NOs: 10, 20, 27, 35, 40, 45, 53, 63, 72, 80, 90, and 128; (e) a CDR-L2 having at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% identity to a CDR-L2 of a VL region selected from SEQ ID
NOs: 10, 20, 27, 35, 40, 45, 53, 63, 72, 80, 90, and 128; and (f) a CDR-L1 having at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% identity to a CDR-L1 of a VL region selected from SEQ ID NOs: 10, 20, 27, 35, 40, 45, 53, 63, 72, 80, 90, and 128.

[28] In one embodiment, the CDR-H3, CDR-H2, CDR-H1, CDR-L3, CDR-L2, and CDR-Li are each identified according to a numbering scheme selected from the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT numbering scheme.
In another embodiment, the CDR-H1 is identified as defined by both the Chothia and Kabat numbering schemes, inclusive of the boundaries of both numbering schemes.

[29] In one embodiment, the CDR-H3 comprises a CDR-H3 selected from SEQ ID
NOs:
13, 23, 30, 48, 61, 66, 75, 83, 93, 103, 131, or a variant thereof having 1, 2, or 3 amino acid substitutions. In another embodiment, the CDR-H2 comprises a CDR-H3 selected from SEQ ID NOs: 12, 22, 29, 47, 60, 65, 74, 82, 92, 96, 100, 102, 130, and 133, or a variant thereof having 1, 2, or 3 amino acid substitutions. In another embodiment, the CDR-H1 comprises a CDR-H1 selected from SEQ ID NOs: 11, 21, 28, 46, 59, 64, 73, 81, 91, 129, 132, or a variant thereof having 1 or 2 amino acid substitutions. In another embodiment, the CDR-L3 comprises a CDR-L3 selected from SEQ ID NOs: 16, 17, 56, 69, 78, 86, 94, 135, or a variant thereof having 1 or 2 amino acid substitutions. In another embodiment, the CDR-L2 comprises a CDR-L2 selected from SEQ ID NOs: 15, 31, 41, 50, 55, 68, 77, and 85, or a variant thereof having 1 amino acid substitution.
In another embodiment, the CDR-L1 comprises a CDR-L1 selected from SEQ ID NOs: 14, 36, 49, 54, 67, 76, and 84, or a variant thereof having 1 or 2 amino acid substitutions. In one embodiment, the amino acid substitutions are conservative amino acid substitutions.

[30] In an embodiment of any of the above aspects, the ABP: (a) competes for binding to GITR with an antibody selected from ABP1, ABP2, ABP3, ABP4, ABP5, ABP6, ABP7, ABP8, ABP9, ABP10, ABP11, ABP12, ABP13, ABP14, ABP15, ABP16, ABP17, ABP18, ABP19, ABP20, ABP21, ABP22, ABP23, ABP24, ABP25, ABP26, ABP27, ABP28, ABP29, ABP30, ABP31, ABP32, ABP33, and ABP34, each as provided in Appendix A of this disclosure; or (b) has at least three antigen-binding domains that specifically bind an epitope on GITR; or (c) has at least three antigen-binding domains that specifically bind a single epitope on GITR; or (d) has at least four antigen-binding domains that specifically bind an epitope on GITR; or (e) has at least four antigen-binding domains that specifically bind a single epitope on GITR; or (f) agonizes GITR
expressed on the surface of a target cell; or (g) enhances the binding of GITRL to GITR;
or (h) co-stimulates an effector T cell in combination with antigen presentation from an antigen-presenting cell; or (i) inhibits the suppression of an effector T cell by a regulatory T cell; or (j) reduces the number of regulatory T cells in a tissue or in systemic circulation; (k) is capable of binding to one or more of GITR (SEQ ID NO:1) residues from the group consisting of R56, C58, R59, D60, Y61, P62, E64, E65, C66, and C67; or (1) is capable of any combination of (a) - (k).

[31] In an embodiment of any of the above aspects, the GITR is selected from hGITR
(SEQ ID NO: 1), hGITR-T43R (SEQ ID NO: 2), cGITR (SEQ ID NO: 3), mGITR (SEQ
ID NO: 4), and combinations thereof In another embodiment, the ABP (a) specifically binds cynomolgus monkey GITR (cGITR; SEQ ID NO: 3); (b) binds murine GITR
(mGITR; SEQ ID NO: 4) with an affinity lower (as indicated by higher KD) than the affinity of the ABP for hGITR, or does not bind mGITR; or (c) is capable of any combination of (a) - (b). In another embodiment, the ABP: (a) specifically binds cGITR
(SEQ ID NO: 3); (b) binds mGITR (SEQ ID NO: 4) with an affinity lower (as indicated by higher KD) than the affinity of the ABP for hGITR and cGITR; and (c) enhances binding of GITRL to GITR.

[32] In another aspect is provided an ABP that competes for binding to GITR
with an ABP
of any one of claims 1-26, wherein the ABP: (a) specifically binds cGITR (SEQ
ID NO:
3); (b) binds mGITR (SEQ ID NO: 4) with an affinity lower (as indicated by higher KD) than the affinity of the ABP for hGITR and cGITR; and (c) enhances binding of GITRL to GITR. In one embodiment, the ABP comprises an antibody. In another embodiment, the antibody is a monoclonal antibody. In another embodiment, the antibody is selected from a human antibody, a humanized antibody or a chimeric antibody. In another embodiment, the ABP is multivalent. In another embodiment, the ABP comprises an antibody fragment.

[33] In another embodiment, the ABP comprises an alternative scaffold. In another embodiment, the ABP comprises an immunoglobulin constant region. In another embodiment, the ABP comprises heavy chain constant region of a class selected from IgA, IgD, IgE, IgG, or IgM. In another embodiment, the ABP comprises a heavy chain constant region of the class IgG and a subclass selected from IgG4, IgGl, IgG2, or IgG3.

[34] In an embodiment of any of the above aspects, at least one Fab is fused to a C-terminus of an Fc domain of an IgG. In another embodiment, the ABP further comprises at least one linker. In another embodiment, the IgG is an IgG4. In another embodiment, the IgG is an IgGl. In another embodiment, at least one Fab is fused to an N-terminus of an Fc domain of an IgG. In one embodiment, the at least one Fab is at least two Fabs. In another embodiment, the at least one Fab is at least three Fabs. In another embodiment, the at least one Fab is at least four Fabs. In another embodiment, two Fabs are independently fused to an N-terminus of the IgG. In another embodiment, two Fabs are independently fused to a C-terminus of the IgG. In another embodiment, a Fab is attached to each N-terminus of the IgG, a linker is attached to each said Fab, and a Fab is attached to each linker. In another embodiment, a Fab is attached to each C-terminus of the IgG, a linker is attached to each said Fab, and a Fab is attached to each linker. In another embodiment, wherein each linker comprises SEQ ID NO:5. In another embodiment, each linker comprises SEQ ID
NO:6.

[35] In an embodiment of any of the above aspects, the ABP comprises a common light chain antibody, an antibody with a knobs-into-holes modification, an scFy attached to an IgG, a Fab attached to an IgG, a diabody, a tetravalent bispecific antibody, a DVD-Iirm, a DART, a DuoBody0, a CovX-Body, an Fcab antibody, a TandAbO, a tandem Fab, a ZybodyTm, or combinations thereof In one embodiment, the ABP binds more than one GITR molecule. In another embodiment, the ABP is independent of GITRL binding.
In another embodiment, the ABP enhances binding of GITRL to GITR by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%. In another embodiment, the ABP enhances binding of GITRL to GITR by at least about 50%.
In another embodiment, the target cell is selected from an effector T cell, a regulatory T cell, a natural killer (NK) cell, a natural killer T (NKT) cell, a dendritic cell, and a B cell. In another embodiment, the target cell is an effector T cell selected from a helper (CD4+) T
cell, a cytotoxic (CD8+) T cell, and combinations thereof In another embodiment, the target cell is a regulatory T cell selected from a CD4+CD25+Foxp3+ regulatory T cell, a CD8+CD25+ regulatory T cell, and combinations thereof. In another embodiment, the tissue is a tumor.

[36] In an embodiment of any of the above aspects, the KD of the first antigen-binding domain for hGITR (SEQ ID NO: 1) or hGITR-T43R (SEQ ID NO: 2) is less than about 20 nM. In one embodiment, the KD of the first antigen-binding domain for cGITR
(SEQ ID
NO: 3) is less than about 200 nM. In another embodiment, the KD of the second antigen-binding domain for hGITR (SEQ ID NO: 1) or hGITR-T43R (SEQ ID NO: 2) is less than about 100 nM. In another embodiment, the KD of the second antigen-binding domain for cGITR (SEQ ID NO: 3) is less than about 1 [IM. In another embodiment, the ABP
comprises an Fc domain with reduced effector function when compared to an IgG1 Fc domain. In another embodiment, the ABP comprises an aglycosylated Fc domain.
In another embodiment, the ABP comprises an IgG1 Fc domain with an alanine at one or more of positions 234, 235, 265, and 297.

[37] In an embodiment of any of the above aspects, the GITR is expressed on the surface of a target cell. In one embodiment, the ABP multimerizes GITR expressed on the surface of a target cell. In one embodiment, the ABP multimerizes 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 GITR molecules.

[38] In an embodiment of any of the above aspects, the ABP specifically binds an epitope of human GITR (hGITR; SEQ ID NO:1) and is capable of binding one or more residues from the group consisting of R56, C58, R59, D60, Y61, P62, E64, E65, C66, and C67.

[39] In an embodiment of any of the above aspects, the ABP comprises an immunoglobulin comprising at least two different (i.e., have different sequences and/or bind to different residues) heavy chain variable regions each paired with a common light chain variable region. In another embodiment, the common light chain variable region forms a distinct antigen-binding domain with each of the two different heavy chain variable regions. In another embodiment, the ABP comprises a first VH variable domain having SEQ ID NO:189, a second VH variable domain having SEQ ID NO:215, and a common variable light chain having SEQ ID NO:190. In another embodiment, the ABP
comprises a first VH variable domain having SEQ ID NO:199, a second VH
variable domain having SEQ ID NO:216, and a common variable light chain having SEQ ID
NO :200.

[40] Provided in another aspect is a kit comprising an ABP of any of the above aspects or set forth in Appendix A, and instructions for use of the ABP. In one embodiment, the ABP
is lyophilized. In another embodiment, the kit further comprises a fluid for reconstitution of the lyophilized ABP.

[41] It is known that when an antibody is expressed in cells, the antibody is modified after translation. Examples of the posttranslational modification include cleavage of lysine at the C terminal of the heavy chain by a carboxypeptidase; modification of glutamine or glutamic acid at the N terminal of the heavy chain and the light chain to pyroglutamic acid by pyroglutamylation; glycosylation; oxidation; deamidation; and glycation, and it is known that such posttranslational modifications occur in various antibodies (See journal of Pharmaceutical Sciences, 2008, Vol. 97, p. 2426-2447, incorporated by reference in its entirety). In some embodiments, an ABP of the invention is an antibody or antigen-binding fragment thereof which has undergone posttranslational modification. Examples of an antibody or antigen binding fragment thereof which have undergone posttranslational modification include an antibody or antigen-binding fragments thereof which have undergone pyroglutamylation at the N terminal of the heavy chain variable region and/or deletion of lysine at the C terminal of the heavy chain. It is known in the art that such posttranslational modification due to pyroglutamylation at the terminal and deletion of lysine at the C terminal does not have any influence on the activity of the antibody or fragment thereof (Analytical Biochemistry, 2006, Vol. 348, p. 24-39, incorporated by reference in its entirety).

[42] In an embodiment of any of the above aspects, the ABP comprises a polypeptide sequence having a pyroglutamate (pE) residue at its N-terminus. In one embodiment, the ABP comprises a VH sequence in which an N-terminal Q is substituted with pE.
In another embodiment, the ABP comprises a VL sequence in which an N-terminal E
is substituted with pE. In another embodiment, the ABP comprises a heavy chain sequence in which an N-terminal Q is substituted with pE.

[43] In an embodiment of any of the above aspects, the ABP comprises a light chain sequence in which an N-terminal E is substituted with pE. In another embodiment, the ABP is for use as a medicament. In another embodiment, the ABP is for use in the treatment of a cancer or viral infection.

[44] In one embodiment, the ABP is for use in the treatment of a cancer, wherein the cancer is selected from a solid tumor and a hematological tumor.

[45] In another aspect is provided an isolated polynucleotide encoding an ABP of any of the above aspects or set forth in Appendix A, a VH thereof, a VL thereof, a light chain thereof, a heavy chain thereof or an antigen-binding portion thereof

[46] In another aspect is provided a vector comprising the polynucleotide of the above aspect. In another aspect is provided a host cell comprising the polynucleotide or the vector of any of the above aspects. In one embodiment, the host cell is selected from a bacterial cell, a fungal cell, and a mammalian cell. In another embodiment, the host cell is selected from an E. coli cell, a Saccharomyces cerevisiae cell, and a CHO
cell.

[47] In another aspect is provided a cell-free expression reaction comprising the polynucleotide or vector of the above aspects.

[48] In another aspect is provided a method of producing an ABP of any of the above aspects or set forth in Appendix A, comprising expressing the ABP in the host cell and isolating the expressed ABP.

[49] In another aspect is provided a pharmaceutical composition comprising an ABP of any of the above aspects or set forth in Appendix A, and a pharmaceutically acceptable excipient. In one embodiment, the amount of the ABP in the pharmaceutical composition is sufficient to (a) reduce the suppression of effector T cells by regulatory T cells; (b) activate effector T cells; (c) reduce the number of regulatory T cells in a tissue or systemically; (d) induce or enhance proliferation of effector T cells; (e) inhibit the rate of tumor growth; (0 induce tumor regression; or (g) combinations thereof, in a subject. In one embodiment, the pharmaceutical composition is for use as a medicament, e.g., for use in the treatment of a cancer or a viral infection. In one embodiment, the pharmaceutical composition is for use in the treatment of a cancer, wherein the cancer is selected from a solid tumor and a hematological tumor.

[50] In another embodiment, the amount of the ABP in the pharmaceutical composition is sufficient to (a) reduce the suppression of effector T cells by regulatory T
cells; (b) activate effector T cells; (c) reduce the number of regulatory T cells in a tissue or systemically; (d) induce or enhance proliferation of effector T cells; (e) inhibit the rate of tumor growth; (f) induce tumor regression; or (g) combinations thereof, in a subject.

[51] In another aspect is provided a method of treating or preventing a disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of an ABP of any of the above aspects or set forth in Appendix A, or a pharmaceutical composition thereof

[52] In another aspect is provided a method of method of increasing activation of immune cells in a subject, comprising administering to the subject an effective amount of an ABP
of any of the above aspects or set forth in Appendix A, or a pharmaceutical composition thereof In one embodiment, disease or condition is a cancer.

[53] In another embodiment, the method induces or enhances an immune response to a cancer-associated antigen. In another embodiment, the ABP is administered in an amount sufficient to (a) reduce the suppression of effector T cells by regulatory T
cells; (b) activate effector T cells; (c) reduce the number of regulatory T cells in a tissue or systemically; (d) induce or enhance proliferation of effector T cells; (e) inhibit the rate of tumor growth; (f) induce tumor regression; or (g) combinations thereof In another embodiment, the cancer is a solid cancer. In another embodiment, the cancer is a hematological cancer.
In another embodiment, the method further comprises administering one or more additional therapeutic agents. In one embodiment, the additional therapeutic agent is selected from radiation, a cytotoxic agent, a chemotherapeutic agent, a cytostatic agent, an anti-hormonal agent, an EGFR inhibitor, an immunostimulatory agent, an anti-angiogenic agent, and combinations thereof In one embodiment, the additional therapeutic agent is an immunostimulatory agent. In one embodiment, the immunostimulatory agent comprises an agent that blocks signaling of an inhibitory receptor expressed by an immune cell or a ligand thereof In one embodiment, the inhibitory receptor expressed by an immune cell or ligand thereof is selected from CTLA-4, PD-1, PD-L1, NRP1, LAG-3, Tim3, TIGIT, neuritin, BTLA, KIR, and combinations thereof In one embodiment, the immunostimulatory agent comprises an agonist to a stimulatory receptor expressed by an immune cell. In another embodiment, the stimulatory receptor expressed by an immune cell is selected from 0X40, ICOS, CD27, CD28, 4-1BB, CD40, and combinations thereof In another embodiment, the immunostimulatory agent comprises a cytokine. In another embodiment, the cytokine is selected from IL-2, IL-5, IL-7, IL-12, IL-15, IL-21, and combinations thereof In another embodiment, the immunostimulatory agent comprises an oncolytic virus. In another embodiment, the oncolytic virus is selected from herpes simplex virus, vesicular stomatitis virus, adenovirus, Newcastle disease virus, vaccinia virus, a maraba virus, and combinations thereof. In another embodiment, the immunostimulatory agent comprises a T cell expressing a chimeric antigen receptor. In another embodiment, the immunostimulatory agent comprises a bi- or multi-specific T cell directed antibody. In another embodiment, the immunostimulatory agent comprises an anti-TGF-B antibody, a TGF-B trap, or a combination thereof In another embodiment, the immunostimulatory agent comprises a vaccine to a cancer-associated antigen.

[54] In another aspect is provided a method of modulating an immune response in a subject in need thereof, comprising administering to the subject an effective amount of an ABP of any of the above aspects or set forth in Appendix A, or a pharmaceutical composition thereof In one embodiment, the method further comprises administering one or more additional therapeutic agents to the subject. In one embodiment, the additional therapeutic agent is an agonist to a stimulatory receptor of an immune cell, and the stimulatory receptor of an immune cell is selected from 0X40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), 4-1BB (CD137), CD28, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, CD83 ligand, and combinations thereof. In one embodiment, the additional therapeutic agent is a cytokine selected from IL-2, IL-5, IL-7, IL-12, IL-15, IL-21, and combinations thereof In one embodiment, the additional therapeutic agent is an oncolytic virus selected from herpes simplex virus, vesicular stomatitis virus, adenovirus, Newcastle disease virus, vaccinia virus, a maraba virus, and combinations thereof. In one embodiment, the additional therapeutic agent is formulated in the same pharmaceutical composition as the ABP. In one embodiment, the additional therapeutic agent is formulated in a different pharmaceutical composition from the ABP. In one embodiment, the additional therapeutic agent is administered prior to administering the ABP. In one embodiment, the additional therapeutic agent is administered after administering the ABP. In one embodiment, the additional therapeutic agent is administered contemporaneously with the ABP.

[55] In another aspect is provided an isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), wherein the ABP
competes for binding with one or more of ABP1, ABP2, ABP3, ABP4, ABP5, ABP6, ABP7, ABP8, ABP9, ABP10, ABP11, ABP12, ABP13, ABP14, ABP15, ABP16, ABP17, ABP18, ABP19, ABP20, ABP21, ABP22, ABP23, ABP24, ABP25, ABP26, ABP27, ABP28, ABP29, ABP30, ABP31, ABP32, ABP33, and ABP34, ABP50, ABP51, ABP52, ABP53, ABP54, ABP55, ABP56, ABP57, ABP62, ABP63, ABP64, ABP65, ABP66, ABP67, ABP68, ABP67, ABP68, ABP69, ABP70, ABP71, ABP72, ABP73, ABP74, ABP75, ABP76, ABP77, ABP78, ABP79, ABP80, ABP812, ABP82, ABP83, ABP84, ABP85, ABP86, ABP87, ABP88, ABP89, ABP90, ABP91, ABP92, ABP93, ABP94, ABP95, ABP96, ABP97, ABP98, ABP99, ABP100, ABP102, ABP103, ABP104, ABP105, ABP106, ABP107, ABP108, and ABP109, each as provided in Appendix A of this disclosure.
1561 In another aspect is provided an anti-human GITR antibody or an antigen-binding fragment thereof comprising four heavy chain variable regions and four light chain variable regions, wherein the heavy chain variable region comprises a CDR-H3 consisting of SEQ ID NO:13, a CDR-H2 consisting of SEQ ID NO:12 and a CDR-H1 consisting of SEQ ID NO:11; and the light chain variable region comprises a CDR-L3 consisting of SEQ ID NO:16, a CDR-L2 consisting of SEQ ID NO:15, and a CDR-L1 consisting of SEQ ID NO:14; and the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody or the antigen-binding fragment comprises four antigen-binding sites.
[57] In one embodiment, the anti-human GITR antibody or the antigen-binding fragment thereof comprises four heavy chain variable regions and four light chain variable regions, in which the heavy chain variable region consists of SEQ ID NO: 9, the light chain variable region consists of SEQ ID NO: 10, and the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody or the antigen-binding fragment comprises four antigen-binding sites.
[58] In one embodiment, the anti-human GITR antibody or the antigen-binding fragment thereof comprises four heavy chain variable regions and four light chain variable regions, in which the heavy chain variable region consists of SEQ ID NO: 9, wherein Q
at position 1 of the sequence is modified to pyroglutamate, the light chain variable region consists of SEQ ID NO: 10, and the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody or the antigen-binding fragment comprises four antigen-binding sites.
[59] In one embodiment, the anti-human GITR antibody comprises two heavy chains and four light chains, each heavy chain comprises two structures consisting of a heavy chain variable region and a CH1 region, a CH2 region, and a CH3 region, and the C
terminus of one of the structures is linked to the N terminus of the other structure through a linker, and each light chain comprises a light chain variable region and a light chain constant region (left panel in FIG. 1B).
[60] In one embodiment, the anti-human GITR antibody comprises two heavy chains and four light chains, the heavy chains each comprising a first heavy chain variable region and a first CH1 region, a linker, a second heavy chain variable region, a second CH1 region, a CH2 region, and a CH3 region, and each light chain comprises a light chain variable region and a light chain constant region (left panel in FIG. 1B).
[61] In one embodiment, the anti-human GITR antibody comprises two heavy chains and four light chains; each heavy chain comprises two structures consisting of a heavy chain variable region comprising a CDR-H3 consisting of SEQ ID NO:13, a CDR-H2 consisting of SEQ ID NO:12 and a CDR-H1 consisting of SEQ ID NO:11 and a CH1 region, a region, and a CH3 region, and the carboxy terminus (C terminus) of one of the structures is linked to the amino terminus (N terminus) of the other structure through a linker; and each light chain comprises a light chain variable region comprising a CDR-L3 consisting of SEQ ID NO:16, a CDR-L2 consisting of SEQ ID NO:15, and a CDR-L1 consisting of SEQ ID NO:14.
[62] In one embodiment, the anti-human GITR antibody comprises two heavy chains and four light chains; each heavy chain comprising a first heavy chain variable region and a second heavy chain variable region, each comprising a CDR-H3 consisting of SEQ
ID
NO:13, a CDR-H2 consisting of SEQ ID NO:12 and a CDR-H1 consisting of SEQ ID
NO:11; a first CH1 region, a linker, a second CH1 region, a CH2 region, and a region; and each light chain comprises a light chain variable region comprising a CDR-L3 consisting of SEQ ID NO:16, a CDR-L2 consisting of SEQ ID NO:15, and a CDR-L1 consisting of SEQ ID NO:14.
[63] In one embodiment, the anti-human GITR antibody comprising two heavy chains and four light chains, in which each heavy chain comprises two structures consisting of a heavy chain variable region of SEQ ID NO: 9 and a CH1 region, a CH2 region, and a CH3 region, and the C terminus of one of the structures is linked to the N
terminus of the other structure through a linker, and each light chain comprises a light chain variable region of SEQ ID NO: 10, and a light chain constant region.
[64] In one embodiment, the anti-human GITR antibody comprises two heavy chains and four light chains, each heavy chain comprising a first heavy chain variable region and a second heavy chain variable region, each as set forth as SEQ ID NO: 9; a first CH1 region, a linker, a second CH1 region, a CH2 region, and a CH3 region; and wherein each light chain comprises a light chain variable region of SEQ ID NO: 10, and a light chain constant region.
[65] In one embodiment, the anti-human GITR antibody comprising two heavy chains and four light chains, in which each heavy chain comprises two structures consisting of a heavy chain variable region of SEQ ID NO: 9 and a CH1 region, a CH2 region, and a CH3 region, and the C terminus of one of the structures is linked to the N
terminus of the other structure through a linker, wherein Q at position 1 of the sequence is modified to pyroglutamate, and each light chain comprises a light chain variable region of SEQ ID
NO: 10, and a light chain constant region.
[66] In one embodiment, the anti-human GITR antibody comprises two heavy chains and four light chains, each heavy chain comprising a first heavy chain variable region and a second heavy chain variable region, each as set forth as SEQ ID NO: 9; a first CH1 region, a linker, a second CH1 region, a CH2 region, and a CH3 region; wherein Q at position 1 of the sequence is modified to pyroglutamate, and each light chain comprises a light chain variable region of SEQ ID NO: 10, and a light chain constant region.
[67] In one embodiment, the anti-human GITR antibody comprises two heavy chains, each having two variable regions, of SEQ ID NO: 7 and four light chains of SEQ ID
NO: 8.
[68] In one embodiment, the anti-human GITR antibody comprises two heavy chains, each having two variable regions, of SEQ ID NO: 7, wherein the Q at position 1 of the sequence is modified to pyroglutamate and four light chains of SEQ ID NO: 8.
[69] In one embodiment, the anti-human GITR antibody comprises two heavy chains, each having two variable regions, consisting of the amino acid sequence ranging from Q at position 1 to G at position 686 of SEQ ID NO: 7, and four light chains of SEQ
ID NO: 8.
[70] In one embodiment, the anti-human GITR antibody comprises two heavy chains consisting of the amino acid sequence ranging from Q at position 1 to G at position 686 of SEQ ID NO: 7, wherein the Q is modified to pyroglutamate, and four light chains of SEQ
ID NO: 8.
BRIEF DESCRIPTION OF THE DRAWINGS
[71] FIG. 1 provides a schematic illustration of a mechanism of action of certain illustrative GITR ABPs provided herein. FIG. lA shows three GITR molecules (one labeled 101) embedded in a cell membrane (102). A cartoon of a traditional format antibody is shown binding just two GITR molecules (103). FIG. 1B shows a cartoon of the tetravalent monospecific (TM) format antibodies disclosed herein: the left panel (105) shows a TM comprising two N-terminal IgG1 Fabs, with a C-terminal IgG4 5228P
antibody; the right panel (106) shows a TM comprising two C-terminal IgG1 Fabs and an N-terminal IgG4 5228P antibody. The antigen binding domains are illustrated by open circles (107). FIG. 1C shows a cartoon of the tetravalent bispecific format antibodies disclosed herein: the left panel (105) shows a bispecific antibody comprising two N-terminal IgG1 Fabs, with a C-terminal IgG4 S228P antibody; the right panel (106) shows a bispecific antibody comprising two C-terminal IgG1 Fabs and an N-terminal IgG4 antibody. The antigen binding domains having specificity for two non-overlapping epitope specificities are illustrated by open circles (107 and 108). FIG. 1D
shows multimerization of GITR following binding of three illustrative tetravalent monospecific (TM) format ABPs. Such multimerization is expected to agonize GITR signaling, as described elsewhere in this disclosure.
[72] FIG. 2 is a graph showing exemplary results of determination of KD by OCTET for N-terminal Fab format ABPs 1-8.
[73] FIG. 3 is a series of graphs showing the results of FACS analysis demonstrating binding of an exemplary panel of N-Terminal Fab TM format ABPs to CD4+ (Figure 3A) and CD8+ (Figure 3B) T cells. The distribution of CD4+ and CD8+ is shown in the top left panel of each Figure. In the top row, from left to right, is shown an anti-GITR positive control, and anti-human IgG4 isotype control, ABP9, ABP2, ABP1, and ABP7. On the bottom row is shown ABP8, ABP3, ABP4, ABP5, ABP6, ABP23, and ABP24. The percentage of positively stained IgG4+ CD4/8+ cells is indicated; MRI is indicated in brackets..
[74] FIG. 4 is a series of graphs showing the activity of eight optimized agonist antibodies in the N-terminal Fab TM format. HT1080 cells that stably express human (left panels) or cynomolgus monkey (right panels) GITR were then incubated with ABP1 (FIG. 4A), ABP2 (FIG. 4B), ABP3 (FIG. 4C), ABP4 (FIG. 4D), ABP5 (FIG. 4E), ABP6 (FIG.
4F), ABP7 (FIG. 4G), and ABP8 (FIG 4H) (shown as circles in the FIGs), and IL-8 induction was measured. GITRL was used as a control (squares). A table of EC50 values is shown on the bottom of each panel of each FIG.
[75] FIG. 5 is a series of graphs comparing the agonist activity in GITR-expressing HT1080 cells of a parental N-terminal Fab TM format antibody, ABP43, to a number of further optimized antibodies having either N-terminal or C-terminal format.
FIG. 5A
shows ABP43 (squares), ABP23 (circles), ABP24 (triangles), and ABP29 (open circles), ABP30 (open triangles), ABP31 (open circles), and ABP32 (open triangles), all in comparison to GITRL (+ sign). FIG. 5B shows ABP19 (N-terminal Fab, triangles) and ABP25 (C terminal Fab, upside down triangles). GITRL is shown as plus signs.
FIG. 5C
shows ABP21 (N-terminal Fab, triangles) and ABP27 (C terminal Fab, upside down triangles). GITRL is shown as plus signs. FIG. 5D shows ABP20 (N-terminal Fab, triangles) and ABP26 (C terminal Fab, upside down triangles). GITRL is shown as plus signs. FIG. 5E shows ABP22 (N-terminal Fab, triangles) and ABP28 (C terminal Fab, upside down triangles). GITRL is shown as plus signs. IgG4 control is shown as X sign in each figure.

[76] FIG. 6 shows the results of EC50 determination for ABP33 and ABP34 in the HT1080 assay as described in the Examples. ABP33 (tetravalent version combining the IgG4 ABP61 with the IgG1 Fab of ABP58 on the N-terminus) and ABP34 (tetravalent version combining the IgG4 of ABP61 with the IgG1 Fab of ABP58 on the C-terminus) were compared to the bivalent ABPs 59 and 61 (IgG4 S228P), which were the basis for ABP33 and ABP34. As shown in the FIG., the bispecific tetravalent antibodies both had superior EC50, as measured by IL-8 induction, when compared to the individual bivalent antibodies used to construct the bispecific tetravalent antibodies.
[77] FIG. 7 shows the results of EC50 determination in a Jurkat T cell assay as described for the HT1080 cells above. Optimized N terminal Fab TM format ABPs were compared to GITRL for their ability to agonize GITR, as measured by IL-8 production.
FIG. 7A-7H
show ABPs 1-8, respectively.
[78] FIG. 8A shows FACS analysis from triplicate quantifications of T cells isolated from two human donors, and shows the percentage of GITR+ CD4+ cells (left) and CD8+
cells (right) at various time points, +/- stimulation with PHA.
[79] FIGs 8B- 8M show results of treatment of T-blasts from 4 different donors treated with controls or ABPs and the resultant IL-2 production (data normalized to levels of IL-2 production achieved in control media). In each FIG. the top row, from left to right is FACS
measurement of the ABP binding to CD4+ cells, IL-2 production in cells from Donor 1, IL-2 production in cells from Donor 2. In the bottom row, from left to right, is FACS
measurement of the ABP binding to CD8+ cells, IL-2 production in cells from Donor 3, IL-2 production in cells from Donor 4. Shown are data as follows: 8B: IgG4 isotype control; 8C: SEC4 antibody; 8D: IgG4 TM format negative control; 8E: ABP9 (TM
Format IgG4 non-optimized parent of ABPs 1-8). 8F: ABP1; 8G: ABP2; 8H: ABP3;
81:
ABP4; 8J: ABP5; 8K:ABP6; 8L: ABP7; 8M: ABP8.
[80] FIG. 9A-9H is a series of graphs showing a comparison of the activity of the optimized N-terminal Fab TM ABPs ("IgG4 TM") against the corresponding optimized non-TM IgG1 N297A ABPs ("IgGl"). HT1080 cells that stably express human (left panel) or cynomolgus (right panel) were then treated with each N-terminal Fab TM ABP
and corresponding IgG1 ABP as follows: ABP1 IgG4 TM /ABP35 IgG1 (FIG. 9A), ABP2 IgG4 TM /ABP36 IgG1 (FIG. 9B), ABP3 IgG4 TM /ABP37 IgG1 (FIG. 9C), ABP4 IgG4 TM /ABP38 IgG1 (FIG. 9D), ABP5 IgG4 TM /ABP38 P45L IgG1 (FIG. 9E), ABP6 IgG4 TM /ABP39 IgG1 (FIG. 9F), ABP7 IgG4 TM /ABP40 IgG1 (FIG. 9G) and ABP8 IgG4 TM /ABP41 IgG1 (FIG. 9H) and IgG4 as a positive control. Induction of IL-8 by GITRL
is shown as circles, by IgG4 TM format ABPs as triangles, by the corresponding IgG1 ABPs as diamonds, and by IgG4 control antibodies as squares. A table of EC50 values is shown on the bottom of each panel of each FIG.

[81] FIG. 10 is a graph showing EC50data in the HT1080 assay as described comparing a non-TM parental antibody with corresponding TM format versions. ABP43 (diamonds) is the non-TM IgG4 S228P parent of ABP9 (IgG4 N-terminal Fab, squares) and ABP10 (IgG4 C-terminal Fab, circles). IL-8 induction by GITRL (positive control) is shown as a single data point (star). IL-8 production is shown in pg/mL.
[82] FIG. 11A is a graph showing induction of IL-8 by representative benchmark antibodies SEC4 and SEC9 in HT1080 cells that were engineered to stably express human GITR. Cultured cells were treated for six hours with a range of concentrations of two benchmark agonist antibodies SEC4 (35E6 formatted to have mouse variable regions with human IgG4 S228P/kappa regions, diamonds) and SEC9 (humanized 6C8 N62Q IgG1 N297A, circles), as well as an IgG4 negative control (closed triangles), an IgG1 negative control (open triangles), and trimeric human GITR ligand ("hGITRL", squares) as a positive control. Induction of IL-8 was measured by ELISA. As shown in the Figure, GITRL had a better EC50 (inset) and max induction compared to both SEC4 and SEC9.
FIGs 11B-11I show comparison of ABPs 1-8, respectively, with SEC4 and SEC9. TM

ABPs are indicated with circles, SEC4 with squares and SEC9 with triangles. IL-production is shown in pg/mL.
[83] FIG. 12 is two graphs showing cytokine production in stimulated isolated human NSCLC adenocarcinoma cells after treatment with TM-format ABP1 alone or in combination with pembrolizumab. Cells were either unstimulated controls, or were stimulated with lug/mL aCD3 (Soluble) +2 ug/mL aCD28 (Soluble) + IL-2 (50ng/mL);
cells either received no immunotherapy treatment (for assessment of checkpoint protein levels), pembrolizumab (10 g/mL), TM format ABP control (2 g/mL), ABP1 (2 g/mL), or ABP1 + pembrolizumab. Cells were incubated for 48 hours before supernatants were collected and cells were stained for checkpoint expression. In some samples, brefeldin A
(an inhibitor of cytokine secretion) was added to the last five hours of stimulation for detection of cytokines by intracellular cytokine staining. Shown are TNF
production (FIG.
12A) and IFNy production (FIG. 12B).
[84] FIG. 13 is a series of graphs showing GITR clustering and internalization after antibody binding. GITR internalization was measured in CD4+ cells (FIGs 13A-E) and CD8+ cells (Figures 13F-J) from either Donor 1 (Figures 13A-B, 13F-G) or Donor (Figures 13C-D, 13H-I). Cells were treated with either ABP1 TM format antibody or ABP35 standard bivalent antibody. As can be observed, incubation with either ABP1 or ABP35 inhibits the subsequent staining with ABP1Dylight650 (Figures 13A, 13C, 13F, 13H) but only incubation with ABP1 induces GITR internalization as measured by staining with non-competitive clone 108-17 (Figures 13B, 13D, 13G, 131). A
determination of the EC50 of ABP1 on cells from both donors is shown in Figure (CD4+ cells) and Figure 13J (CD8+ cells).
[85] FIG. 14 shows production of cytokine (IL-2) from activated T- blasts from two healthy human donors (Donor 1 and Donor 2, FIG. 14A and 14B, respectively) after treatment with anti-GITR IgG4 TM format antibody ABP1, its IgG1 format counterpart ABP35, and IgG4 TM format and IgG1 isotype controls. Activated CD4+/CD8+ T
cells were treated with medium alone, recombinant GITR-Ligand, ABP1, hIgG4 TM Format isotype control, ABP35, or hIgG1 standard format isotype control at nine doses each: 10 ug/mL, 2 ug/mL, 0.4 ug/mL, 80 ng/mL, 16 ng/mL, 3.2 ng/mL, 0.64 ng/mL, 0.13 ng/mL, and 0.026 ng/mL. Cells were stimulated by adding 1 ug/m1 anti-CD3 antibodies and 2 ug/m1 anti-CD28 antibodies. FIG. 14C shows the same data for ABP1 as in FIG.
14A and 14B with a calculation of the EC50 determination in each donor.
[86] FIG. 15 shows production of cytokine (IL-2) from activated T blasts from two healthy human donors (Donor 1 and Donor 2, FIG. 15A and 15B, respectively) after treatment with anti-GITR IgG4 TM format antibody ABP1, IgG4 TM format control ("IsoTM"), SEC4, SEC9, recombinant hGITRL and IgG1 and IgG4 isotype controls.
Activated CD4+/CD8+ T cells were treated with medium alone, recombinant GITR-Ligand, ABP1, hIgG4 TM Format isotype control, SEC4, SEC9, IgG1 standard format isotype control, or hIgG1 standard format isotype control at nine doses each:
10 ug/mL, 2 ug/mL, 0.4 ug/mL, 80 ng/mL, 16 ng/mL, 3.2 ng/mL, 0.64 ng/mL, 0.13 ng/mL, and 0.026 ng/mL. Cells were stimulated by adding 1 ug/m1 anti-CD3 antibodies and 2 ug/m1 anti-CD28 antibodies. FIGS 15C (Donor 1) and 15D (Donor 2) show the same data for as in 15A and 15B with a calculation of the EC50 determination in each donor.
DETAILED DESCRIPTION
Definitions [87] Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodologies by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 4th ed. (2012) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer-defined protocols and conditions unless otherwise noted.
[88] As used herein, the singular forms "a," "an," and "the" include the plural referents unless the context clearly indicates otherwise. The terms "include," "such as," and the like are intended to convey inclusion without limitation, unless otherwise specifically indicated.
[89] As used herein, the term "comprising" also specifically includes embodiments µ`consisting of' and "consisting essentially of' the recited elements, unless specifically indicated otherwise. For example, a multispecific ABP "comprising a diabody"
includes a multispecific ABP "consisting of a diabody" and a multispecific ABP
"consisting essentially of a diabody."
[90] The term "about" indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term "about" indicates the designated value 10%, 5%, or 1%. In certain embodiments, the term "about" indicates the designated value one standard deviation of that value.
[91] The terms "GITR," "GITR protein," and "GITR antigen" are used interchangeably herein to refer to human GITR, or any variants (e.g., splice variants and allelic variants), isoforms, and species homologs of human GITR that are naturally expressed by cells, or that are expressed by cells transfected with a gitr gene. In some aspects, the GITR protein is a GITR protein naturally expressed by a primate (e.g., a monkey or a human), a rodent (e.g., a mouse or a rat), a dog, a camel, a cat, a cow, a goat, a horse, or a sheep. In some aspects, the GITR protein is human GITR (hGITR; SEQ ID NO: 1). In some aspects, the GITR protein is a human GITR T43R variant (hGITR-T43R; SEQ ID NO: 2). In some aspects, the GITR protein comprises the extracellular domain of hGITR, located at positions 26 - 162 of SEQ ID NOs: 1-2. In some aspects, the GITR protein is a cynomolgus monkey GITR (cGITR; SEQ ID NO: 3). In some aspects, the GITR
protein comprises the extracellular domain of cGITR, located at positions 20 - 156 of SEQ ID
NOs: 3. In some aspects, the GITR protein is a murine GITR (mGITR; SEQ ID NO:
4). In some aspects, the GITR protein comprises the extracellular domain of mGITR, located at positions 20 - 153 of SEQ ID NOs: 4. In some aspects, the GITR protein is a full-length or unprocessed GITR protein. In some aspects, the GITR protein is a truncated or processed GITR protein produced by post-translational modification. GITR is also known by a variety of synonyms, including tumor necrosis factor receptor superfamily, member 18 (TNFRSF18); AITR, glucocorticoid-induced TNFR-related protein; activation-inducible TNFR family receptor; TNF receptor superfamily activation-inducible protein;
CD357;
and GITR-D.

[92] The term "immunoglobulin" refers to a class of structurally related proteins generally comprising two pairs of polypeptide chains: one pair of light (L) chains and one pair of heavy (H) chains. In an "intact immunoglobulin," all four of these chains are interconnected by disulfide bonds. The structure of immunoglobulins has been well characterized. See, e.g., Paul, Fundamental Immunology 7th ed., Ch. 5 (2013) Lippincott Williams & Wilkins, Philadelphia, PA. Briefly, each heavy chain typically comprises a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region typically comprises three domains, abbreviated Cm, CH2, and CH3. Each light chain typically comprises a light chain variable region (VL) and a light chain constant region. The light chain constant region typically comprises one domain, abbreviated CL.
[93] The term "antigen-binding protein" (ABP) refers to a protein comprising one or more antigen-binding domains that specifically bind to an antigen or epitope. In some embodiments, the antigen-binding domain binds the antigen or epitope with specificity and affinity similar to that of naturally occurring antibodies. In some embodiments, the ABP
comprises, consists of, or consists essentially of an antibody. In some embodiments, the ABP comprises, consists of, or consists essentially of an antibody fragment.
In some embodiments, the ABP comprises, consists of, or consists essentially of an alternative scaffold. A "GITR ABP," "anti-GITR ABP," or "GITR-specific ABP" is an ABP, as provided herein, which specifically binds to the antigen GITR. In some embodiments, the ABP binds the extracellular domain of GITR. In certain embodiments, a GITR ABP

provided herein binds to an epitope of GITR that is conserved between or among GITR
proteins from different species.
[94] The term "antibody" is used herein in its broadest sense and includes certain types of immunoglobulin molecules comprising one or more antigen-binding domains that specifically bind to an antigen or epitope. An antibody specifically includes intact antibodies (e.g., intact immunoglobulins), antibody fragments, and multi-specific antibodies. One example of an antigen-binding domain is an antigen-binding domain formed by a VH -VL dimer. An antibody is one type of ABP.
[95] The term "alternative scaffold" refers to a molecule in which one or more regions may be diversified to produce one or more antigen-binding domains that specifically bind to an antigen or epitope. In some embodiments, the antigen-binding domain binds the antigen or epitope with specificity and affinity similar to that of naturally occurring antibodies. Exemplary alternative scaffolds include those derived from fibronectin (e.g., AdnectinsTm), the I3-sandwich (e.g., iMab), lipocalin (e.g., Anticalins ), EETI-II/AGRP, BPTI/LACI-D1/ITI-D2 (e.g., Kunitz domains), thioredoxin peptide aptamers, protein A
(e.g., Affibody ), ankyrin repeats (e.g., DARPins), gamma-B-crystallin/ubiquitin (e.g., Affilins), CTLD3 (e.g., Tetranectins), Fynomers, and (LDLR-A module) (e.g., Avimers).

Additional information on alternative scaffolds is provided in Binz et al., Nat. Biotechnol., 2005 23:1257-1268; Skerra, Current Op/n. in Biotech., 2007 18:295-304; and Silacci et al., I Biol. Chem., 2014, 289:14392-14398; each of which is incorporated by reference in its entirety. An alternative scaffold is one type of ABP.
[96] The term "antigen-binding domain" means the portion of an ABP that is capable of specifically binding to an antigen or epitope.
[97] The terms "full length antibody," "intact antibody," and "whole antibody" are used herein interchangeably to refer to an antibody having a structure substantially similar to a naturally occurring antibody structure and having heavy chains that comprise an Fc region.
[98] The term "Fc region" means the C-terminal region of an immunoglobulin heavy chain that, in naturally occurring antibodies, interacts with Fc receptors and certain proteins of the complement system. The structures of the Fc regions of various immunoglobulins, and the glycosylation sites contained therein, are known in the art. See Schroeder and Cavacini, I Allergy Cl/n. Immunol., 2010, 125:S41-52, incorporated by reference in its entirety. The Fc region may be a naturally occurring Fc region, or an Fc region modified as described elsewhere in this disclosure.
[99] The VH and VL regions may be further subdivided into regions of hypervariability ("hypervariable regions (HVRs);" also called "complementarity determining regions"
(CDRs)) interspersed with regions that are more conserved. The more conserved regions are called framework regions (FRs). Each VH and VL generally comprises three CDRs and four FRs, arranged in the following order (from N-terminus to C-terminus): FR1 FR2 - CDR2 - FR3 - CDR3 - FR4. The CDRs are involved in antigen binding, and influence antigen specificity and binding affinity of the antibody. See Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, MD, incorporated by reference in its entirety.
[100] The light chain from any vertebrate species can be assigned to one of two types, called kappa (K) and lambda (2), based on the sequence of its constant domain.
[101] The heavy chain from any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated a, 6, e, y, and a, respectively. The IgG and IgA classes are further divided into subclasses on the basis of differences in sequence and function. Humans express the following subclasses:
IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2.
[102] The amino acid sequence boundaries of a CDR can be determined by one of skill in the art using any of a number of known numbering schemes, including those described by Kabat et al., supra ("Kabat" numbering scheme); Al-Lazikani et al., 1997,1 Mol. Biol., 273:927-948 ("Chothia" numbering scheme); MacCallum et al., 1996,1 Mol. Biol.
262:732-745 ("Contact" numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 ("IMGT" numbering scheme); and Honegge and Pliickthun, I Mol. Biol., 2001, 309:657-70 ("AHo" numbering scheme); each of which is incorporated by reference in its entirety.
[103] Table 1 provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 as identified by the Kabat and Chothia schemes. For CDR-H1, residue numbering is provided using both the Kabat and Chothia numbering schemes.
[104] Unless otherwise specified, the numbering scheme used for identification of a particular CDR herein is the Kabat/Chothia numbering scheme. Where the residues encompassed by these two numbering schemes diverge (e.g., CDR-H1 and/or CDR-H2), the numbering scheme is specified as either Kabat or Chothia. For convenience, is sometimes referred to herein as either Kabat or Chothia. However, this is not intended to imply differences in sequence where they do not exist, and one of skill in the art can readily confirm whether the sequences are the same or different by examining the sequences.
[105] CDRs may be assigned, for example, using antibody numbering software, such as Abnum, available at www.bioinf.org.uk/abs/abnum/, and described in Abhinandan and Martin, Immunology, 2008, 45:3832-3839, incorporated by reference in its entirety.
Table 1. Residues in CDRs according to Kabat and Chothia numbering schemes.
CDR Kabat Chothia Li L24-L34 L24-L34 H1 (Kabat Numbering) H26-H32 or H34*
H1 (Chothia Numbering) H31-H35 H26-H32 * The C-terminus of CDR-H1, when numbered using the Kabat numbering convention, varies between H32 and H34, depending on the length of the CDR.
[106] The "EU numbering scheme" is generally used when referring to a residue in an antibody heavy chain constant region (e.g., as reported in Kabat et al., supra). Unless stated otherwise, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein.
[107] An "antibody fragment" or "antigen-binding fragment" comprises a portion of an intact antibody, such as the antigen-binding or variable region of an intact antibody.
Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab')2 fragments, Fab' fragments, scFv (sFv) fragments, and scFv-Fc fragments.
[108] "Fv" fragments comprise a non-covalently-linked dimer of one heavy chain variable domain and one light chain variable domain.
[109] "Fab" fragments comprise, in addition to the heavy and light chain variable domains, the constant domain of the light chain and the first constant domain (Cm) of the heavy chain. Fab fragments may be generated, for example, by recombinant methods or by papain digestion of a full-length antibody.
[110] "F(ab')2" fragments contain two Fab' fragments joined, near the hinge region, by disulfide bonds. F(ab')2 fragments may be generated, for example, by recombinant methods or by pepsin digestion of an intact antibody. The F(ab') fragments can be dissociated, for example, by treatment with B-mercaptoethanol.
[111] "Single-chain Fv" or "sFv" or "scFv" antibody fragments comprise a VH
domain and a VL domain in a single polypeptide chain. The VH and VL are generally linked by a peptide linker. See Phickthun A. (1994). In some embodiments, the linker is a (GGGGS).
(SEQ ID NO: 5). In other embodiments, the linker is GGGGSGGGGSGGGGS (SEQ ID
NO:6). In some embodiments, n = 1, 2, 3, 4, 5, or 6. See Antibodies from Escherichia coil.
In Rosenberg M. & Moore G.P. (Eds.), The Pharmacology ofMonoclonal Antibodies vol.
113 (pp. 269-315). Springer-Verlag, New York, incorporated by reference in its entirety.
[112] "scFv-Fc" fragments comprise an scFv attached to an Fc domain. For example, an Fc domain may be attached to the C-terminal of the scFv. The Fc domain may follow the VH
or VL, depending on the orientation of the variable domains in the scFv (i.e., VH -VL or VL
-VH). Any suitable Fc domain known in the art or described herein may be used.
In some cases, the Fc domain comprises an IgG4 Fc domain.
[113] The term "single domain antibody" refers to a molecule in which one variable domain of an antibody specifically binds to an antigen without the presence of the other variable domain. Single domain antibodies, and fragments thereof, are described in Arabi Ghahroudi et al., FEBS Letters, 1998, 414:521-526 and Muyldermans et al., Trends in Biochem. Sc., 2001, 26:230-245, each of which is incorporated by reference in its entirety.
[114] A "multispecific ABP" is an ABP that comprises two or more different antigen-binding domains that collectively specifically bind two or more different epitopes. The two or more different epitopes may be epitopes on the same antigen (e.g., a single GITR
molecule expressed by a cell) or on different antigens (e.g., different GITR
molecules expressed by the same cell). In some aspects, a multi-specific ABP binds two different epitopes (i.e., a "bispecific ABP"). In some aspects, a multi-specific ABP
binds three different epitopes (i.e., a "trispecific ABP"). In some aspects, a multi-specific ABP binds four different epitopes (i.e., a "quadspecific ABP"). In some aspects, a multi-specific ABP
binds six different epitopes (i.e., a "quintspecific ABP"). In some aspects, a multi-specific ABP binds 6, 7, 8, or more different epitopes. Each binding specificity may be present in any suitable valency. Examples of multispecific ABPs are provided elsewhere in this disclosure.
[115] A "monospecific ABP" is an ABP that comprises a binding site that specifically binds to a single epitope. An example of a monospecific ABP is a naturally occurring IgG
molecule which, while divalent, recognizes the same epitope at each antigen-binding domain. The binding specificity may be present in any suitable valency.
[116] The term "monoclonal antibody" refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies comprises antibodies that are substantially similar and that bind the same epitope(s), except for variants that may normally arise during production of the monoclonal antibody. Such variants are generally present in only minor amounts. A
monoclonal antibody is typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA
clones. The selected antibody can be further altered, for example, to improve affinity for the target ("affinity maturation"), to humanize the antibody, to improve its production in cell culture, and/or to reduce its immunogenicity in a subject.
[117] The term "chimeric antibody" refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
[118] "Humanized" forms of non-human antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. A humanized antibody is generally a human antibody (recipient antibody) in which residues from one or more CDRs are replaced by residues from one or more CDRs of a non-human antibody (donor antibody). The donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody having a desired specificity, affinity, or biological effect. In some instances, selected framework region residues of the recipient antibody are replaced by the corresponding framework region residues from the donor antibody. Humanized antibodies may also comprise residues that are not found in either the recipient antibody or the donor antibody. Such modifications may be made to further refine antibody function. For further details, see Jones et al., Nature, 1986, 321:522-525;
Riechmann et al., Nature, 1988, 332:323-329; and Presta, Curr. Op. Struct.
Biol., 1992, 2:593-596, each of which is incorporated by reference in its entirety.

[119] A "human antibody" is one which possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or derived from a non-human source that utilizes a human antibody repertoire or human antibody-encoding sequences (e.g., obtained from human sources or designed de novo). Human antibodies specifically exclude humanized antibodies.
[120] An "isolated ABP" or "isolated nucleic acid" is an ABP or nucleic acid that has been separated and/or recovered from a component of its natural environment.
Components of the natural environment may include enzymes, hormones, and other proteinaceous or nonproteinaceous materials. In some embodiments, an isolated ABP is purified to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence, for example by use of a spinning cup sequenator. In some embodiments, an isolated ABP is purified to homogeneity by gel electrophoresis (e.g., SDS-PAGE) under reducing or nonreducing conditions, with detection by Coomassie0 blue or silver stain. An isolated ABP includes an ABP in situ within recombinant cells, since at least one component of the ABP's natural environment is not present. In some aspects, an isolated ABP or isolated nucleic acid is prepared by at least one purification step. In some embodiments, an isolated ABP or isolated nucleic acid is purified to at least 80%, 85%, 90%, 95%, or 99% by weight. In some embodiments, an isolated ABP or isolated nucleic acid is purified to at least 80%, 85%, 90%, 95%, or 99% by volume. In some embodiments, an isolated ABP or isolated nucleic acid is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99% to 100% ABP or nucleic acid by weight. In some embodiments, an isolated ABP or isolated nucleic acid is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99% to 100% ABP or nucleic acid by volume.
[121] "Affinity" refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an ABP) and its binding partner (e.g., an antigen or epitope). Unless indicated otherwise, as used herein, "affinity" refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., ABP and antigen or epitope). The affinity of a molecule X for its partner Y can be represented by the dissociation equilibrium constant (KD). The kinetic components that contribute to the dissociation equilibrium constant are described in more detail below. Affinity can be measured by common methods known in the art, including those described herein.
Affinity can be determined, for example, using surface plasmon resonance (SPR) technology (e.g., BIACORE ) or biolayer interferometry (e.g., FORTEBI0 ).
[122] With regard to the binding of an ABP to a target molecule, the terms "bind," "specific binding," "specifically binds to," "specific for," "selectively binds," and "selective for" a particular antigen (e.g., a polypeptide target) or an epitope on a particular antigen mean binding that is measurably different from a non-specific or non-selective interaction (e.g., with a non-target molecule). Specific binding can be measured, for example, by measuring binding to a target molecule and comparing it to binding to a non-target molecule. Specific binding can also be determined by competition with a control molecule that mimics the epitope recognized on the target molecule. In that case, specific binding is indicated if the binding of the ABP to the target molecule is competitively inhibited by the control molecule. In some aspects, the affinity of a GITR ABP for a non-target molecule is less than about 50% of the affinity for GITR. In some aspects, the affinity of a GITR ABP for a non-target molecule is less than about 40% of the affinity for GITR. In some aspects, the affinity of a GITR ABP for a non-target molecule is less than about 30% of the affinity for GITR. In some aspects, the affinity of a GITR ABP for a non-target molecule is less than about 20% of the affinity for GITR. In some aspects, the affinity of a GITR
ABP for a non-target molecule is less than about 10% of the affinity for GITR. In some aspects, the affinity of a GITR ABP for a non-target molecule is less than about 1% of the affinity for GITR. In some aspects, the affinity of a GITR ABP for a non-target molecule is less than about 0.1% of the affinity for GITR.
[123] The term "kd" (sec-1), as used herein, refers to the dissociation rate constant of a particular ABP -antigen interaction. This value is also referred to as the koff value.
[124] The term "ka" (M-lxsec-1), as used herein, refers to the association rate constant of a particular ABP -antigen interaction. This value is also referred to as the k.11 value.
[125] The term "KD" (M), as used herein, refers to the dissociation equilibrium constant of a particular ABP -antigen interaction. KD = kdka.
[126] The term "KA" (M-1), as used herein, refers to the association equilibrium constant of a particular ABP -antigen interaction. KA = kaika.
[127] An "affinity matured" ABP is one with one or more alterations (e.g., in one or more CDRs or FRs) that result in an improvement in the affinity of the ABP for its antigen, compared to a parent ABP which does not possess the alteration(s). In one embodiment, an affinity matured ABP has nanomolar or picomolar affinity for the target antigen. Affinity matured ABPs may be produced using a variety of methods known in the art. For example, Marks et al. (Bio/Technology, 1992, 10:779-783, incorporated by reference in its entirety) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and/or framework residues is described by, for example, Barbas et al.
(Proc. Nat.
Acad. Sci. USA., 1994, 91:3809-3813); Schier et al., Gene, 1995, 169:147-155;
Yelton et al., 1 Immunol., 1995, 155:1994-2004; Jackson et al., 1 Immunol., 1995, 154:3310-33199;
and Hawkins et al, I Mol. Biol., 1992, 226:889-896; each of which is incorporated by reference in its entirety.
[128] An "immunoconjugate" is an ABP conjugated to one or more heterologous molecule(s).

[129] "Effector functions" refer to those biological activities mediated by the Fc region of an antibody, which activities may vary depending on the antibody isotype.
Examples of antibody effector functions include Clq binding to activate complement dependent cytotoxicity (CDC), Fc receptor binding to activate antibody-dependent cellular cytotoxicity (ADCC), and antibody dependent cellular phagocytosis (ADCP).
[130] When used herein in the context of two or more ABPs, the term "competes with" or µ`cross-competes with" indicates that the two or more ABPs compete for binding to an antigen (e.g., GITR). In one exemplary assay, GITR is coated on a surface and contacted with a first GITR ABP, after which a second GITR ABP is added. In another exemplary assay, a first GITR ABP is coated on a surface and contacted with GITR, and then a second GITR ABP is added. If the presence of the first GITR ABP reduces binding of the second GITR ABP, in either assay, then the ABPs compete. The term "competes with"
also includes combinations of ABPs where one ABP reduces binding of another ABP, but where no competition is observed when the ABPs are added in the reverse order.
However, in some embodiments, the first and second ABPs inhibit binding of each other, regardless of the order in which they are added. In some embodiments, one ABP reduces binding of another ABP to its antigen by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
[131] The term "epitope" means a portion of an antigen the specifically binds to an ABP.
Epitopes frequently consist of surface-accessible amino acid residues and/or sugar side chains and may have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter may be lost in the presence of denaturing solvents. An epitope may comprise amino acid residues that are directly involved in the binding, and other amino acid residues, which are not directly involved in the binding. The epitope to which an ABP binds can be determined using known techniques for epitope determination such as, for example, testing for ABP
binding to GITR variants with different point-mutations, or to chimeric GITR variants.
[132] Percent "identity" between a polypeptide sequence and a reference sequence, is defined as the percentage of amino acid residues in the polypeptide sequence that are identical to the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.
Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, MEGALIGN
(DNASTAR), CLUSTALW, CLUSTAL OMEGA, or MUSCLE software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
[133] A
"conservative substitution" or a "conservative amino acid substitution,"
refers to the substitution an amino acid with a chemically or functionally similar amino acid.
Conservative substitution tables providing similar amino acids are well known in the art.
By way of example, the groups of amino acids provided in Tables 2-4 are, in some embodiments, considered conservative substitutions for one another.
Table 2. Selected groups of amino acids that are considered conservative substitutions for one another, in certain embodiments.
Acidic Residues '13, and E
Basic Residues 1K, R, and H
Hydrophilic Uncharged Residues S, T, N, and Q
Aliphatic Uncharged Residues G, A, V, L, and I
Non-polar Uncharged Residues C, M, and P
Aromatic Residues Y, and W
Table 3. Additional selected groups of amino acids that are considered conservative substitutions for one another, in certain embodiments.
Group 1 A, S, and T
Group 2 D and E
Group 3 N and Q
Group 4 R and K
Group 5 I, L, and M
Group 6 F, Y, and W
Table 4. Further selected groups of amino acids that are considered conservative substitutions for one another, in certain embodiments.
Group A A and G
Group B D and E
Group C N and Q
Group D R, K, and H
Group E I, L, M, V
Group F F, Y, and W
Group G S and T

Group H C and M
[134] Additional conservative substitutions may be found, for example, in Creighton, Proteins: Structures and Molecular Properties 2nd ed. (1993) W. H. Freeman &
Co., New York, NY. An ABP generated by making one or more conservative substitutions of amino acid residues in a parent ABP is referred to as a "conservatively modified variant."
[135] The term "amino acid" refers to the twenty common naturally occurring amino acids.
Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C); glutamic acid (Glu; E), glutamine (Gln; Q), Glycine (Gly; G); histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val;
V).
[136] The term "vector," as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors."
[137] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" (or "transformed cells") and "transfectants" (or "transfected cells"), which each include the primary transformed or transfected cell and progeny derived therefrom. Such progeny may not be completely identical in nucleic acid content to a parent cell, and may contain mutations.
[138] The term "treating" (and variations thereof such as "treat" or "treatment") refers to clinical intervention in an attempt to alter the natural course of a disease or condition in a subject in need thereof. Treatment can be performed both for prophylaxis and during the course of clinical pathology. Desirable effects of treatment include preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.
[139] As used herein, the term "therapeutically effective amount" or "effective amount"
refers to an amount of an ABP or pharmaceutical composition provided herein that, when administered to a subject, is effective to treat a disease or disorder.
[140] As used herein, the term "subject" means a mammalian subject.
Exemplary subjects include humans, monkeys, dogs, cats, mice, rats, cows, horses, camels, goats, rabbits, and sheep. In certain embodiments, the subject is a human. In some embodiments the subject has a disease or condition that can be treated with an ABP provided herein. In some aspects, the disease or condition is a cancer.
[141] The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic or diagnostic products (e.g., kits) that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic or diagnostic products.
[142] The term "cytotoxic agent," as used herein, refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction.
[143] A "chemotherapeutic agent" refers to a chemical compound useful in the treatment of cancer. Chemotherapeutic agents include "anti-hormonal agents" or "endocrine therapeutics" which act to regulate, reduce, block, or inhibit the effects of hormones that can promote the growth of cancer.
[144] The term "cytostatic agent" refers to a compound or composition which arrests growth of a cell either in vitro or in vivo. In some embodiments, a cytostatic agent is an agent that reduces the percentage of cells in S phase. In some embodiments, a cytostatic agent reduces the percentage of cells in S phase by at least about 20%, at least about 40%, at least about 60%, or at least about 80%.
[145] The term "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
The terms µ`cancer," "cancerous," "cell proliferative disorder," "proliferative disorder" and "tumor"
are not mutually exclusive as referred to herein. The terms "cell proliferative disorder" and "proliferative disorder" refer to disorders that are associated with some degree of abnormal cell proliferation. In some embodiments, the cell proliferative disorder is a cancer.
[146] The term "pharmaceutical composition" refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective in treating a subject, and which contains no additional components which are unacceptably toxic to the subject.
[147] The terms "modulate" and "modulation" refer to reducing or inhibiting or, alternatively, activating or increasing, a recited variable.
[148] The terms "increase" and "activate" refer to an increase of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, or greater in a recited variable, such as GITR
signaling activity.
[149] The terms "reduce" and "inhibit" refer to a decrease of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, or greater in a recited variable, such as (a) a number of regulatory T cells and/or (b) the symptoms of a disease or condition, such as the presence or size of metastases or the size of a primary tumor.
[150] The term "agonize" refers to the activation of receptor signaling to induce a biological response associated with activation of the receptor. An "agonist"
is an entity, such as an ABP provided herein, that binds to and agonizes a receptor.
[151] The term "antagonize" refers to the inhibition of receptor signaling to inhibit a biological response associated with activation of the receptor. An "antagonist" is an entity, such as an ABP, that binds to and antagonizes a receptor.
[152] The term "multimerize" refers to the act of forming "multimers" of an entity by assembling the entity to form a supra-entity structure held together by non-covalent or covalent interactions. Multimers include "homo-multimers," which are assemblies formed from multiple units of the same entity, or "hetero-multimers," which are assemblies comprising at least one unit of a first entity and at least one unit of a second entity. When used herein to refer to GITR, the term multimerize refers to the assembly of multiple GITR
molecules expressed on the surface of a cell that is induced, for example, by binding of an ABP provided herein or by GITRL. Such multimerization is associated with the activation of GITR signaling. See Nocentini et al., Br. I Pharmacol., 2012, 165:2089-2099, incorporated by reference in its entirety.
[153] The term "effector T cell" includes T helper (i.e., CD4+) cells and cytotoxic (i.e., CD8+) T cells. CD4+ effector T cells contribute to the development of several immunologic processes, including maturation of B cells into plasma cells and memory B
cells, and activation of cytotoxic T cells and macrophages. CD8+ effector T
cells destroy virus-infected cells and tumor cells. See Seder and Ahmed, Nature Immunol., 2003, 4:835-842, incorporated by reference in its entirety, for additional information on effector T cells.
[154] The term "regulatory T cell" includes cells that regulate immunological tolerance, for example, by suppressing effector T cells. In some aspects, the regulatory T
cell has a CD4+CD25+Foxp3+ phenotype. In some aspects, the regulatory T cell has a CD8+CD25+
phenotype. See Nocentini et al., Br. I Pharmacol., 2012, 165:2089-2099, incorporated by reference in its entirety, for additional information on regulatory T cells expressing GITR.
[155] The term "dendritic cell" refers to a professional antigen-presenting cell capable of activating a naive T cell and stimulating growth and differentiation of a B
cell.
GITR Antigen-Binding Proteins 1.1. GITR Binding and Target Cells [156] Provided herein are ABPs that specifically bind to GITR. In some aspects, the GITR

is hGITR (SEQ ID NO: 1). In some aspects, the GITR is hGITR-T43R (SEQ ID NO:
2). In some aspects, the GITR is cGITR (SEQ ID NO: 3). In some embodiments, the GITR
is mGITR (SEQ ID NO: 4).
[157] In some embodiments, the ABPs provided herein specifically bind to hGITR (SEQ ID
NO: 1), hGITR-T43R (SEQ ID NO: 2), cGITR (SEQ ID NO: 3), and mGITR (SEQ ID
NO: 4). In some embodiments, the ABPs provided herein specifically bind to hGITR (SEQ
ID NO: 1), hGITR-T43R (SEQ ID NO: 2), and cGITR (SEQ ID NO: 3). In some embodiments, the ABPs provided herein specifically bind to hGITR (SEQ ID NO:
1) and hGITR-T43R (SEQ ID NO: 2). In some embodiments, the ABPs provided herein do not bind mGITR (SEQ ID NO: 4).
[158] In some embodiments, the ABPs provided herein specifically bind to the extracellular domain of GITR.
[159] The GITR may be expressed on the surface of any suitable target cell.
In some embodiments, the target cell is an effector T cell. In some embodiments, the target cell is a regulatory T cell. In some embodiments, the target cell is a natural killer (NK) cell. In some embodiments, the target cell is a natural killer T (NKT) cell. In some embodiments, the target cell is a dendritic cell. In some aspects, the dendritic cell is a plasmacytoid dendritic cell. In some embodiments, the target cell is a B cell. In some aspects, the B cell is a plasma cell. See Nocentini et al., Br. I Pharmacol., 2012, 165:2089-2099, incorporated by reference in its entirety.
[160] In some embodiments, the ABPs provided herein specifically bind to a GITR
monomer.
[161] In some embodiments, the ABPs provided herein specifically bind to a GITR
multimer. In some aspects, the multimer comprises two GITR molecules. In some aspects, the multimer comprises three GITR molecules. In some aspects, the multimer comprises four GITR molecules. In some aspects, the multimer comprises five GITR
molecules. In some aspects, the multimer comprises six GITR molecules. In some aspects, the multimer comprises more than six GITR molecules.
[162] In some embodiments, the ABPs provided herein comprise, consist of, or consist essentially of an immunoglobulin molecule. In some aspects, the immunoglobulin molecule comprises, consists of, or consists essentially of an antibody.
[163] In some embodiments, the ABPs provided herein comprise a light chain.
In some aspects, the light chain is a kappa light chain. In some aspects, the light chain is a lambda light chain.
[164] In some embodiments, the ABPs provided herein comprise a heavy chain.
In some aspects, the heavy chain is an IgA. In some aspects, the heavy chain is an IgD. In some aspects, the heavy chain is an IgE. In some aspects, the heavy chain is an IgG. In some aspects, the heavy chain is an IgM. In some aspects, the heavy chain is an IgGl. In some aspects, the heavy chain is an IgG2. In some aspects, the heavy chain is an IgG3. In some aspects, the heavy chain is an IgG4. In some aspects, the heavy chain is an IgAl. In some aspects, the heavy chain is an IgA2.
[165] In some embodiments, the ABPs provided herein comprise, consist of, or consist essentially of an antibody fragment. In some aspects, the antibody fragment is an Fv fragment. In some aspects, the antibody fragment is a Fab fragment. In some aspects, the antibody fragment is a F(ab')2fragment. In some aspects, the antibody fragment is a Fab' fragment. In some aspects, the antibody fragment is an scFv (sFv) fragment. In some aspects, the antibody fragment is an scFv-Fc fragment. In some aspects, the antibody fragment is a fragment of a single domain antibody.
[166] In some embodiments, the ABPs provided herein are monoclonal antibodies. In some embodiments, the ABPs provided herein are polyclonal antibodies.
[167] In some embodiments, the ABPs provided herein comprise, consist of, or consist essentially of chimeric antibodies. In some embodiments, the ABPs provided herein comprise, consist of, or consist essentially of humanized antibodies. In some embodiments, the ABPs provided herein comprise, consist of, or consist essentially of human antibodies.
[168] In some embodiments, the ABPs provided herein comprise, consist of, or consist essentially of affinity matured ABPs. In some aspects, the ABPs are affinity matured ABPs derived from an ABP provided herein.
[169] In some embodiments, the ABPs provided herein comprise, consist of, or consist essentially of an alternative scaffold. Any suitable alternative scaffold may be used. In some aspects, the ABPs provided herein comprise, consist of, or consist essentially of an alternative scaffold selected from an AdnectinTm, an iMab, an Anticalin , an EETI-II/AGRP, a Kunitz domain, a thioredoxin peptide aptamer, an Affibody , a DARPin, an Affilin, a Tetranectin, a Fynomer, and an Avimer.
[170] In some embodiments, an ABP provided herein inhibits binding of GITR
to GITRL.
In some aspects, the ABP inhibits binding of GITR to GITRL by at least about 50%. In some aspects, the ABP inhibits binding of GITR to GITRL by at least about 75%.
In some aspects, the ABP inhibits binding of GITR to GITRL by at least about 90%. In some aspects, the ABP inhibits binding of GITR to GITRL by at least about 95%.
1.2. Monospecific and Multispecific GITR Antigen-Binding Proteins [171] In some embodiments, the ABPs provided herein are monospecific ABPs.
In some aspects, the monospecific ABPs bind to the same epitope on two or more different GITR
molecules. In some aspects, the monospecific ABPs bind to the same epitope on two GITR

molecules. In some aspects, the monospecific ABPs bind to the same epitope on three GITR molecules. In some aspects, the monospecific ABPs bind to the same epitope on four GITR molecules. In some aspects, the monospecific ABPs bind to the same epitope on five GITR molecules. In some aspects, the monospecific ABPs bind to the same epitope on six GITR molecules. In some aspects, the monospecific ABPs bind to the same epitope on more than six GITR molecules.
[172] In some embodiments, the monospecific ABPs provided herein are multivalent. As used herein, the term "multivalent" refers to an antibody with, e.g., more than two binding regions (i.e., that comprise VH and VL regions). In some aspects, the monospecific ABPs are bivalent. In some aspects, the monospecific ABPs are trivalent. In some aspects, the monospecific ABPs are tetravalent. In some aspects, the monospecific ABPs are pentavalent. In some aspects, the monospecific ABPs are hexavalent. In some aspects, the monospecific ABPs are septivalent. In some aspects, the monospecific ABPs are octavalent.
[173] In some embodiments, the monospecific multivalent ABPs disclosed herein are tetravalent.
[174] In some embodiments, the ABPs provided herein are multispecific ABPs.
In some aspects, the multispecific ABPs bind to two or more epitopes on two or more different GITR molecules. In some aspects, the multispecific ABPs bind to two or more epitopes on two GITR molecules. In some aspects, the multispecific ABPs bind to two or more epitopes on three GITR molecules. In some aspects, the multispecific ABPs bind to two or more epitopes on four GITR molecules. In some aspects, the multispecific ABPs bind to two or more epitopes on five GITR molecules. In some aspects, the multispecific ABPs bind to two or more epitopes on six GITR molecules. In some aspects, the multispecific ABPs bind to two or more epitopes on seven GITR molecules. In some aspects, the multispecific ABPs bind to two or more epitopes on eight GITR molecules. In some aspects, the multispecific ABPs bind to two or more epitopes on nine GITR
molecules. In some aspects, the multispecific ABPs bind to two or more epitopes on ten GITR
molecules. In some aspects, the multispecific ABPs bind to two or more epitopes on eleven GITR molecules. In some aspects, the multispecific ABPs bind to two or more epitopes on twelve GITR molecules. In some aspects, the multispecific ABPs bind to two or more epitopes on more than twelve GITR molecules.
[175] The multispecific ABPs provided herein may bind any suitable number of epitopes on GITR. In some aspects, the multispecific ABPs bind two epitopes on GITR. In some aspects, the multispecific ABPs bind three epitopes on GITR. In some aspects, the multispecific ABPs bind four epitopes on GITR. In some aspects, the multispecific ABPs bind five epitopes on GITR. In some aspects, the multispecific ABPs bind six epitopes on GITR. In some aspects, the multispecific ABPs bind seven epitopes on GITR. In some aspects, the multispecific ABPs bind eight epitopes on GITR. In some aspects, the multispecific ABPs bind nine epitopes on GITR. In some aspects, the multispecific ABPs bind ten epitopes on GITR. In some aspects, the multispecific ABPs bind eleven epitopes on GITR. In some aspects, the multispecific ABPs bind twelve epitopes on GITR.
In some aspects, the multispecific ABPs bind more than twelve epitopes on GITR.
[176] In some aspects, a multispecific ABP provided herein binds at least two different epitopes on at least two different GITR molecules. In some aspects, a multispecific ABP
provided herein binds at least three different epitopes on at least three different GITR
molecules. In some aspects, a multispecific ABP provided herein binds at least four different epitopes on at least four different GITR molecules. In some aspects, a multispecific ABP provided herein binds at least five different epitopes on at least five different GITR molecules.
[177] In some embodiments, a multispecific ABP provided herein comprises a first antigen-binding domain that specifically binds a first epitope on GITR and a second antigen-binding domain that specifically binds a second epitope on GITR, wherein the first epitope and the second epitope are different. In some aspects, the multispecific ABP
further comprises one or more additional antigen-binding domains that specifically bind to one or more additional epitopes on GITR, wherein each of the additional epitopes are different from the epitopes bound by the first antigen-binding domain, the second antigen-binding domain, or any other further antigen-binding domains of the ABP.
[178] In some embodiments, a multispecific ABP provided herein binds to an epitope on a GITR molecule and an epitope on another molecule that is not GITR. Any suitable non-GITR molecule may be bound by an ABP provided herein. In some aspects, the non-GITR
molecule is another member of the tumor necrosis factor receptor superfamily (TNFRSF).
In some aspects, the other member of the TNFRSF is selected from CD27, CD40, EDA2R, EDAR, FAS, LTBR, NGFR, RELT, TNFRSF1A, TNFRSF1B, TNFRSF4, TNFRSF6B, TNFRSF8, TNFRSF9, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TFNRSF11A, TNFRSF11B, TNFRSF12A, TNFRSF13B, TNFRSF13C, TNFRSF14, TNFRSF17, TNFRSF18, TNFRSF19, TNFRSF21, and TNFRSF25.
[179] Many multispecific ABP constructs are known in the art, and the ABPs provided herein may be provided in the form of any suitable multispecific suitable construct.
[180] In some embodiments, the multispecific ABP comprises an immunoglobulin comprising at least two different heavy chain variable regions each paired with a common light chain variable region (i.e., a "common light chain antibody"). The common light chain variable region forms a distinct antigen-binding domain with each of the two different heavy chain variable regions. See Merchant et al., Nature Biotechnol., 1998, 16:677-681, incorporated by reference in its entirety.
[181] In some embodiments, the multivalent ABPs disclosed herein comprise an immunoglobulin comprising an antibody or fragment thereof attached to one or more of the N- or C-termini of the heavy or light chains of such immunoglobulin. See, e.g.,U U.S.
Patent No. 8,722,859 and Coloma and Morrison, Nature Biotechnol., 1997, 15:159-163, each incorporated by reference in its entirety. In some aspects, such ABP
comprises a tetravalent bispecific antibody. In some aspects, such ABP comprises a tetravalent monospecific (TM) antibody.
[182] In some embodiments, the multivalent ABP comprises a hybrid immunoglobulin comprising at least two different heavy chain variable regions and at least two different light chain variable regions. See Milstein and Cuello, Nature, 1983, 305:537-540; and Staerz and Bevan, Proc. Natl. Acad. Sci. USA, 1986, 83:1453-1457; each of which is incorporated by reference in its entirety.
[183] In some embodiments, the multivalent ABP comprises immunoglobulin chains with alterations to reduce the formation of side products that do not have multispecificity. In some aspects, the ABPs comprise one or more "knobs-into-holes" modifications as described in U.S. Pat. No. 5,731,168, incorporated by reference in its entirety.
[184] In some embodiments, the multivalent ABP comprises immunoglobulin chains with one or more electrostatic modifications to promote the assembly of Fc hetero-multimers.
See WO 2009/089004, incorporated by reference in its entirety.
[185] In some embodiments, the multivalent ABP comprises a bispecific single chain molecule. See Traunecker et al., EiVIBO 1, 1991, 10:3655-3659; and Gruber et al., I
Immunol., 1994, 152:5368-5374; each of which is incorporated by reference in its entirety.
[186] In some embodiments, the multivalent ABP comprises a heavy chain variable domain and a light chain variable domain, or a single domain antibody VHH domain, connected by a polypeptide linker, where the length of the linker is selected to promote assembly of multivalent ABPs with the desired multispecificity. For example, monospecific scFvs generally form when a heavy chain V residue prevents pairing of heavy and light chain variable domains on the same polypeptide chain, thereby allowing pairing of heavy and light chain variable domains from one chain with the complementary domains on another chain. The resulting ABPs therefore have multispecificity, with the specificity of each binding site contributed by more than one polypeptide chain. Polypeptide chains comprising heavy and light chain variable domains that are joined by linkers between 3 and 12 amino acid residues form predominantly dimers (termed diabodies). With linkers between 0 and 2 amino acid residues, trimers (termed triabodies) and tetramers (termed tetrabodies) are favored. However, the exact type of oligomerization appears to depend on the amino acid residue composition and the order of the variable domain in each polypeptide chain (e.g., VH-linker-VL vs. VL-linker-VH), in addition to the linker length. A
skilled person can select the appropriate linker length based on the desired multispecificity.
[187] In some embodiments, the monospecific or multispecific ABP comprises a diabody.
See Hollinger et al., Proc. Natl. Acad. Sci. USA, 1993, 90:6444-6448, incorporated by reference in its entirety. In some embodiments, the monospecific or multispecific ABP
comprises a triabody. See Todorovska et al., I Immunol. Methods, 2001, 248:47-66, incorporated by reference in its entirety. In some embodiments, the monospecific or multispecific ABP comprises a tetrabody. See id, incorporated by reference in its entirety.
[188] In some embodiments, the multispecific ABP comprises a trispecific F(ab')3 derivative. See Tuft et al. I Immunol., 1991, 147:60-69, incorporated by reference in its entirety.
[189] In some embodiments, the monospecific or multispecific ABP comprises a cross-linked antibody. See U.S. Patent No. 4,676,980; Brennan et al., Science, 1985, 229:81-83;
Staerz, et al. Nature, 1985, 314:628-631; and EP 0453082; each of which is incorporated by reference in its entirety.
[190] In some embodiments, the monospecific or multispecific ABP comprises antigen-binding domains assembled by leucine zippers. See Kostelny et al., I Immunol., 1992, 148:1547-1553, incorporated by reference in its entirety.
[191] In some embodiments, the monospecific or multispecific ABP comprises complementary protein domains. In some aspects, the complementary protein domains comprise an anchoring domain (AD) and a dimerization and docking domain (DDD).
In some embodiments, the AD and DDD bind to each other and thereby enable assembly of multispecific ABP structures via the "dock and lock" (DNL) approach. ABPs of many specificities may be assembled, including bispecific ABPs, trispecific ABPs, tetraspecific ABPs, pentaspecific ABPs, and hexaspecific ABPs. Multispecific ABPs comprising complementary protein domains are described, for example, in U.S. Pat. Nos.
7,521,056;
7,550,143; 7,534,866; and 7,527,787; each of which is incorporated by reference in its entirety.
[192] In some embodiments, the monospecific or multispecific ABP comprises a hybrid of an antibody molecule and a non-antibody molecule with specificity for GITR or another target. See WO 93/08829, incorporated by reference in its entirety, for examples of such ABPs. In some aspects the non-antibody molecule is GITRL.
[193] In some embodiments, the monospecific or multispecific ABP comprises a dual action Fab (DAF) antibody as described in U.S. Pat. Pub. No. 2008/0069820, incorporated by reference in its entirety.
[194] In some embodiments, the multispecific ABP comprises an antibody formed by reduction of two parental molecules followed by mixing of the two parental molecules and reoxidation to assembly a hybrid structure. See Carlring et al., PLoS One, 2011, 6:e22533, incorporated by reference in its entirety.
[195] In some embodiments, the monospecific or multispecific ABP comprises a DVD-Tem. A DVD-Iirm is a dual variable domain immunoglobulin that can bind to two or more antigens. DVD-IgsTm are described in U.S. Pat. No. 7,612,181, incorporated by reference in its entirety.
[196] In some embodiments, the monospecific or multispecific ABP comprises a DART.
DARTs TM are described in Moore et al., Blood, 2011, 117:454-451, incorporated by reference in its entirety.
[197] In some embodiments, the multispecific ABP comprises a DuoBody .
DuoBodies are described in Labrijn et al., Proc. Natl. Acad. Sci. USA, 2013, 110:5145-5150; Gramer et al., mAbs, 2013, 5:962-972; and Labrijn et al., Nature Protocols, 2014, 9:2450-2463;
each of which is incorporated by reference in its entirety.
[198] In some embodiments, the monospecific or multispecific ABP disclosed herein comprises an antibody fragment attached to another antibody or fragment. The attachment can be covalent or non-covalent. When the attachment is covalent, it may be in the form of a fusion protein or via a chemical linker. Illustrative examples of multispecific ABPs comprising antibody fragments attached to other antibodies include tetravalent bispecific antibodies, where an scFv is fused to the C-terminus of the CH3 from an IgG.
See Coloma and Morrison, Nature Biotechnol., 1997, 15:159-163. Other examples include antibodies in which a Fab molecule is attached to the constant region of an immunoglobulin.
See Miler et al., I Immunol., 2003, 170:4854-4861, incorporated by reference in its entirety. Any suitable fragment may be used, including any of the fragments described herein or known in the art.
[199] In some embodiments, the monospecific or multispecific ABP comprises a CovX-Body. CovX-Bodies are described, for example, in Doppalapudi et al., Proc.
Natl. Acad.
Sci. USA, 2010, 107:22611-22616, incorporated by reference in its entirety.
[200] In some embodiments, the monospecific or multispecific ABP comprises an Fcab antibody, where one or more antigen-binding domains are introduced into an Fc region.
Fcab antibodies are described in Wozniak-Knopp et al., Protein Eng. Des. Se., 2010, 23:289-297, incorporated by reference in its entirety.
[201] In some embodiments, the monospecific or multispecific ABP comprises an TandAb antibody. TandAb antibodies are described in Kipriyanov et al., I Mol. Biol., 1999, 293:41-56 and Zhukovsky et al., Blood, 2013, 122:5116, each of which is incorporated by reference in its entirety.
[202] In some embodiments, the multispecific ABP comprises a tandem Fab.
Tandem Fabs are described in WO 2015/103072, incorporated by reference in its entirety.

[203] In some embodiments, the multispecific ABP comprises a ZybodyTm.
ZybodiesTm are described in LaFleur et al., mAbs, 2013, 5:208-218, incorporated by reference in its entirety.
1.3. Antigen-Binding Proteins Multimerizing GITR
[204] In some embodiments, the ABPs provided herein multimerize GITR
expressed on the surface of a target cell. The ABPs provided herein may be designed, based on their valency and specificity, to multimerize any suitable number of GITR molecules.
[205] In some embodiments, the ABPs provided herein multimerize two GITR
molecules.
In some embodiments, the ABPs provided herein multimerize three GITR
molecules. In some embodiments, the ABPs provided herein multimerize four GITR molecules. In some embodiments, the ABPs provided herein multimerize five GITR molecules. In some embodiments, the ABPs provided herein multimerize six GITR molecules. In some embodiments, the ABPs provided herein multimerize seven GITR molecules. In some embodiments, the ABPs provided herein multimerize eight GITR molecules. In some embodiments, the ABPs provided herein multimerize nine GITR molecules. In some embodiments, the ABPs provided herein multimerize ten GITR molecules. In some embodiments, the ABPs provided herein multimerize eleven GITR molecules. In some embodiments, the ABPs provided herein multimerize twelve GITR molecules.
[206] In some embodiments, the ABPs provided herein multimerize at least two GITR
molecules. In some embodiments, the ABPs provided herein multimerize at least three GITR molecules. In some embodiments, the ABPs provided herein multimerize at least four GITR molecules. In some embodiments, the ABPs provided herein multimerize at least five GITR molecules. In some embodiments, the ABPs provided herein multimerize at least six GITR molecules. In some embodiments, the ABPs provided herein multimerize at least seven GITR molecules. In some embodiments, the ABPs provided herein multimerize at least eight GITR molecules. In some embodiments, the ABPs provided herein multimerize at least nine GITR molecules. In some embodiments, the ABPs provided herein multimerize at least ten GITR molecules. In some embodiments, the ABPs provided herein multimerize at least eleven GITR molecules. In some embodiments, the ABPs provided herein multimerize at least twelve GITR molecules.
[207] In some embodiments, the ABPs provided herein multimerize two to twelve GITR
molecules. In some embodiments, the ABPs provided herein multimerize three to ten GITR molecules. In some embodiments, the ABPs provided herein multimerize three to six GITR molecules. In some embodiments, the ABPs provided herein multimerize three to five GITR molecules. In some embodiments, the ABPs provided herein multimerize three to four GITR molecules.
1.4. GITR Agonism [208] In some embodiments, the ABPs provided herein agonize GITR upon binding. Such agonism can result from the multimerization of GITR by the ABPs as described elsewhere in this disclosure. See FIG. 1.
[209] In some embodiments, agonism of GITR by an ABP provided herein results in modulation of NF-KB activity in a target cell. See U.S. Pat. No. 7,812,135, herein incorporated by reference in its entirety. In some aspects, agonism of GITR
results in modulation of fkB activity or stability in a target cell.
[210] In some embodiments, agonism of GITR by an ABP provided herein results in activation of the MAPK pathway in a target cell. In some aspects, the components of the MAPK pathway that are activated by an ABP provided herein include one or more of p38, JNK, and ERK. See Nocentini et al., Proc. Natl. Acad. Sci. USA, 1997, 94:6216-6221;
Ronchetti et al., Eur. I Immunol., 2004, 34:613-622; and Esparza et al., I
Immunol., 2005, 174:7869-7874; each of which is incorporated by reference in its entirety.
[211] In some embodiments, agonism of GITR by an ABP provided herein results in increased secretion of IL-2Ra, IL-2, IL-8, and/or IFNy by a target cell. See Ronchetti et al., Eur. I Immunol., 2004, 34:613-622, incorporated by reference in its entirety.
[212] In some embodiments, agonism of GITR by an ABP provided herein increases the proliferation, survival, and/or function of an effector T cell. In some aspects the effector T
cell is a CD4+ effector T cell. In some aspects, the effector T cell is a CD8+
effector T
cell.
[213] In some embodiments, agonism of GITR by an ABP provided herein abrogates suppression of an effector T cell by a regulatory T cell. In some aspects, the regulatory T
cell is a CD4+CD25+Foxp3+ regulatory T cell. In some aspects, the regulatory T
cell is a CD8+CD25+ regulatory T cell.
[214] In some embodiments, agonism of GITR by an ABP provided herein alters the frequency of occurrence or distribution of regulatory T cells. In some aspects, the frequency of regulatory T cells is decreased. In some aspects, the frequency of regulatory T cells is reduced in a particular tissue. In some aspects, the intratumoral accumulation of regulatory T cells is decreased, resulting in a more favorable ratio of effector T cells to regulatory T cells, and enhancing CD8+ T cell activity. See Cohen et al., PLoS
One, 2010, 5:e10436.
[215] In some embodiments, agonism of GITR by an ABP provided herein increases the activity of a natural killer (NK) cell. In some embodiments, agonism of GITR
by an ABP

provided herein increases the activity of an antigen presenting cell. In some embodiments, agonism of GITR by an ABP provided herein increases the activity of a dendritic cell. In some embodiments, agonism of GITR by an ABP provided herein increases the activity of a B cell.
[216] In some embodiments, agonism of GITR by an ABP provided herein results in an enhancement of an immune response. In some embodiments, agonism of GITR by an ABP
provided herein results in the delay of onset of a tumor. In some embodiments, agonism of GITR by an ABP provided herein results in the reduction of the size of a tumor. In some embodiments, agonism of GITR by an ABP provided herein results in a reduction in the number of metastases.
[217] In some embodiments, agonism of GITR by a multivalent monospecific ABP
provided herein results in a greater maximum amount of agonism than a bivalent monospecific antibody. In some embodiments, the additional valency results in an effect on the EC50 that that is more than the additive effects of each of the binding domains. In some embodiments, a tetravalent monospecific ABP provided herein has a greater maximum amount of agonism than a bivalent monospecific antibody.
[218] In some embodiments, the multispecific ABPs provided herein are more potent agonists of GITR than mixtures of the corresponding monospecific ABPs. For example, if a multispecific ABP provided herein comprises two different epitope specificities (e.g., A
and B) then, in some embodiments, the agonism of GITR by such multispecific ABP is greater than the agonism of GITR by a mixture of two monospecific ABPs that each comprise one of the two specificities (e.g., A or B). In some embodiments, the additional specificities of a multispecific ABP provided herein yield a synergistic (i.e., greater than additive) increase in potency when compared to mixtures of monospecific ABPs each having only one of the specificities of the multispecific ABP.
1.5. Affinity of Antigen-Binding Proteins for GITR
[219] In some embodiments, the affinity of an ABP provided herein for GITR
as indicated by KD, is less than about 10-5 M, less than about 10-6 M, less than about 10-7 M, less than about 10-8 M, less than about 10-9 M, less than about 10-10 M, less than about 10-11M, or less than about 10-12 M. In some embodiments, the affinity of the ABP is between about 10-7 M and 10-12 M. In some embodiments, the affinity of the ABP is between about 10-7 M
and 10-11 M. In some embodiments, the affinity of the ABP is between about 10-7 M and 10-10 M. In some embodiments, the affinity of the ABP is between about 10-7 M
and 10-9 M. In some embodiments, the affinity of the ABP is between about 10-7 M and 10-8 M. In some embodiments, the affinity of the ABP is between about 10-8 M and 10-12 M.
In some embodiments, the affinity of the ABP is between about 10-8 M and 10-11 M. In some embodiments, the affinity of the ABP is between about 10-9 M and 10-11 M. In some embodiments, the affinity of the ABP is between about 10-10 M and 10-11 M.
[220] In some embodiments, the ABPs provided herein specifically bind to hGITR (SEQ ID
NO: 1) with a KD ofX and to cGITR with a KD of <10X. In some embodiments, the ABPs provided herein specifically bind to hGITR (SEQ ID NO: 1) with a KD ofX and to cGITR
with a KD of <5X. In some embodiments, the ABPs provided herein specifically bind to hGITR (SEQ ID NO: 1) with a KD ofX and to cGITR with a KD of <2X. In some aspects, Xis any KD described in this disclosure. In some aspects, Xis 0.01 nM, 0.1 nM, 1 nM, 10 nM, 20 nM, 50 nM, or 100 nM.
[221] In some embodiments, KD, ka, and ka are determined using surface plasmon resonance (SPR). In some aspects, the SPR analysis utilizes a BIACORE instrument. In some aspects, the antigen is immobilized on a carboxymethylated dextran biosensor chip (CM4 or CM5) and contacted with an ABP provided herein. Association and dissociation rate constants may be calculated using the BlAevaluation software and a one-to-one Langmuir binding model. In some aspects, the assay is performed at 25 C. In some aspects, the assay is performed at 37 C.
[222] In some embodiments, KD, ka, and ka are determined using biolayer interferometry (BLI). Any suitable BLI method may be used. In some aspects, the BLI analysis utilizes a FORTEBIO instrument. In some aspects, an anti-human IgG Fc capture (AHC) biosensor is used to capture ABPs onto the surface of a sensor. Subsequently, association of the ABP
and antigen is monitored by contacting the immobilized ABP with different concentrations of GITR. Dissociation of the antigen and ABP is then measured in a buffer without GITR.
Association and dissociation rate constants are calculated using the kinetic modules of the FORTEBIO Analysis Software. In some aspects, the assay is performed at 30 C.
[223] In other embodiments, KD may be determined by a radiolabeled antigen-binding assay, as described in Chen et al. I Mol. Biol., 1999, 293:865-881, incorporated by reference in its entirety.
1.5.1.Glycosylation Variants [224] In certain embodiments, an ABP provided herein may be altered to increase, decrease or eliminate the extent to which it is glycosylated. Glycosylation of polypeptides is typically either "N-linked" or "0-linked."
[225] "N-linked" glycosylation refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site.
[226] "0-linked" glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
[227] Addition or deletion of N-linked glycosylation sites to or from an ABP provided herein may be accomplished by altering the amino acid sequence such that one or more of the above-described tripeptide sequences is created or removed. Addition or deletion of 0-linked glycosylation sites may be accomplished by addition, deletion, or substitution of one or more serine or threonine residues in or to (as the case may be) the sequence of an ABP.
[228] In some embodiments, an ABP provided herein comprises a glycosylation motif that is different from a naturally occurring ABP. Any suitable naturally occurring glycosylation motif can be modified in the ABPs provided herein. The structural and glycosylation properties of immunoglobulins, for example, are known in the art and summarized, for example, in Schroeder and Cavacini, I Allergy Cl/n. Immunol., 2010, 125:S41-52, incorporated by reference in its entirety.
[229] In some embodiments, an ABP provided herein comprises an IgG1 Fc region with modification to the oligosaccharide attached to asparagine 297 (Asn 297).
Naturally occurring IgG1 antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn 297 of the CH2 domain of the Fc region. See Wright et al., TIB TECH, 1997, 15:26-32, incorporated by reference in its entirety. The oligosaccharide attached to Asn 297 may include various carbohydrates such as mannose, N-acetyl glucosamine (G1cNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the "stem" of the biantennary oligosaccharide structure.
[230] In some embodiments, the oligosaccharide attached to Asn 297 is modified to create ABPs having altered ADCC. In some embodiments, the oligosaccharide is altered to improve ADCC. In some embodiments, the oligosaccharide is altered to reduce ADCC.
[231] In some aspects, an ABP provided herein comprises an IgG1 domain with reduced fucose content at position Asn 297 compared to a naturally occurring IgG1 domain. Such Fc domains are known to have improved ADCC. See Shields et al., I Biol. Chem., 2002, 277:26733-26740, incorporated by reference in its entirety. In some aspects, such ABPs do not comprise any fucose at position Asn 297. The amount of fucose may be determined using any suitable method, for example as described in WO 2008/077546, incorporated by reference in its entirety.

[232] In some embodiments, an ABP provided herein comprises a bisected oligosaccharide, such as a biantennary oligosaccharide attached to the Fc region of the ABP
that is bisected by GlcNAc. Such ABP variants may have reduced fucosylation and/or improved ADCC
function. Examples of such ABP variants are described, for example, in WO
2003/011878;
U.S. Pat. No. 6,602,684; and U.S. Pat. Pub. No. 2005/0123546; each of which is incorporated by reference in its entirety.
[233] Other illustrative glycosylation variants are described, for example, in U.S. Pat. Pub.
Nos. 2003/0157108, 2004/0093621, 2003/0157108, 2003/0115614, 2002/0164328, 2004/0093621, 2004/0132140, 2004/0110704, 2004/0110282, 2004/0109865;
International Pat. Pub. Nos. 2000/61739, 2001/29246, 2003/085119, 2003/084570, 2005/035586, 2005/035778; 2005/053742, 2002/031140; Okazaki et al., 1 Mol. Biol., 2004, 336:1239-1249; and Yamane-Ohnuki et al., Biotech. Bioeng., 2004, 87: 614-622; each of which is incorporated by reference in its entirety.
[234] In some embodiments, an ABP provided herein comprises an Fc region with at least one galactose residue in the oligosaccharide attached to the Fc region. Such ABP variants may have improved CDC function. Examples of such ABP variants are described, for example, in WO 1997/30087; WO 1998/58964; and WO 1999/22764; each of which his incorporated by reference in its entirety.
[235] Examples of cell lines capable of producing defucosylated ABPs include Lec13 CHO
cells, which are deficient in protein fucosylation (see Ripka et al., Arch.
Biochem.
Biophys., 1986, 249:533-545; U.S. Pat. Pub. No. 2003/0157108; WO 2004/056312;
each of which is incorporated by reference in its entirety), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene or FUT8 knockout CHO cells (see Yamane-Ohnuki et al., Biotech. Bioeng., 2004, 87: 614-622; Kanda et al., Biotechnol. Bioeng., 2006, 94:680-688; and WO 2003/085107; each of which is incorporated by reference in its entirety).
[236] In some embodiments, an ABP provided herein is an aglycosylated ABP.
An aglycosylated ABP can be produced using any method known in the art or described herein. In some aspects, an aglycosylated ABP is produced by modifying the ABP
to remove all glycosylation sites. In some aspects, the glycosylation sites are removed only from the Fc region of the ABP. In some aspects, an aglycosylated ABP is produced by expressing the ABP in an organism that is not capable of glycosylation, such as E. coil, or by expressing the ABP in a cell-free reaction mixture.
[237] In some embodiments, an ABP provided herein has a constant region with reduced effector function compared to a native IgG1 antibody. In some embodiments, the affinity of a constant region of an Fc region of an ABP provided herein for Fc receptor is less than the affinity of a native IgG1 constant region for such Fc receptor.

1.6. Fc Region Amino Acid Sequence Variants [238] In certain embodiments, an ABP provided herein comprises an Fc region with one or more amino acid substitutions, insertions, or deletions in comparison to a naturally occurring Fc region. In some aspects, such substitutions, insertions, or deletions yield ABPs with altered stability, glycosylation, or other characteristics. In some aspects, such substitutions, insertions, or deletions yield aglycosylated ABPs.
[239] In some aspects, the Fc region of an ABP provided herein is modified to yield an ABP with altered affinity for an Fc receptor, or an ABP that is more immunologically inert. In some embodiments, the ABP variants provided herein possess some, but not all, effector functions. Such ABPs may be useful, for example, when the half-life of the ABP
is important in vivo, but when certain effector functions (e.g., complement activation and ADCC) are unnecessary or deleterious.
[240] In some embodiments, the Fc region of an ABP provided herein is a human IgG4 Fc region comprising the hinge stabilizing mutation 5228P or L235E. In some embodiment, the IgG4 Fc region comprises the hinge stabilizing mutations 5228P and L235E.
See Aalberse et al., Immunology, 2002, 105:9-19, incorporated by reference in its entirety. In some embodiments, the IgG4 Fc region comprises one or more of the following mutations:
E233P, F234V, and L235A. See Armour et al., Mol. Immunol., 2003, 40:585-593, incorporated by reference in its entirety. In some embodiments, the IgG4 Fc region comprises a deletion at position G236.
[241] In some embodiments, the Fc region of an ABP provided herein is a human IgG1 Fc region comprising one or more mutations to reduce Fc receptor binding. In some aspects, the one or more mutations are in residues selected from S228 (e.g., 5228A), L234 (e.g., L234A), L235 (e.g., L235A), D265 (e.g., D265A), and N297 (e.g., N297A). In some aspects, the ABP comprises a PVA236 mutation. PVA236 means that the amino acid sequence ELLG, from amino acid position 233 to 236 of IgG1 or EFLG of IgG4, is replaced by PVA. See U.S. Pat. Pub. No. 2013/0065277, incorporated by reference in its entirety.
[242] In some embodiments, the Fc region of an ABP provided herein is modified as described in Armour et al., Eur. I Immunol., 1999, 29:2613-2624; WO
1999/058572;
and/or U.K. Pat. App. No. 98099518; each of which is incorporated by reference in its entirety.
[243] In some embodiments, the Fc region of an ABP provided herein is a human IgG2 Fc region comprising one or more of mutations A3 30S and P33 1S.
[244] In some embodiments, the Fc region of an ABP provided herein has an amino acid substitution at one or more positions selected from 238, 265, 269, 270, 297, 327 and 329.

See U.S. Pat. No. 6,737,056, incorporated by reference in its entirety. Such Fc mutants include Fe mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called "DANA" Fe mutant with substitution of residues 265 and 297 with alanine. See U.S. Pat. No. 7,332,581, incorporated by reference in its entirety. In some embodiments, the ABP comprises an alanine at amino acid position 265.
In some embodiments, the ABP comprises an alanine at amino acid position 297.
[245] In certain embodiments, an ABP provided herein comprises an Fe region with one or more amino acid substitutions which improve ADCC, such as a substitution at one or more of positions 298, 333, and 334 of the Fe region. In some embodiments, an ABP
provided herein comprises an Fe region with one or more amino acid substitutions at positions 239, 332, and 330, as described in Lazar et al., Proc. Natl. Acad. Sci. USA, 2006,103:4005-4010, incorporated by reference in its entirety.
[246] In some embodiments, an ABP provided herein comprises one or more alterations that improves or diminishes Clq binding and/or CDC. See U.S. Pat. No.
6,194,551; WO
99/51642; and Idusogie et al., I Immunol., 2000, 164:4178-4184; each of which is incorporated by reference in its entirety.
[247] In some embodiments, an ABP provided herein comprises one or more alterations to increase half-life. ABPs with increased half-lives and improved binding to the neonatal Fe receptor (FcRn) are described, for example, in Hinton et al., I Immunol., 2006, 176:346-356; and U.S. Pat. Pub. No. 2005/0014934; each of which is incorporated by reference in its entirety. Such Fe variants include those with substitutions at one or more of Fe region residues: 238, 250, 256, 265, 272, 286, 303, 305, 307, 311, 312, 314, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, 428, and 434 of an IgG.
[248] In some embodiments, an ABP provided herein comprises one or more Fe region variants as described in U.S. Pat. Nos. 7,371,826 5,648,260, and 5,624,821;
Duncan and Winter, Nature, 1988, 322:738-740; and WO 94/29351; each of which is incorporated by reference in its entirety.
1.7. Cysteine Engineered Antigen-Binding Protein Variants [249] In certain embodiments, provided herein are cysteine engineered ABPs, also known as "thioMAbs," in which one or more residues of the ABP are substituted with cysteine residues. In particular embodiments, the substituted residues occur at solvent accessible sites of the ABP. By substituting such residues with cysteine, reactive thiol groups are introduced at solvent accessible sites of the ABP and may be used to conjugate the ABP to other moieties, such as drug moieties or linker-drug moieties, for example, to create an immunoconjugate.

[250] In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 of the light chain; A118 of the heavy chain Fc region; and S400 of the heavy chain Fc region. Cysteine engineered ABPs may be generated as described, for example, in U.S. Pat. No. 7,521,541, which is incorporated by reference in its entirety.
1.7.1.Immunoconjugates 1.7.1.1. Antigen-Binding Protein-Polymer Conjugates [251] In some embodiments, an ABP provided herein is derivatized by conjugation with a polymer. Any suitable polymer may be conjugated to the ABP.
[252] In some embodiments, the polymer is a water soluble polymer.
Illustrative examples of water soluble polymers include polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), poly(n-vinyl pyrrolidone)-co-polyethylene glycol, propropylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof In some aspects, polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
[253] The polymer may be of any molecular weight, and may be branched or unbranched.
The number of polymers attached to each ABP may vary, and if more than one polymer is attached, they may be the same polymer or different polymers. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including the particular properties or functions of the ABP to be improved and the intended use of the ABP.
1.7.1.2. Antigen-Binding Protein-Drug Conjugates [254] In some embodiments, the ABPs provided herein are conjugated to one or more therapeutic agents. Any suitable therapeutic agent may be conjugated to the ABP.
Exemplary therapeutic agents include cytokines, chemokines, and other agents that induce a desired T cell activity, such as GITRL, OX4OL, 4-1BBL, TNF-alpha, IL-2, IL-15 fusion, CXCL9, CXCL10, IL-10 trap, IL-27 trap, and IL-35 trap. Cytokine traps and their use are known in the art and described, for example, in Economides et al., Nature Medicine, 2003, 9:47-52, incorporated by reference in its entirety.
Methods of Making GITR Antigen-Binding Proteins 1.8. GITR Antigen Preparation [255] The GITR antigen used for isolation of the ABPs provided herein may be intact GITR
or a fragment of GITR. The GITR antigen may be in the form of an isolated protein or a protein expressed on the surface of a cell.
[256] In some embodiments, the GITR antigen is a non-naturally occurring variant of GITR, such as a GITR protein having an amino acid sequence or post-translational modification that does not occur in nature.
[257] In some embodiments, the GITR antigen is truncated by removal of, for example, intracellular or membrane-spanning sequences, or signal sequences. In some embodiments, the GITR antigen is fused at its C-terminus to a human IgG1 Fc domain or a polyhistidine tag.
1.9. Methods of Making Monoclonal Antibodies [258] Monoclonal antibodies may be obtained, for example, using the hybridoma method first described by Kohler et al., Nature, 1975, 256:495-497 (incorporated by reference in its entirety), and/or by recombinant DNA methods (see e.g., U.S. Patent No.
4,816,567, incorporated by reference in its entirety). Monoclonal antibodies may also be obtained, for example, using phage or yeast-based libraries. See e.g., U.S. Patent Nos.
8,258,082 and 8,691,730, each of which is incorporated by reference in its entirety.
[259] In the hybridoma method, a mouse or other appropriate host animal is immunized to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes are then fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell. See Goding J.W., Monoclonal Antibodies: Principles and Practice 3rd ed. (1986) Academic Press, San Diego, CA, incorporated by reference in its entirety.
[260] The hybridoma cells are seeded and grown in a suitable culture medium that contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT
medium), which substances prevent the growth of HGPRT-deficient cells.
[261] Useful myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive media conditions, such as the presence or absence of HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOP-21 and MC-11 mouse tumors (available from the Salk Institute Cell Distribution Center, San Diego, CA), and SP-2 or X63-Ag8-653 cells (available from the American Type Culture Collection, Rockville, MD). Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies.
See e.g., Kozbor, I Immunol., 1984, 133:3001, incorporated by reference in its entirety.
[262] After the identification of hybridoma cells that produce antibodies of the desired specificity, affinity, and/or biological activity, selected clones may be subcloned by limiting dilution procedures and grown by standard methods. See Goding, supra.
Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal.
[263] DNA encoding the monoclonal antibodies may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). Thus, the hybridoma cells can serve as a useful source of DNA
encoding antibodies with the desired properties. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as bacteria (e.g., E.
coil), yeast (e.g., Saccharomyces or Pichia sp.), COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce antibody, to produce the monoclonal antibodies.
1.10. Methods of Making Chimeric Antibodies [264] Illustrative methods of making chimeric antibodies are described, for example, in U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 1984, 81:6851-6855; each of which is incorporated by reference in its entirety. In some embodiments, a chimeric antibody is made by using recombinant techniques to combine a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) with a human constant region.
1.11. Methods of Making Humanized Antibodies [265] Humanized antibodies may be generated by replacing most, or all, of the structural portions of a non-human monoclonal antibody with corresponding human antibody sequences. Consequently, a hybrid molecule is generated in which only the antigen-specific variable, or CDR, is composed of non-human sequence. Methods to obtain humanized antibodies include those described in, for example, Winter and Milstein, Nature, 1991, 349:293-299; Rader et al., Proc. Nat. Acad. Sci. USA., 1998, 95:8910-8915; Steinberger et al., I Biol. Chem., 2000, 275:36073-36078; Queen et al., Proc. Natl.

Acad. Sci. USA., 1989, 86:10029-10033; and U.S. Patent Nos. 5,585,089, 5,693,761, 5,693,762, and 6,180,370; each of which is incorporated by reference in its entirety.
1.12. Methods of making Human Antibodies [266] Human antibodies can be generated by a variety of techniques known in the art, for example by using transgenic animals (e.g., humanized mice). See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA., 1993, 90:2551; Jakobovits et al., Nature, 1993, 362:255-258;
Bruggermann et al., Year in Immuno., 1993, 7:33; and U.S. Patent Nos.
5,591,669, 5,589,369 and 5,545,807; each of which is incorporated by reference in its entirety. Human antibodies can also be derived from phage-display libraries (see e.g., Hoogenboom et al., I
Mol. Biol., 1991, 227:381-388; Marks et al., I Mol. Biol., 1991, 222:581-597;
and U.S.
Pat. Nos. 5,565,332 and 5,573,905; each of which is incorporated by reference in its entirety). Human antibodies may also be generated by in vitro activated B
cells (see e.g., U.S. Patent. Nos. 5,567,610 and 5,229,275, each of which is incorporated by reference in its entirety). Human antibodies may also be derived from yeast-based libraries (see e.g., U.S. Patent No. 8,691,730, incorporated by reference in its entirety).
1.13. Methods of Making Antibody Fragments [267] The antibody fragments provided herein may be made by any suitable method, including the illustrative methods described herein or those known in the art.
Suitable methods include recombinant techniques and proteolytic digestion of whole antibodies.
Illustrative methods of making antibody fragments are described, for example, in Hudson et al., Nat. Med., 2003, 9:129-134, incorporated by reference in its entirety.
Methods of making scFy antibodies are described, for example, in Pliickthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); WO 93/16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458;
each of which is incorporated by reference in its entirety.
1.14. Methods of Making Alternative Scaffolds [268] The alternative scaffolds provided herein may be made by any suitable method, including the illustrative methods described herein or those known in the art.
For example, methods of preparing AdnectinsTm are described in Emanuel et al., mAbs, 2011, 3:38-48, incorporated by reference in its entirety. Methods of preparing iMabs are described in U.S.
Pat. Pub. No. 2003/0215914, incorporated by reference in its entirety. Methods of preparing Anticalins are described in Vogt and Skerra, Chem. Biochem., 2004, 5:191-199, incorporated by reference in its entirety. Methods of preparing Kunitz domains are described in Wagner etal., Biochem. & Biophys. Res. Comm., 1992, 186:118-1145, incorporated by reference in its entirety. Methods of preparing thioredoxin peptide aptamers are provided in Geyer and Brent, Meth. Enzymol., 2000, 328:171-208, incorporated by reference in its entirety. Methods of preparing Affibodies are provided in Fernandez, Curr. Opinion in Biotech., 2004, 15:364-373, incorporated by reference in its entirety. Methods of preparing DARPins are provided in Zahnd etal., I Mol.
Biol., 2007, 369:1015-1028, incorporated by reference in its entirety. Methods of preparing Affilins are provided in Ebersbach etal., I Mol. Biol., 2007, 372:172-185, incorporated by reference in its entirety. Methods of preparing Tetranectins are provided in Graversen et al., I Biol.
Chem., 2000, 275:37390-37396, incorporated by reference in its entirety.
Methods of preparing Avimers are provided in Silverman etal., Nature Biotech., 2005, 23:1556-1561, incorporated by reference in its entirety. Methods of preparing Fynomers are provided in Silacci etal., I Biol. Chem., 2014, 289:14392-14398, incorporated by reference in its entirety.
[269] Further information on alternative scaffolds is provided in Binz et al., Nat.
Biotechnol., 2005 23:1257-1268; and Skerra, Current Opin. in Biotech., 2007 18:295-304, each of which is incorporated by reference in its entirety.
1.15. Methods of Making Multispecific ABPs [270] The multispecific or multivalent monospecific ABPs provided herein may be made by any suitable method, including the illustrative methods described herein or those known in the art. Methods of making common light chain antibodies are described in Merchant et al., Nature Biotechnol., 1998, 16:677-681, incorporated by reference in its entirety.
Methods of making tetravalent bispecific antibodies are described in Coloma and Morrison, Nature Biotechnol., 1997, 15:159-163, incorporated by reference in its entirety.
Methods of making hybrid immunoglobulins are described in Milstein and Cuello, Nature, 1983, 305:537-540; and Staerz and Bevan, Proc. Natl. Acad. Sci. USA, 1986, 83:1453-1457; each of which is incorporated by reference in its entirety. Methods of making immunoglobulins with knobs-into-holes modification are described in U.S. Pat.
No.
5,731,168, incorporated by reference in its entirety. Methods of making immunoglobulins with electrostatic modifications are provided in WO 2009/089004, incorporated by reference in its entirety. Methods of making multivalent (e.g., tetravalent) mono specific antibodies are described in Miller et al., 2003, U.S. Patent No. 8,722,859, incorporated by reference in its entirety. Methods of making bispecific single chain antibodies are described in Traunecker etal., EiVIBO 1, 1991, 10:3655-3659; and Gruber etal., I
Immunol., 1994, 152:5368-5374; each of which is incorporated by reference in its entirety.

Methods of making single-chain antibodies, whose linker length may be varied, are described in U.S. Pat. Nos. 4,946,778 and 5,132,405, each of which is incorporated by reference in its entirety. Methods of making diabodies are described in Hollinger et al., Proc. Natl. Acad. Sci. USA, 1993, 90:6444-6448, incorporated by reference in its entirety.
Methods of making triabodies and tetrabodies are described in Todorovska et al., I
Immunol. Methods, 2001, 248:47-66, incorporated by reference in its entirety.
Methods of making trispecific F(ab')3 derivatives are described in Tuft et al. I
Immunol., 1991, 147:60-69, incorporated by reference in its entirety. Methods of making cross-linked antibodies are described in U.S. Patent No. 4,676,980; Brennan et al., Science, 1985, 229:81-83; Staerz, et al. Nature, 1985, 314:628-631; and EP 0453082; each of which is incorporated by reference in its entirety. Methods of making antigen-binding domains assembled by leucine zippers are described in Kostelny et al., I Immunol., 1992, 148:1547-1553, incorporated by reference in its entirety. Methods of making ABPs via the DNL approach are described in U.S. Pat. Nos. 7,521,056; 7,550,143; 7,534,866;
and 7,527,787; each of which is incorporated by reference in its entirety. Methods of making hybrids of antibody and non-antibody molecules are described in WO 93/08829, incorporated by reference in its entirety, for examples of such ABPs. Methods of making DAF antibodies are described in U.S. Pat. Pub. No. 2008/0069820, incorporated by reference in its entirety. Methods of making ABPs via reduction and oxidation are described in Carlring et al., PLoS One, 2011, 6:e22533, incorporated by reference in its entirety. Methods of making DVD-IgsTM are described in U.S. Pat. No.
7,612,181, incorporated by reference in its entirety. Methods of making DARTsTm are described in Moore et al., Blood, 2011, 117:454-451, incorporated by reference in its entirety. Methods of making DuoBodies are described in Labrijn et al., Proc. Natl. Acad. Sci.
USA, 2013, 110:5145-5150; Gramer et al., mAbs, 2013, 5:962-972; and Labrijn et al., Nature Protocols, 2014, 9:2450-2463; each of which is incorporated by reference in its entirety.
Methods of making antibodies comprising scFvs fused to the C-terminus of the CH3 from an IgG are described in Coloma and Morrison, Nature Biotechnol., 1997, 15:159-163, incorporated by reference in its entirety. Methods of making antibodies in which a Fab molecule is attached to the constant region of an immunoglobulin are described in Miler et al., I Immunol., 2003, 170:4854-4861, incorporated by reference in its entirety. Methods of making CovX-Bodies are described in Doppalapudi et al., Proc. Natl. Acad.
Sci. USA, 2010, 107:22611-22616, incorporated by reference in its entirety. Methods of making Fcab antibodies are described in Wozniak-Knopp et al., Protein Eng. Des. Se!., 2010, 23:289-297, incorporated by reference in its entirety. Methods of making TandAb antibodies are described in Kipriyanov et al., I Mol. Biol., 1999, 293:41-56 and Zhukovsky et al., Blood, 2013, 122:5116, each of which is incorporated by reference in its entirety.
Methods of making tandem Fabs are described in WO 2015/103072, incorporated by reference in its entirety. Methods of making ZybodiesTm are described in LaFleur etal., mAbs, 2013, 5:208-218, incorporated by reference in its entirety.
[271] In another aspect is provided a method for producing an anti-human GITR antibody or an antigen-binding fragment thereof, comprising culturing host cell(s) selected from the group consisting of (a) to (c) below to express a tetravalent anti-human GITR
antibody or an antigen-binding fragment thereof: (a) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof provided herein and a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody or the antigen-binding fragment thereof; (b) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR
antibody or the antigen-binding fragment thereof provided herein and an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody or the antigen-binding fragment thereof; and (c) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof provided herein and a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody or the antigen-binding fragment thereof.
[272] In another aspect is provided a method for producing an anti-human GITR antibody, comprising culturing host cell(s) selected from the group consisting of (a) to (c) below to express an anti-human GITR antibody: (a) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR antibody provided herein and a polynucleotide comprising a base sequence encoding the light chain of the antibody; (b) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR antibody provided herein and an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain of the antibody; and (c) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR antibody provided herein and a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain of the antibody.
1.16. Methods of Making Variants [273] In some embodiments, an ABP provided herein is an affinity matured variant of a parent ABP, which may be generated, for example, using phage display-based affinity maturation techniques. Briefly, one or more CDR residues may be mutated and the variant ABPs, or portions thereof, displayed on phage and screened for affinity. Such alterations may be made in CDR "hotspots," or residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see Chowdhury, Methods Mol.
Biol., 2008, 207:179-196, incorporated by reference in its entirety), and/or residues that contact the antigen. In some embodiments, affinity maturation can be used for altering or introducing species binding, i.e., an anti-mouse antibody may be engineered to bind to human and cynomolgus monkey versions of the same target antigen, etc.
[274] Any suitable method can be used to introduce variability into a polynucleotide sequence(s) encoding an ABP, including error-prone PCR, chain shuffling, and oligonucleotide-directed mutagenesis such as trinucleotide-directed mutagenesis (TRIM).
In some aspects, several CDR residues (e.g., 4-6 residues at a time) are randomized. CDR
residues involved in antigen binding may be specifically identified, for example, using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted for mutation.
[275] The introduction of diversity into the variable regions and/or CDRs can be used to produce a secondary library. The secondary library is then screened to identify ABP
variants with improved affinity. Affinity maturation by constructing and reselecting from secondary libraries has been described, for example, in Hoogenboom et al., Methods in Molecular Biology, 2001, 178:1-37, incorporated by reference in its entirety.
1.17. Vectors, Host Cells, and Recombinant Methods [276] Also provided are isolated nucleic acids encoding GITR ABPs, vectors comprising the nucleic acids, and host cells comprising the vectors and nucleic acids, as well as recombinant techniques for the production of the ABPs.
[277] In another aspect is provided a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof provided herein. In another aspect is provided a polynucleotide comprising a base sequence encoding the light chain variable region of the anti-human GTIR antibody or the antigen-binding fragment thereof provided herein.
[278] In another aspect is provided a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR antibody provided herein. In another aspect is provided a polynucleotide comprising a base sequence encoding the light chain of the anti-human GTIR antibody provided herein.

[279] For recombinant production of an ABP, the nucleic acid(s) encoding it may be isolated and inserted into a replicable vector for further cloning (i.e., amplification of the DNA) or expression. In some aspects, the nucleic acid may be produced by homologous recombination, for example as described in U.S. Patent No. 5,204,244, incorporated by reference in its entirety.
[280] In another aspect is provided an expression vector comprising (a) a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof provided herein and/or (b) a polynucleotide comprising a base sequence encoding the light chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof [281] In another aspect is provided an expression vector comprising (a) a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR
antibody provided herein and/or (b) a polynucleotide comprising a base sequence encoding the light chain of the anti-human GITR antibody.
[282] Many different vectors are known in the art. The vector components generally include one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence, for example as described in U.S. Patent No. 5,534,615, incorporated by reference in its entirety.
[283] Illustrative examples of suitable host cells are provided below.
These host cells are not meant to be limiting, and any suitable host cell may be used to produce the ABPs provided herein.
[284] In another aspect is provided a host cell transformed with an expression vector selected from the group consisting of (a) to (d): (a) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof provided herein, and a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody or the antigen-binding fragment thereof; (b) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR antibody or the antigen-biding fragment thereof provided herein and an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody or the antigen-binding fragment thereof, (c) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR
antibody or the antigen-binding fragment thereof provided herein; and (d) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding

56 the light chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof provided herein.
[285] In another aspect is provided host cell transformed with an expression vector selected from the group consisting of (a) to (d): (a) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR antibody provided herein and a polynucleotide comprising a base sequence encoding the light chain of the antibody; (b) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR antibody provided herein and an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain of the antibody; (c) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR antibody provided herein; and (d) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain of the anti-human GITR antibody provided herein.
[286] Suitable host cells include any prokaryotic (e.g., bacterial), lower eukaryotic (e.g., yeast), or higher eukaryotic (e.g., mammalian) cells. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia (E. coil), Enterobacter, , Erwinia, Klebsiella, Proteus, Salmonella (S. typhimurium), Serratia (S. marcescans), Shigella, Bacilli (B.
subtilis and B. licheniformis), Pseudomonas P. aeruginosa), and Streptomyces.
One useful E. coil cloning host is E. coil 294, although other strains such as E. coil B, E. coil X1776, and E. coil W3110 are also suitable.
[287] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are also suitable cloning or expression hosts for GITR ABP -encoding vectors.
Saccharomyces cerevisiae, or common baker's yeast, is a commonly used lower eukaryotic host microorganism. However, a number of other genera, species, and strains are available and useful, such as Schizosaccharomyces pombe, Kluyveromyces (K lactis, K
fragilis, K
bulgaricus K wickeramii, K waltii, K drosophilarum, K thermotolerans, and K
marxianus), Yarrowia, Pichia pastor's, Candida (C. albicans), Trichoderma reesia, Neurospora crassa, Schwanniomyces (S. occidentalis), and filamentous fungi such as, for example Penicillium, Tolypocladium, and Aspergillus (A. nidulans and A.
niger).
[288] Useful mammalian host cells include COS-7 cells, HEK293 cells; baby hamster kidney (BHK) cells; Chinese hamster ovary (CHO); mouse sertoli cells; African green monkey kidney cells (VERO-76), and the like.
[289] The host cells used to produce the GITR ABP of this invention may be cultured in a variety of media. Commercially available media such as, for example, Ham's F10,

57 Minimal Essential Medium (MEM), RPMI-1640, and Dulbecco's Modified Eagle's Medium (DMEM) are suitable for culturing the host cells. In addition, any of the media described in Ham et al., Meth. Enz., 1979, 58:44; Barnes et al., Anal.
Biochem., 1980, 102:255; and U.S. Patent Nos. 4,767,704, 4,657,866, 4,927,762, 4,560,655, and 5,122,469;
or WO 90/03430 and WO 87/00195 may be used. Each of the foregoing references is incorporated by reference in its entirety.
[290] Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics, trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
[291] The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
[292] When using recombinant techniques, the ABP can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the ABP is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration. For example, Carter et al.
(Bio/Technology, 1992, 10:163-167, incorporated by reference in its entirety) describes a procedure for isolating ABPs which are secreted to the periplasmic space of E.
coli.
Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 min. Cell debris can be removed by centrifugation.
[293] In some embodiments, the ABP is produced in a cell-free system. In some aspects, the cell-free system is an in vitro transcription and translation system as described in Yin et al., mAbs, 2012, 4:217-225, incorporated by reference in its entirety. In some aspects, the cell-free system utilizes a cell-free extract from a eukaryotic cell or from a prokaryotic cell. In some aspects, the prokaryotic cell is E. coli. Cell-free expression of the ABP may be useful, for example, where the ABP accumulates in a cell as an insoluble aggregate, or where yields from periplasmic expression are low.
[294] Where the ABP is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellcon ultrafiltration unit. A
protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious

58 contaminants.
[295] The ABP composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being a particularly useful purification technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the ABP. Protein A
can be used to purify ABPs that comprise human yl, y2, or y4 heavy chains (Lindmark et al., Immunol. Meth., 1983, 62:1-13, incorporated by reference in its entirety).
Protein G is useful for all mouse isotypes and for human y3 (Guss et al., EiVIBO 1, 1986, 5:1567-1575, incorporated by reference in its entirety).
[296] The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. Where the ABP comprises a CH3 domain, the BakerBond ABX resin is useful for purification.
[297] Other techniques for protein purification, such as fractionation on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin Sepharose , chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available, and can be applied by one of skill in the art.
[298] Following any preliminary purification step(s), the mixture comprising the ABP of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5 to about 4.5, generally performed at low salt concentrations (e.g., from about 0 to about 0.25 M
salt).
Assays [299] A variety of assays known in the art may be used to identify and characterize the GITR ABPs provided herein.
1.18. Binding, Competition, and Epitope Mapping Assays [300] Specific antigen-binding activity of the ABPs provided herein may be evaluated by any suitable method, including using SPR, BLI, and RIA, as described elsewhere in this disclosure. Additionally, antigen-binding activity may be evaluated by ELISA
assays and Western blot assays.
[301] Assays for measuring competition between two ABPs, or an ABP and another molecule (e.g., GITRL) are described elsewhere in this disclosure and, for example, in Harlow and Lane, Antibodies: A Laboratory Manual ch.14, 1988, Cold Spring Harbor

59 Laboratory, Cold Spring Harbor, N.Y, incorporated by reference in its entirety.
[302] Assays for mapping the epitopes to which the ABPs provided herein bind are described, for example, in Morris "Epitope Mapping Protocols," in Methods in Molecular Biology vol. 66, 1996, Humana Press, Totowa, N.J., incorporated by reference in its entirety. In some embodiments, the epitope is determined by peptide competition. In some embodiments, the epitope is determined by mass spectrometry. In some embodiments, the epitope is determined by crystallography.
1.19. GITR Agonism Assays [303] In some embodiments, the ABPs provided herein are screened to identify or characterize ABPs with agonistic activity against GITR. Any suitable assay may be used to identify or characterize such ABPs. In some aspects, the assay measures the amount of a cytokine secreted by an effector T cell after contacting the effector T cell with an ABP
provided herein. In some aspects, the cytokine is selected from IL-2Ra, IL-2, IL-8, IFNy, and combinations thereof In some aspects, the cytokine is selected from sCD40L, VEGF, TNF-I3, TNF-a, TGF-a, RANTES, PDGF-AB/BB, PDGF-AA, MIP-113, MIP-la, MDC
(CCL22), MCP-3, MCP-1, IP-10, IL-17A, IL-15, IL-13, IL-12 (p70), IL-12 (p40), IL-10, IL-9, IL-8, IL-7, IL-6, IL-5, IL-4, IL-3, IL-2, IL-2Ra, IL-1RA, IL-113, IL-la, IFNy, IFNa2, GRO, GM-CSF, G-CSF, fractalkine, Flt-3 ligand, FGF-2, eotaxin, EGF, and combinations thereof [304] In some embodiments, the effector cells are co-stimulated with an agonist of CD3, to promote the secretion of cytokines by the effector cell. In some aspects, the CD3 agonist is provided at a submaximal level.
[305] In some embodiments, functional assays are used such as the HT1080 or Jurkat cell-based assays described in more detail in Example 2. Additional assays are described in Wyzgol et al., J Immunol 2009; 183:1851-1861, incorporated herein by reference.
[306] In some aspects, such assays may measure the proliferation of an effector T cell after contacting the effector T cell with an ABP provided herein. In some aspects, proliferation of the effector T cell is measured by dilution of a dye (e.g., carboxyfluorescein diacetate succinimidyl ester; CFSE), by tritiated thymidine uptake, by luminescent cell viability assays, or by other assays known in the art.
[307] In some aspects, such assays may measure the differentiation, cytokine production, viability (e.g., survival), proliferation, or suppressive activity of a regulatory T cell after contacting the regulatory T cell with an ABP provided herein.
[308] In some aspects, such assays may measure the cytotoxic activity of an NK cell after contacting the NK cell with an ABP provided herein. In some aspects, the cytotoxic activity of the NK cell is measured using a cytotoxicity assay that quantifies NK-mediated killing of target cells (e.g., a K562 cell line). See Jang et al., Ann. Cl/n.
Lab. Sci., 2012, 42:42-49, incorporated by reference in its entirety.
[309] Additional assays for measuring GITR agonism are described elsewhere in this disclosure, including in the Examples, and known in the art. A skilled person can readily select an appropriate assay for evaluating GITR agonism.
1.20. Assays for Effector Functions [310] Effector function of the ABPs provided herein may be evaluated using a variety of in vitro and in vivo assays known in the art, including those described in Ravetch and Kinet, Annu. Rev. Immunol., 1991, 9:457-492; U.S. Pat. Nos. 5,500,362, 5,821,337;
Hellstrom et al., Proc. Nat'l Acad. Sci. USA, 1986, 83:7059-7063; Hellstrom et al., Proc.
Nat'l Acad.
Sci. USA, 1985, 82:1499-1502; Bruggemann et al., 1 Exp. Med., 1987, 166:1351-1361;
Clynes et al., Proc. Nat'l Acad. Sci. USA, 1998, 95:652-656; WO 2006/029879;
WO
2005/100402; Gazzano-Santoro et al., I Immunol. Methods, 1996, 202:163-171;
Cragg et al., Blood, 2003, 101:1045-1052; Cragg et al. Blood, 2004, 103:2738-2743; and Petkova et al., Intl Immunol., 2006, 18:1759-1769; each of which is incorporated by reference in its entirety.
Pharmaceutical Compositions [311] The ABPs provided herein can be formulated in any appropriate pharmaceutical composition and administered by any suitable route of administration. Suitable routes of administration include, but are not limited to, the intraarterial, intradermal, intramuscular, intraperitoneal, intravenous, nasal, parenteral, pulmonary, and subcutaneous routes.
[312] In another aspect is provided a pharmaceutical composition comprising plural kinds of anti-human GITR antibodies or antigen-binding fragments thereof provided herein. For example, the pharmaceutical composition comprises an antibody or an antigen-binding fragment thereof, which does not undergo posttranslational modification and an antibody or an antigen-binding fragment thereof derived from posttranslational modification of the antibody or the antigen-binding fragment thereof.
[313] In one embodiment, the pharmaceutical composition comprises at least two kinds of anti-human GITR antibodies selected from (1) to (4): (1) an anti-human GITR
antibody comprises two heavy chains consisting of SEQ ID NO: 7 and four light chains consisting of SEQ ID NO: 8; (2) an anti-human GITR antibody comprises two heavy chains consisting of SEQ ID NO: 7, wherein the Q at position 1 is modified to pyroglutamate and four light chains consisting of SEQ ID NO: 8; (3) an anti-human GITR antibody comprises two heavy chains consisting of the amino acid sequence ranging from Q at position 1 to G
at position 686 of SEQ ID NO: 7, and four light chains consisting of SEQ ID
NO: 8; and (4) an anti-human GITR antibody comprises two heavy chains consisting of the amino acid sequence ranging from Q at position 1 to G at position 686 of SEQ ID NO: 7, wherein the Q at position 1 is modified to pyroglutamate and four light chains of SEQ ID
NO: 8.
[314] In one embodiment, the pharmaceutical composition comprises an anti-human GITR
antibody comprises two heavy chains consisting of SEQ ID NO: 7 and four light chains consisting of SEQ ID NO: 8; and an anti-human GITR antibody comprises two heavy chains consisting of the amino acid sequence ranging from Q at position 1 to G
at position 686 of SEQ ID NO: 7, wherein the Q at position 1 is modified to pyroglutamate and four light chains of SEQ ID NO: 8, and a pharmaceutically acceptable excipient.
[315] The pharmaceutical composition may comprise one or more pharmaceutical excipients. Any suitable pharmaceutical excipient may be used, and one of ordinary skill in the art is capable of selecting suitable pharmaceutical excipients.
Accordingly, the pharmaceutical excipients provided below are intended to be illustrative, and not limiting.
Additional pharmaceutical excipients include, for example, those described in the Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009), incorporated by reference in its entirety.
[316] In some embodiments, the pharmaceutical composition comprises an anti-foaming agent. Any suitable anti-foaming agent may be used. In some aspects, the anti-foaming agent is selected from an alcohol, an ether, an oil, a wax, a silicone, a surfactant, and combinations thereof In some aspects, the anti-foaming agent is selected from a mineral oil, a vegetable oil, ethylene bis stearamide, a paraffin wax, an ester wax, a fatty alcohol wax, a long chain fatty alcohol, a fatty acid soap, a fatty acid ester, a silicon glycol, a fluorosilicone, a polyethylene glycol-polypropylene glycol copolymer, polydimethylsiloxane-silicon dioxide, ether, octyl alcohol, capryl alcohol, sorbitan trioleate, ethyl alcohol, 2-ethyl-hexanol, dimethicone, oleyl alcohol, simethicone, and combinations thereof [317] In some embodiments, the pharmaceutical composition comprises a cosolvent.
Illustrative examples of cosolvents include ethanol, poly(ethylene) glycol, butylene glycol, dimethylacetamide, glycerin, propylene glycol, and combinations thereof [318] In some embodiments, the pharmaceutical composition comprises a buffer.
Illustrative examples of buffers include acetate, borate, carbonate, lactate, malate, phosphate, citrate, hydroxide, diethanolamine, monoethanolamine, glycine, methionine, guar gum, monosodium glutamate, and combinations thereof.
[319] In some embodiments, the pharmaceutical composition comprises a carrier or filler.
Illustrative examples of carriers or fillers include lactose, maltodextrin, mannitol, sorbitol, chitosan, stearic acid, xanthan gum, guar gum, and combinations thereof [320] In some embodiments, the pharmaceutical composition comprises a surfactant.
Illustrative examples of surfactants include d-alpha tocopherol, benzalkonium chloride, benzethonium chloride, cetrimide, cetylpyridinium chloride, docusate sodium, glyceryl behenate, glyceryl monooleate, lauric acid, macrogol 15 hydroxystearate, myristyl alcohol, phospholipids, polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polyoxylglycerides, sodium lauryl sulfate, sorbitan esters, vitamin E polyethylene(glycol) succinate, and combinations thereof.
[321] In some embodiments, the pharmaceutical composition comprises an anti-caking agent. Illustrative examples of anti-caking agents include calcium phosphate (tribasic), hydroxymethyl cellulose, hydroxypropyl cellulose, magnesium oxide, and combinations thereof [322] Other excipients that may be used with the pharmaceutical compositions include, for example, albumin, antioxidants, antibacterial agents, antifungal agents, bioabsorbable polymers, chelating agents, controlled release agents, diluents, dispersing agents, dissolution enhancers, emulsifying agents, gelling agents, ointment bases, penetration enhancers, preservatives, solubilizing agents, solvents, stabilizing agents, sugars, and combinations thereof Specific examples of each of these agents are described, for example, in the Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed.
(2009), The Pharmaceutical Press, incorporated by reference in its entirety.
[323] In some embodiments, the pharmaceutical composition comprises a solvent. In some aspects, the solvent is saline solution, such as a sterile isotonic saline solution or dextrose solution. In some aspects, the solvent is water for injection.
[324] In some embodiments, the pharmaceutical compositions are in a particulate form, such as a microparticle or a nanoparticle. Microparticles and nanoparticles may be formed from any suitable material, such as a polymer or a lipid. In some aspects, the microparticles or nanoparticles are micelles, liposomes, or polymersomes.
[325] Further provided herein are anhydrous pharmaceutical compositions and dosage forms comprising an ABP, since water can facilitate the degradation of some ABPs.
[326] Anhydrous pharmaceutical compositions and dosage forms provided herein can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprises a primary or secondary amine can be anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.
[327] An anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions can be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
1.21. Parenteral Dosage Forms [328] In certain embodiments, the ABPs provided herein are formulated as parenteral dosage forms. Parenteral dosage forms can be administered to subjects by various routes including, but not limited to, subcutaneous, intravenous (including infusions and bolus injections), intramuscular, and intraarterial. Because their administration typically bypasses subjects' natural defenses against contaminants, parenteral dosage forms are typically, sterile or capable of being sterilized prior to administration to a subject.
Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry (e.g., lyophilized) products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
[329] Suitable vehicles that can be used to provide parenteral dosage forms are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
[330] Excipients that increase the solubility of one or more of the ABPs disclosed herein can also be incorporated into the parenteral dosage forms.
[331] In some embodiments, the parenteral dosage form is lyophilized.
Exemplary lyophilized formulations are described, for example, in U.S. Pat. Nos.
6,267,958 and 6,171,586; and WO 2006/044908; each of which is incorporated by reference in its entirety.
Dosage and Unit Dosage Forms [332] In human therapeutics, the doctor will determine the posology which he considers most appropriate according to a preventive or curative treatment and according to the age, weight, condition and other factors specific to the subject to be treated.
[333] In certain embodiments, a composition provided herein is a pharmaceutical composition or a single unit dosage form. Pharmaceutical compositions and single unit dosage forms provided herein comprise a prophylactically or therapeutically effective amount of one or more prophylactic or therapeutic ABPs.
[334] The amount of the ABP or composition which will be effective in the prevention or treatment of a disorder or one or more symptoms thereof will vary with the nature and severity of the disease or condition, and the route by which the ABP is administered. The frequency and dosage will also vary according to factors specific for each subject depending on the specific therapy (e.g., therapeutic or prophylactic agents) administered, the severity of the disorder, disease, or condition, the route of administration, as well as age, body, weight, response, and the past medical history of the subject.
Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
[335] In certain embodiments, exemplary doses of a composition include milligram or microgram amounts of the ABP per kilogram of subject or sample weight (e.g., about 100 micrograms per kilogram to about 25 milligrams per kilogram, or about 100 micrograms per kilogram to about 10 milligrams per kilogram). In certain embodiment, the dosage of the ABP provided herein, based on weight of the ABP, administered to prevent, treat, manage, or ameliorate a disorder, or one or more symptoms thereof in a subject is 0.1 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, or 40 mg/kg or more of a subject's body weight.
[336] The dose can be administered according to a suitable schedule, for example, weekly, once every two weeks, once every three weeks, or once every four weeks. In some embodiments, an antibody to be administered once every three or four weeks may be administered at a higher dose than the antibody administered every one or two weeks. In some embodiments, a loading dose is administered that is higher than the maintenance dose administered thereafter. It may be necessary to use dosages of the ABP
outside the ranges disclosed herein in some cases, as will be apparent to those of ordinary skill in the art. Furthermore, it is noted that the clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with subject response.
[337] Different therapeutically effective amounts may be applicable for different diseases and conditions, as will be readily known by those of ordinary skill in the art. Similarly, amounts sufficient to prevent, manage, treat or ameliorate such disorders, but insufficient to cause, or sufficient to reduce, adverse effects associated with the ABPs provided herein are also encompassed by the dosage amounts and dose frequency schedules provided herein. Further, when a subject is administered multiple dosages of a composition provided herein, not all of the dosages need be the same. For example, the dosage administered to the subject may be increased to improve the prophylactic or therapeutic effect of the composition or it may be decreased to reduce one or more side effects that a particular subject is experiencing.
[338] In certain embodiments, treatment or prevention can be initiated with one or more loading doses of an ABP or composition provided herein followed by one or more maintenance doses.
[339] In certain embodiments, a dose of an ABP or composition provided herein can be administered to achieve a steady-state concentration of the ABP in blood or serum of the subject. The steady-state concentration can be determined by measurement according to techniques available to those of skill or can be based on the physical characteristics of the subject such as height, weight and age.
[340] In certain embodiments, administration of the same composition may be repeated and the administrations may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or 6 months.
[341] As discussed in more detail elsewhere in this disclosure, an ABP
provided herein may optionally be administered with one or more additional agents useful to prevent or treat a disease or disorder. The effective amount of such additional agents may depend on the amount of ABP present in the formulation, the type of disorder or treatment, and the other factors known in the art or described herein.
Therapeutic Applications [342] For therapeutic applications, the ABPs of the invention are administered to a mammal, generally a human, in a pharmaceutically acceptable dosage form such as those known in the art and those discussed above. For example, the ABPs of the invention may be administered to a human intravenously as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intra-cerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, or intratumoral routes. The ABPs also are suitably administered by peritumoral, intralesional, or perilesional routes, to exert local as well as systemic therapeutic effects. The intraperitoneal route may be particularly useful, for example, in the treatment of ovarian tumors.
[343] The ABPs provided herein may be useful for the treatment of any disease or condition involving GITR. In some embodiments, the disease or condition is a disease or condition that can benefit from treatment with an anti-GITR ABP. In some embodiments, the disease or condition is a tumor. In some embodiments, the disease or condition is a cell proliferative disorder. In some embodiments, the disease or condition is a cancer.
[344] In some embodiments, the ABPs provided herein are provided for use as a medicament. In some embodiments, the ABPs provided herein are provided for use in the manufacture or preparation of a medicament. In some embodiments, the medicament is for the treatment of a disease or condition that can benefit from an anti-GITR
ABP. In some embodiments, the disease or condition is a tumor. In some embodiments, the disease or condition is a cell proliferative disorder. In some embodiments, the disease or condition is a cancer.
[345] Any suitable cancer may be treated with the ABPs provided herein.
Illustrative suitable cancers include, for example, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, anal cancer, appendix cancer, astrocytoma, basal cell carcinoma, brain tumor, bile duct cancer, bladder cancer, bone cancer, breast cancer, bronchial tumor, carcinoma of unknown primary origin, cardiac tumor, cervical cancer, chordoma, colon cancer, colorectal cancer, craniopharyngioma, ductal carcinoma, embryonal tumor, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, fibrous histiocytoma, Ewing sarcoma, eye cancer, germ cell tumor, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gestational trophoblastic disease, glioma, head and neck cancer, hepatocellular cancer, histiocytosis, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumor, Kaposi sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, lip and oral cavity cancer, liver cancer, lobular carcinoma in situ, lung cancer, macroglobulinemia, malignant fibrous histiocytoma, melanoma, Merkel cell carcinoma, mesothelioma, metastatic squamous neck cancer with occult primary, midline tract carcinoma involving NUT gene, mouth cancer, multiple endocrine neoplasia syndrome, multiple myeloma, mycosis fungoides, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, nasal cavity and par nasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-small cell lung cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytomas, pituitary tumor, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell cancer, renal pelvis and ureter cancer, retinoblastoma, rhabdoid tumor, salivary gland cancer, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, spinal cord tumor, stomach cancer, T-cell lymphoma, teratoid tumor, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer, vulvar cancer, and Wilms tumor.
[346] In some embodiments, provided herein is a method of treating a disease or condition in a subject in need thereof by administering an effective amount of an ABP
provided herein to the subject. In some aspects, the disease or condition is a cancer.
[347] In some embodiments, provided herein is a method of multimerizing GITR in a target cell of a subject in need thereof by administering an effective amount of an ABP provided herein to the subject.
[348] In some embodiments, provided herein is a method of agonizing GITR in a target cell of a subject in need thereof by administering an effective amount of an ABP
provided herein to the subject. In some aspects, agonism of GITR by an ABP provided herein results in increased secretion of IL-2Ra, IL-2, IL-8, and/or IFNy by a target cell.
[349] In some embodiments, provided herein is a method of modulating NF-KB
activity in a target cell of a subject in need thereof by administering an effective amount of an ABP
provided herein to the subject.
[350] In some embodiments, provided herein is a method of modulating degradation of IKB
in a target cell of a subject in need thereof by administering an effective amount of an ABP
provided herein to the subject.
[351] In some embodiments, provided herein is a method of activating the MAPK
pathway in a target cell of a subject in need thereof by administering an effective amount of an ABP
provided herein to the subject. In some aspects, the components of the MAPK
pathway that are activated by an ABP provided herein include one or more of p38, JNK, and ERK.
[352] In some embodiments, provided herein is a method of increasing the proliferation, survival, and/or function of an effector T cell in a subject in need thereof by administering an effective amount of an ABP provided herein to the subject. In some aspects the effector T cell is a CD4+ effector T cell. In some aspects, the effector T cell is a CD8+ effector T
cell.
[353] In some embodiments, provided herein is a method of abrogating suppression of an effector T cell by a regulatory T cell in a subject in need thereof by administering an effective amount of an ABP provided herein to the subject. In some aspects, the regulatory T cell is a CD4+CD25+Foxp3+ regulatory T cell. In some aspects, the regulatory T cell is a CD8+CD25+ regulatory T cell.
[354] In some embodiments, provided herein is a method of altering the frequency of occurrence or distribution or regulatory T cells in a subject in need thereof by administering an effective amount of an ABP provided herein to the subject. In some aspects, the frequency of regulatory T cells is decreased. In some aspects, the frequency of regulatory T cells is reduced in a particular tissue. In some aspects, the intratumoral accumulation of regulatory T cells is decreased, resulting in a more favorable ratio of effector T cells to regulatory T cells, and enhancing CD8+ T cell activity.
[355] In some embodiments, provided herein is a method of increasing the activity of a natural killer (NK) cell in a subject in need thereof by administering an effective amount of an ABP provided herein to the subject.
[356] In some embodiments, provided herein is a method of increasing the activity of a dendritic cell in a subject in need thereof by administering an effective amount of an ABP
provided herein to the subject.
[357] In some embodiments, provided herein is a method of increasing the activity of a B
cell in a subject in need thereof by administering an effective amount of an ABP provided herein to the subject.
[358] In some embodiments, provided herein is a method of enhancing an immune response in a subject in need thereof by administering an effective amount of an ABP
provided herein to the subject.
[359] In some embodiments, provided herein is a method delaying the onset of a tumor in a subject in need thereof by administering an effective amount of an ABP
provided herein to the subject.
[360] In some embodiments, provided herein is a method of delaying the onset of a cancer in a subject in need thereof by administering an effective amount of an ABP
provided herein to the subject.
[361] In some embodiments, provided herein is a method of reducing the size of a tumor in a subject in need thereof by administering an effective amount of an ABP
provided herein to the subject.
[362] In some embodiments, provided herein is a method of reducing the number of metastases in a subject in need thereof by administering an effective amount of an ABP
provided herein to the subject.
Combination Therapies [363] In some embodiments, an ABP provided herein is administered with at least one additional therapeutic agent. Any suitable additional therapeutic agent may be administered with an ABP provided herein. In some aspects, the additional therapeutic agent is selected from radiation, a cytotoxic agent, a chemotherapeutic agent, a cytostatic agent, an anti-hormonal agent, an EGFR inhibitor, an immunostimulatory agent, an anti-angiogenic agent, and combinations thereof [364] In some embodiments, the additional therapeutic agent comprises an immunostimulatory agent.
[365] In some embodiments, the immunostimulatory agent is an agent that blocks signaling of an inhibitory receptor of an immune cell, or a ligand thereof In some aspects, the inhibitory receptor or ligand is selected from CTLA-4, PD-1, PD-L1, NRP-1, LAG-3, Tim3, TIGIT, neuritin, BTLA, KIR, and combinations thereof In some aspects, the agent is selected from pembrolizumab (anti-PD-1), nivolumab (anti-PD-1), atezolizumab (anti-PD-L1), ipilimumab (anti-CTLA-4), and combinations thereof [366] In some embodiments, the immunostimulatory agent is an agonist of a co-stimulatory receptor of an immune cell. In some aspects, the co-stimulatory receptor is selected from 0X40, ICOS, CD27, CD28, 4-1BB, or CD40. In some embodiments, the agonist is an antibody.
[367] In some embodiments, the immunostimulatory agent is a cytokine. In some aspects, the cytokine is selected from IL-2, IL-5, IL-7, IL-12, IL-15, IL-21, and combinations thereof [368] In some embodiments, the immunostimulatory agent is an oncolytic virus. In some aspects, the oncolytic virus is selected from a herpes simplex virus, a vesicular stomatitis virus, an adenovirus, a Newcastle disease virus, a vaccinia virus, and a maraba virus.
[369] In some embodiments, the immunostimulatory agent is a T cell with a chimeric antigen receptor (CAR-T cell). In some embodiments, the immunostimulatory agent is a bi- or multi-specific T cell directed antibody. In some embodiments, the immunostimulatory agent is an anti-TGF-B antibody. In some embodiments, the immunostimulatory agent is a TGF-B trap.
[370] In some embodiments, the additional therapeutic agent is a vaccine to a tumor antigen. Any suitable antigen may be targeted by the vaccine, provided that it is present in a tumor treated by the methods provided herein. In some aspects, the tumor antigen is a tumor antigen that is overexpressed in comparison its expression levels in normal tissue. In some aspects, the tumor antigen is selected from cancer testis antigen, differentiation antigen, NY-ESO-1, MAGE-AL MART, and combinations thereof [371] Further examples of additional therapeutic agents include a taxane (e.g., paclitaxel or docetaxel); a platinum agent (e.g., carboplatin, oxaliplatin, and/or cisplatin); a topoisomerase inhibitor (e.g., irinotecan, topotecan, etoposide, and/or mitoxantrone);
folinic acid (e.g., leucovorin); or a nucleoside metabolic inhibitor (e.g., fluorouracil, capecitabine, and/or gemcitabine). In some embodiments, the additional therapeutic agent is folinic acid, 5-fluorouracil, and/or oxaliplatin. In some embodiments, the additional therapeutic agent is 5-fluorouracil and irinotecan. In some embodiments, the additional therapeutic agent is a taxane and a platinum agent. In some embodiments, the additional therapeutic agent is paclitaxel and carboplatin. In some embodiments, the additional therapeutic agent is pemetrexate. In some embodiments, the additional therapeutic agent is a targeted therapeutic such as an EGFR, RAF or MEK-targeted agent.
[372] The additional therapeutic agent may be administered by any suitable means. In some embodiments, an ABP provided herein and the additional therapeutic agent are included in the same pharmaceutical composition. In some embodiments, an ABP provided herein and the additional therapeutic agent are included in different pharmaceutical compositions.
[373] In embodiments where an ABP provided herein and the additional therapeutic agent are included in different pharmaceutical compositions, administration of the ABP can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent. In some aspects, administration of an ABP provided herein and the additional therapeutic agent occur within about one month of each other. In some aspects, administration of an ABP provided herein and the additional therapeutic agent occur within about one week of each other. In some aspects, administration of an ABP
provided herein and the additional therapeutic agent occur within about one day of each other. In some aspects, administration of an ABP provided herein and the additional therapeutic agent occur within about twelve hours of each other. In some aspects, administration of an ABP provided herein and the additional therapeutic agent occur within about one hour of each other.
Diagnostic Methods [374] Also provided are methods for detecting the presence of GITR on cells from a subject. Such methods may be used, for example, to predict and evaluate responsiveness to treatment with an ABP provided herein.
[375] In some embodiments, a blood sample is obtained from a subject and the fraction of cells expressing GITR is determined. In some aspects, the relative amount of GITR
expressed by such cells is determined. The fraction of cells expressing GITR
and the relative amount of GITR expressed by such cells can be determined by any suitable method. In some embodiments, flow cytometry is used to make such measurements.
In some embodiments, fluorescence assisted cell sorting (FACS) is used to make such measurement. See Li et al., I Autoimmunity, 2003, 21:83-92 for methods of evaluating expression of GITR in peripheral blood.
Kits [376] Also provided are kits comprising the ABPs provided herein. The kits may be used for the treatment, prevention, and/or diagnosis of a disease or disorder, as described herein.
[377] In some embodiments, the kit comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, and IV solution bags. The containers may be formed from a variety of materials, such as glass or plastic. The container holds a composition that is by itself, or when combined with another composition, effective for treating, preventing and/or diagnosing a disease or disorder. The container may have a sterile access port. For example, if the container is an intravenous solution bag or a vial, it may have a port that can be pierced by a needle. At least one active agent in the composition is an ABP provided herein. The label or package insert indicates that the composition is used for treating the selected condition.
[378] In some embodiments, the kit comprises (a) a first container with a first composition contained therein, wherein the first composition comprises an ABP provided herein; and (b) a second container with a second composition contained therein, wherein the second composition comprises a further therapeutic agent. The kit in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.
[379] Alternatively, or additionally, the kit may further comprise a second (or third) container comprising a pharmaceutically-acceptable excipient. In some aspects, the excipient is a buffer. The kit may further include other materials desirable from a commercial and user standpoint, including filters, needles, and syringes.
Other Illustrative Embodiments [380] The embodiments provided below are non-limiting and provided by way of illustration of certain embodiments and aspects of the invention, in addition to those described throughout this disclosure.
[381] Embodiment 1: An ABP that binds specifically to a human GITR and/or a human GITR complex and is capable of at least one of the following: a) cross-competes with GITRL for binding to GITR; b) can be internalized into a human cell; c) inhibits suppression of an effector T cell; d) inhibits regulatory T cell inhibition of effector T cells;
e) decreases the number of regulatory T cells in tissues or in circulation; 0 activates an effector T cell; g) associates GITR into a GITR complex; h) modulates an activity of a human GITR and/or a GITR complex.
[382] Embodiment 2: The ABP of embodiment 1, wherein the ABP has one or more of the following characteristics: a) is a monoclonal antibody; b) is a human antibody, a humanized antibody, or a chimeric antibody; c) is a multispecific or multivalent antibody, e.g., a tetravalent antibody; d) comprises a at least one Fab at the N-terminus or the C-terminus; e) is of the IgGl, IgG2, IgG3, or the IgG4 type; f) is an antigen-binding antibody fragment; g) is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, or an Fv fragment; h) is a bispecific antibody, a diabody, a single chain antibody, a single domain antibody, a VH
domain antibody, or a nanobody.
[383] Embodiment 3: The ABP of embodiment 1, wherein the ABP has one or more of the following characteristics: a) binds to a human GITR polypeptide of SEQ ID NOs:
1-2 or a variant thereof, or as otherwise provided herein with a KD of less than about 20 nM; or b) binds to a cyno GITR polypeptide of SEQ ID NO: 3 or a variant thereof, or as otherwise provided herein, with a KD of less than about 200 nM.

[384] Embodiment 4: The ABP of embodiment 1, comprising a first antigen-binding domain that specifically binds to a first antibody recognition domain on human GITR and a second antigen-binding domain that specifically binds to a second antibody recognition domain on human GITR, wherein the first antibody recognition domain and the second antibody recognition domain are not identical.
[385] Embodiment 5: The ABP of embodiment 4, comprising a bispecific binding protein in a format selected from the group consisting of a DVD-IgTM molecule, a BiTe molecule, a DART molecule, molecule, a DuoBody molecule, a scFv/diabody-IgG molecule, a cross-over multispecific molecule, a 2-in-1 bispecific molecule, a knob-in-hole multispecific molecule, a Fab+IgG molecule, a CovX-Body molecule, an affibody molecule, a scFv/diabody-CH2/CH3 bispecific molecule, a IgG-non-Ig protein scaffold-based multispecific molecule, a Fynomer molecule, a FcabTM molecule, a TandAbO, a ZybodyTM, and a scFV/diabody linked to normal human protein like human serum albumin-bispecific molecule.
[386] Embodiment 6: The ABP of embodiment 4, wherein the first antigen-binding domain has a KD of less than about 20 nM and is capable of agonizing human GITR, and wherein the second antigen-binding domain has a KD of less than about 100 nM.
[387] Embodiment 7: An ABP that competes or is capable of competing for binding to human GITR with a reference ABP, wherein the reference ABP is the ABP of embodiment 1.
[388] Embodiment 8: The ABP of embodiment 7, wherein the ABP and the reference antibody cross-compete or are capable of cross-competing for binding to a human GITR.
[389] Embodiment 9: The ABP of embodiment 1, comprising a heavy chain constant region comprising a human heavy chain constant region or fragment or a variant thereof, wherein the constant region variant comprises up to 20 modified amino acid substitutions, wherein from 0 to up to 20 modified amino acid substitutions are conservative amino acid substitutions.
[390] Embodiment 10: The ABP of embodiment 1, that competes or is capable of competing for binding to human GITRL with a GITR protein.
[391] Embodiment 11: The ABP of embodiment 1, that is capable of activating GITR
signaling in a ligand-independent manner.
[392] Embodiment 12: The ABP of embodiment 1, that is capable of enhancing ligand-dependent binding of GITR and GITRL.
[393] Embodiment 13: A pharmaceutical composition comprising an ABP of any one of embodiments 1-12 in a pharmaceutically acceptable carrier.
[394] Embodiment 14: A bispecific antibody comprising a first antigen-binding domain that specifically binds to a first antibody recognition domain on human GITR
and a second antigen-binding domain that specifically binds to a second antibody recognition domain on human GITR, wherein the first antibody recognition domain and the second antibody recognition domain are not identical.
[395] Embodiment 15: The bispecific antibody of embodiment 14, wherein the first antibody recognition domain and the second antibody recognition domain are present in the extracellular domain of human GITR.
[396] Embodiment 16: The bispecific antibody of embodiment 14, wherein the first antibody recognition domain and the second antibody recognition domain are capable of associating at least two human GITR proteins into a functional complex.
[397] Embodiment 17: A complexing ABP comprising a first antigen-binding domain that specifically binds to a first antibody recognition domain on a human GITR
protein or a human GITR complex comprising at least two GITR proteins, and is capable of at least one of the following: a) cross-competes with GITRL for binding to GITR; b) can be internalized into a human cell; c) inhibits suppression of an effector T cell;
d) inhibits regulatory T cell inhibition of effector T cells; e) decreases the number of regulatory T
cells in tissues or in circulation; f) activates an effector T cell; g) associates GITR into a GITR complex; h) modulates an activity of a human GITR and/or a GITR complex.
[398] Embodiment 18: An isolated nucleic acid encoding an ABP according to any one of embodiments 1 to 12 or a bispecific antibody according to any one of embodiments 14-16 or the complexing ABP of embodiment 17.
[399] Embodiment 19: An expression vector comprising the nucleic acid according to embodiment 18.
[400] Embodiment 20: A prokaryotic or eukaryotic host cell comprising a vector of embodiment 19.
[401] Embodiment 21: A method for the production of a recombinant protein comprising the steps of expressing a nucleic acid according to embodiment 18 in a prokaryotic or eukaryotic host cell and recovering said protein from said cell or the cell culture supernatant.
[402] Embodiment 22: A method for treatment of a subject suffering from cancer or from an inflammatory disease, comprising the step of administering to the subject a pharmaceutical composition comprising an ABP according to any one of embodiments 1 to 12 or a bispecific antibody according to any one of embodiments 14-16 or the complexing ABP of embodiment 17.
[403] Embodiment 23: A method for inducing or enhancing an immune response in a subject, comprising the step of administering to the subject a pharmaceutical composition comprising an ABP according to any one of embodiments 1 to 12 or a bispecific antibody according to any one of embodiments 14-16 or the complexing ABP of embodiment 17, wherein the immune response is generated against a tumor antigen.
[404] Embodiment 24: The method of embodiment 23, wherein the ABP, bispecific antibody or the complexing ABP is administered in an amount sufficient to achieve one or more of the following in the subject: a) reduce regulatory T cells suppression of activity of effector T cells; b) decrease levels of regulatory T cells; c) activation of effector T cells; d) induce or enhance effector T cell proliferation; e) inhibit tumor growth; and f) induce tumor regression.
[405] Embodiment 25: The method of embodiment 22, wherein the cancer is a solid cancer.
[406] Embodiment 26: The method of embodiment 22, wherein the cancer is a hematological cancer.
[407] Embodiment 27: The method of any one of embodiments 22-26, wherein the method further comprises one or more of the following a) administering chemotherapy;
b) administering radiation therapy; or c) administering one or more additional therapeutic agents.
[408] Embodiment 28: The method of embodiment 27, wherein the additional therapeutic agent comprises an immunostimulatory agent.
[409] Embodiment 29: The method of embodiment 27, wherein the immunostimulatory agent comprises an antagonist to an inhibitory receptor of an immune cell.
[410] Embodiment 30: The method of embodiment 29, wherein the inhibitory receptor comprises CTLA-4, PD-1, PD-L1, LAG-3, Tim3, TIGIT, neuritin, BTLA or KIR, or a functional fragment thereof [411] Embodiment 31: The method of embodiment 27, wherein the immunostimulatory agent comprises an agonist of co-stimulatory receptor of an immune cell, or a functional fragment thereof [412] Embodiment 32: The method of embodiment 31, wherein the co-stimulatory receptor comprises 0X40, ICOS, CD27, CD28, 4-1BB, or CD40.
[413] Embodiment 33: The method of embodiment 27, wherein the immunostimulatory agent comprises a cytokine.
[414] Embodiment 34: The method of embodiment 27, wherein the cytokine comprises IL-2, IL-5, IL-7, IL-12, IL-15 or IL-21.
[415] Embodiment 35: The method of embodiment 27, wherein the immunostimulatory agent comprises an oncolytic virus.
[416] Embodiment 36: The method of embodiment 35, wherein the oncolytic virus comprises a Herpes simplex virus, a Vesicular stomatitis virus, an adenovirus, a Newcastle disease virus, a vaccinia virus, or a maraba virus.
[417] Embodiment 37: The method of embodiment 27, wherein the immunostimulatory agent comprises a chimeric antigen engineered T cell.
[418] Embodiment 38: The method of embodiment 27, wherein the immunostimulatory agent comprises a bi- or multi-specific T cell directed antibody.
[419] Embodiment 39: The method of embodiment 27, wherein the additional therapeutic agent comprises an anti-TGF-B antibody or a TGF-B receptor trap.
[420] Embodiment 40: The method of any one of embodiments 22-39, wherein administration of the pharmaceutical composition results in induction or enhancement of proliferation of a T-effector cell, or modulation of I-kappaB and/or NF-KB in the T cell, or modulation of GITR activity in the T cell, or T cell receptor induced signaling in a T-effector cell, or a combination thereof [421] Embodiment 41: A method of screening for test compounds comprising an ABP
according to any one of embodiments 1 to 12 that are capable of inhibiting the interaction of GITRL with GITR complex comprising the steps of: contacting a sample containing GITRL and GITR complex with the compound; and determining whether the interaction of GITRL with GITR complex in the sample is decreased relative to the interaction of GITRL
with GITR complex in a sample not contacted with the compound, whereby a decrease in the interaction of GITRL with GITR in the sample contacted with the compound identifies the compound as one that inhibits the interaction of GITRL with GITR complex.
EXAMPLES
[422] The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided herein.
Example 1: Selection of GITR Antigen-Binding Proteins Materials and methods Antigens were biotinylated using the EZ-Link Sulth-NHS-Biotinylation Kit from Pierce.
Goat F(ab):2 anti-human kappa-FITC (LC-FITC), ExtrA.vidi.n. -PE (EA-PE) and Streptavidin-AF633 (SA.-633) were obtained from Southern Biotech, Sigma, and Molecular Probes, respectively.
Streptavidin MicroBeads and MACS LC separation columns were purchased from Miltenyi Biotec.
Goat anti-human IgG-PE (Human-PE) was obtained from Southern Biotech.
Naïve Discovery Eight naïve human synthetic yeast libraries each of ¨109 diversity were propagated as previously described (see, e.g., Y. Xu et al, Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool.
PEDS 26.10, 663-70 (2013); W02009036379; W02010105256; and W02012009568.) For the first two rounds of selection, a magnetic bead sorting technique utilizing the Miltenyi MACS system was performed, as previously described (see, e.g., Siegel et al, High efficiency recovery and epitope-specific sorting of an scFv yeast display library." J Immunol Methods 286(1-2), 141-153 (2004)) Briefly, yeast cells (-1010 cells/library) were incubated with 5 ml of 10 nM
biotinylated Fe fusion antigen for 30 min at 30 C in wash buffer (phosphate-buffered saline (PBS)/0.1% bovine serum albumin (BSA)). After washing once with 40 ml ice-cold wash buffer, the cell pellet was resuspended in 20 mL wash buffer, and Streptavidin MicroBeadsq.1) (500 ill) were added to the yeast and incubated for 15 min at 4 C. Next, the yeast were pelleted, resuspended in 20 mL wash buffer, and loaded onto a Miltenyi LS column. After the 20 mL were loaded, the column was washed 3 times with 3 ml wash buffer. The column was then removed from the magnetic field, and the yeast were eluted with 5 mL
of growth media and then grown overnight. The following rounds of selection were performed using flow cytometry. Approximately 2x107 yeast were pelleted, washed three times with wash buffer, and incubated at 30 C with either decreasing concentrations of biotinylated Fe fusion antigen (10 to 1 nM) under equilibrium conditions, 10 nM biotinylated Fe fusion antigens of different species in order to obtain species cross-reactivity, or with a poly-specificity depletion reagent (PSR) to remove non-specific antibodies from the selection. For the PSR depletion, the libraries were incubated with a 1:10 dilution of biotinylated PSR reagent as previously described (see, e.g., Y. Xu et al, Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. PEDS 26.10, 663-70 (2013)) Yeast were then washed twice with wash buffer and stained with LC-FITC (diluted 1:100) and either SA-633 (diluted 1:500) or EAPE (diluted 1:50) secondary reagents for 15 min at 4 C. After washing twice with wash buffer, the cell pellets were resuspended in 0.3 mL wash buffer and transferred to strainer-capped sort tubes.
Sorting was performed using a FACS ARIA sorter (BD Biosciences) and sort gates were determined to select for antibodies with desired characteristics. Selection rounds were repeated until a population with all of the desired characteristics was obtained. After the final round of sorting, yeast were plated and individual colonies were picked for characterization.
Antibody Optimization Optimization of antibodies was performed via a light chain diversification protocol, and then by introducing diversities into the heavy chain and light chain variable regions as described below. A
combination of some of these approaches was used for each antibody.
Light chain batch diversification protocol: Heavy chain plasmids from a naive selection output were extracted from the yeast via smash and grab, propagated in and subsequently purified from E.coli, and transformed into a light chain library with a diversity of 5 x 106. Selections were perfonned with one round of MACS and four rounds of FACS employing the same conditions as the naive discovery.
Light chain diversification: The heavy chain variable region of a single antibody was amplified via PCR and transfonned, along with the heavy chain expression vector, into a light chain library with a diversity of 5 x 106. Selections were performed with one round of MACS and three rounds of FACS employing the same conditions as the naïve discovery. For each FACS round the libraries were looked at for PSR binding, species cross-reactivity, and affinity pressure, and sorting was performed in order to obtain a population with the desired characteristics.
CDRH1 and CDRH2 selection: The CDRH3 of a single antibody was recombined into a premade library with CDRH1 and CDRH2 variants of a diversity of 1 x 108 and selections were performed with one round of MACS and four rounds of FACS as described in the naive discovery.
For each FACS round, the libraries were looked at for PSR binding, species cross-reactivity, and affinity pressure, and sorting was performed in order to obtain a population with the desired characteristics. For these selections affinity pressures were applied by preincubating the biotinylated antigen with parental IgG for 30 minutes and then applying that precomplexed mixture to the yeast library for a length of time which would allow the selection to reach an equilibrium. The higher affinity antibodies were then able to be sorted.
CDRH3NH Mutant selection: Oligonucleotides (oligos) were ordered from IDT
which comprised the CDRH3 as well as a flanking region on either side of the CDRH3.
Amino acid positions in the CDRH3-encoding portion of the oligo were variegated by NNK
diversity. The CDRH3 oligos were double-stranded using primers which annealed to the flanking region of the CDRH3. The remaining part of the heavy chain variable region was mutagenized via error prone PCR
in order to introduce additional diversity in non-CDR3 regions of the heavy chain. The library was then created by transforming the double stranded CDRH3 oligo, the mutagenized remainder of the heavy chain variable region, and the heavy chain expression vector into yeast already containing the light chain plasmid of the parent. Selections were performed similar to previous cycles using FACS
sorting for four rounds. For each FACS round, the libraries were looked at for PSR binding, species cross-reactivity, and affinity pressure, and sorting was performed in order to obtain a population with the desired characteristics. Affinity pressures for these selections were performed as described above in the CDRH1 and CDRH2 selection.
CDRL1, CDRL2, and CDRL3 selection: Oligos were ordered from IDT which comprised the CDRL3 as well as a flanking region on either side of the CDRL3. Amino acid positions in the CDRL3-encoding portion of the oligo were variegated by NNK diversity. The CDRL3 oligos were double-stranded using primers which annealed to the flanking region of the CDRL3. These double-stranded CDRL3 oligos were then recombined into a premade library with CDRL1 and CDRL2 variants of a diversity of 3 x 105 and selections were performed with one round of MACS and four rounds of FACS as described in the naïve discovery. For each FACS round the libraries were looked at for PSR binding, species cross-reactivity, and affinity pressure, and sorting was performed in order to obtain a population with the desired characteristics. Affinity pressures for these selections were performed as described above in the CDRH1 and CDRH2 selection.
Antibody production and purification Yeast clones were grown to saturation and then induced for 48 h at 30 C with shaking. After induction, yeast cells were pelleted and the supernatants were harvested for purification. igGs were purified using a Protein A column and eluted with acetic acid, pH 2Ø Fab fragments were generated by papain digestion and purified over KappaSelect (GE Healthcare LifeSciences).
ForteBio KD measurements ForteBio affinity measurements were performed on an Octet RED384 generally as previously described (see, e.g., Estep et al, High throughput solution-based measurement of antibody-antigen affinity and epitope binning. Alabs 5(2), 270-278 (2013)). Briefly.
ForteBio affinity measurements were performed by loading IgGs on-line onto AHQ sensors. Sensors were equilibrated off-line in assay buffer for 30 min and then monitored on-line for 60 seconds for baseline establishment. Sensors with loaded IgGs were exposed to 100 nM antigen for 3 minutes, and afterwards were transferred to assay buffer for 3 min for off-rate measurement. For monovalent affinity assessment Fabs were used instead of IgGs. For this assessment, the unbiotinylated Fc fusion antigen was loaded on-line onto the AHQ sensors. Sensors were equilibrated off-line in assay buffer for 30 min and then monitored on-line for 60 seconds for baseline establishment. Sensors with loaded antigen were exposed to 200 nM Fab for 3 minutes, and afterwards they were transferred to assay buffer for 3 min for off-rate measurement. All kinetics were analyzed using the 1:1 binding model.
ForteBio Epitope Binning/Ligand Blocking Epitope binning/ligand blocking was performed using a standard sandwich format cross-blocking assay. Control anti-target IgG was loaded onto AHQ sensors and unoccupied Fc-binding sites on the sensor were blocked with an irrelevant human IgG1 antibody. The sensors were then exposed to 100 nM target antigen followed by a second anti-target antibody or ligand. Additional binding by the second antibody or ligand after antigen association indicates an unoccupied epitope (non-competitor), while no binding indicates epitope blocking (competitor or ligand blocking).
Cell Binding Analysis Approximately 100,000 cells overexpressing the antigen were washed with wash buffer and incubated with 100 [11 100 nM IgG for 5 minutes at room temperature. Cells were then washed twice with wash buffer and incubated with 100u1 of 1:100 Human-PE for 15 minutes on ice. Cells were then washed twice with wash buffer and analyzed on a FACS Canto II analyzer (BD Biosciences.) Size Exclusion Chromatography A TSKgel0 SuperSW mAb HTP column (22855) was used for fast SEC analysis of mammalian produced mAbs at 0.4 mL/min with a cycle time of 6 min/run. 200 mM
Sodium Phosphate and 250 mM Sodium Chloride was used as the mobile phase.
Dynamic Scanning Fluorime try [IL of 20x Sypro Orange is added to 20 uL of 0.2-1mg/mL mAb or Fab solution.
An RT-PCR instrument (BioRad CFX96 RT PCR) is used to ramp the sample plate temperature from 40 to 95 C at 0.5C increment, with 2min equilibrate at each temperature. The negative of first derivative for the raw data is used to extract Tm.
Example 2: Characteristics of TM Format Antibodies Affinity of IgG1 and TM format ABPs for GITR of several species [423] The GITR ABPs were evaluated for their ability to bind recombinant hGITR
(SEQ ID
NO: 1), hGITR-T43R (SEQ ID NO: 2), cGITR (SEQ ID NO: 3), and mGITR (SEQ ID
NO: 4) using a FORTEBIO OCTET instrument. The assay was performed at 30 C, using 1 x Kinetics Buffer (ForteBio, Inc.) as an assay buffer. Anti-human IgG Fc Capture (AHC) biosensors (ForteBio, Inc.) were used to capture GITR ABPs onto the sensors.
The sensors were equilibrated in assay buffer for 600 seconds before the assay. Baseline was established by dipping the sensors into lx assay buffer for 60 seconds. ABPs were loaded onto the sensors by dipping the sensors into ABP solution for 300 seconds.
Baseline was established by dipping the sensors into lx assay buffer for 120 seconds. The sensors were quenched by dipping into 200 ug/m1 human IgG for 300 seconds to prevent non-specific binding of GITR-Fc antigens to the sensor. Baseline was established by dipping the sensors into lx assay buffer for 60 seconds. Next, association was monitored for 300 seconds in 25 nM of recombinant antigens, and dissociation was followed for seconds in buffer alone. KD was determined using the kinetic function of the FORTEBIO
Analysis Software using a 1:1 binding model. Results are shown in Table 5.
Table 5: ABP KD by OCTET using single concentration kinetics KD by Octet, KD by Octet, KD by Octet, KD by Octet, single- single- single-single-concentration concentration concentration ABP Format concentration of human of cyno of mouse of human GITR T43R- GITR-Fc GITR-Fc GITR-Fc, (nM) Fc (nM) (nM) (nM) 1 N-terminal 0.77 0.94 0.88 No binding Fab TM
2 N-terminal 0.55 0.73 0.79 No binding Fab TM
3 N-terminal 0.58 0.71 1.1 No binding Fab TM
4 N-terminal 0.5 0.72 1.19 No binding Fab TM

N-terminal 0.57 0.7 1.21 No binding Fab TM
6 N-terminal 0.63 0.71 1.09 No binding Fab TM
7 N-terminal 0.76 1.1 1.9 No binding Fab TM
8 N-terminal 0.73 1.02 0.94 No binding Fab TM
[424] Other GITR ABPs were evaluated for their ability to bind recombinant hGITR and cGITR (SEQ ID NO: 3) using a FORTEBIO Octet RED384 instrument generally as previously described (see, e.g., Estep et al, High throughput solution-based measurement of antibody-antigen affinity and epitope binning. Mabs 5(2), 270-278 (2013)).
AHQ
biosensors (ForteBio, Inc.) were used to capture GITR ABPs onto the sensors.
The sensors were quenched by dipping into an unrelated human IgG1 antibody to prevent non-specific binding of GITR-Fc antigens to the sensor. The sensors were equilibrated in assay buffer for 30 minutes. Baseline was established by dipping the sensors into assay buffer for 60 seconds. Association was monitored for 180 seconds in 100 nM of recombinant antigens, and dissociation was followed for 180 seconds in buffer alone. KD was determined using the kinetic function of the FORTEBIO Analysis Software using a 1:1 binding model.
Results are shown in Table 6.
Table 6: ABP KD by OCTET using single concentration kinetics MMMMMMRpql KD by Octet, single- illi]!iosIQoggiomglog ABP Format concentration of human 111111rwompg410111=$;0 GITR-Fc, (nM) 35 (non-TM ABP
IgG1 N297A 1.5 5.7 corresponding to ABP1) 36 (non-TM ABP
IgG1 N297A 1.4 7.5 corresponding to ABP2) 37 (non-TM ABP
IgG1 N297A 0.7 8.1 corresponding to ABP3) 38 (non-TM ABP
IgG1 N297A 0.6 11.1 corresponding to ABP4/5) 39 (non-TM ABP
IgG1 N297A 0.7 8.2 corresponding to ABP6) 40 (non-TM ABP
IgG1 N297A 2.2 4.9 corresponding to ABP7) 41 (non-TM ABP
IgG1 N297A 2.3 6.9 corresponding to ABP8) 19 N terminal Fab TM 5.2 12.6 20 N terminal Fab TM 4.4 5.2 21 N terminal Fab TM 4.2 5.5 22 N terminal Fab TM 4.0 4.6 23 N terminal Fab TM 3.7 No Binding 24 N terminal Fab TM 6.6 No Binding 25 C terminal Fab TM, linker = 4.5 11.0 15mer 26 C terminal Fab TM, linker = 5.1 5.1 15mer 27 C terminal Fab TM, linker = 4.2 7.3 15mer 28 C terminal Fab TM, linker = 3.2 4.3 15mer 29 C terminal Fab TM, linker = 5.7 No Binding 15mer 30 C terminal Fab TM, linker = 5.6 No Binding 15mer 31 C terminal Fab 7.6 No Binding TM, linker = 5mer 32 C terminal Fab 6.4 No Binding TM, linker = 5mer 42 (ABPs 1-10, 23, 24, 29-IgG1 N297A* 11.5 No Binding 32, 35-41, 43, 48, 49) 44 (ABPs 11, 12, 19, 25) IgG1 N297A# 46.5 Poor Fit 45 (ABPs 13, 20, 26, 45, IgG1 N297A#
112.2 Poor Fit 52) 46 (ABPs 14-16, 21, 27, IgG1 N297A#
59.8 110.9 53-55) 47 (ABPs 17, 18, 22, 28, IgG1 N297A#
44.3 88.1 56, 57) 48 (ABPs 10, 29, 31) IgG1 N297A# 14.8 No Binding 49 (ABPs 24, 30, 32) IgG1 N297A# 63.5 No Binding 11 IgG1 format 3.1 8.5 12 IgG1 format 2.8 7.9 13 IgG1 format 5.5 6.4 14 IgG1 format 2.8 5.9 15 IgG1 format 3.3 5.2 16 IgG1 format 2.9 5.4 17 IgG1 format 4.2 4.6 18 IgG1 format 4.0 8.4 * non-optimized, non-TM IgG1 ABPs corresponding to ABPs in parentheses # H1H2-optimized, non-TM IgG1 ABPs corresponding to ABPs in parentheses [425] Additional KD measurements were performed on 8 N-terminal Fab TM format antibodies using multi-concentration kinetics. The GITR ABPs were evaluated for their ability to bind recombinant hGITR (SEQ ID NO: 1), hGITR-T43R (SEQ ID NO: 2), and cGITR (SEQ ID NO: 3) using a FORTEBIO OCTET instrument. The assay was performed at 30 C, using lx Kinetics Buffer (ForteBio, Inc.) as an assay buffer. Anti-human IgG Fc Capture (AHC) biosensors (ForteBio, Inc.) were used to capture GITR
ABPs onto the sensors. The sensors were saturated in assay buffer for 600 seconds before the assay. Baseline was established by dipping the sensors into lx assay buffer for 60 seconds. ABPs were loaded onto the sensors by dipping the sensors into ABP
solution for 300 seconds. Baseline was established by dipping the sensors into lx assay buffer for 120 seconds. Next, association was monitored for 300 seconds in various concentrations of recombinant antigens (50 nM to 0.78 nM, 2-fold dilutions in assay buffer), and dissociation was followed for 600 or 1200 seconds in buffer alone. KD was determined using the kinetic function of the FORTEBIO Analysis Software using a 1:1 binding model. Results of determination of KD by OCTET are shown in FIG.2 and in Table 7. As can be seen in the Figure, the KDs for human GITR are each less than 1nM, and the KDs for cynomolgus GITR are within 15-fold of that of human. In addition, the TM
format antibodies bind the T43R SNP variant of human GITR.
Table 7. N-terminal Fab TM format ABP Binding Characteristics ABP Human GITR-Fc Human GITR-Fc T43R Cyno GITR-Fc KD (M), n=3 KD (M), n=1 KD (M), n=3 1 3.2E-10 5.3E-10 6.2E-10 2 2.3E-10 1.0E-10 7.1E-10 3 1.2E-10 2.7E-12 1.1E-09 4 1.1E-10 4.5E-12 1.5E-09 1.2E-10 7.3E-11 1.1E-09 6 1.5E-10 3.5E-11 1.6E-09 7 4.5E-10 7.0E-10 1.7E-09 8 5.2E-10 6.6E-10 6.6E-10 GITR Binding Assays [426] Peripheral Blood Mononuclear Cells (PBMCs) were cultured in growth medium in the presence of phytohemagglutinin (PHA) for 5 days at 37 C to upregulate GITR

expression. T cells were collected and washed and then incubated at 4 C with one of eight TM format GITR ABPs or a human isotype control antibody. After washing, cells were incubated at 4 C with fluorochrome conjugated anti-human CD4 antibody and anti-human CD8 antibody as well as fluorochrome-conjugated anti-human IgG to detect bound anti-human GITR ABPs. The percentage of GITR+ CD4 and CD8 cells as well as the mean fluorescence intensity (MFI) is determined by flow cytometry.
[427] Exemplary results are shown in FIG. 3. Figure 3A shows CD4+ cells and Figure 3B
shows CD8+ cells. In the top row, from left to right, is shown an anti-GITR
positive control, and anti-human IgG4 isotype control, and N-terminal Fab TM format ABPs ABP9, ABP2, ABP1, and ABP7. On the bottom row is shown ABP8, ABP3, ABP4, ABP5, ABP6, ABP23, and ABP24. The percentage of IgG4+ CD4/8+ cells is indicated.
[428] Binding to cell surface human, cynomolgus, and murine GITR is evaluated by transfecting HT1080, CHO, or 293T cells with the respective (human, cynomolgus or murine) GITR. Binding to cynomolgus GITR is further evaluated using primary cynomolgus T cells and the HSC-F T cell line, each after stimulation with anti-antibody, to increase GITR expression.
Activity Assays for GITR Antigen-Binding Proteins [429] The GITR ABPs were tested for their ability to agonize GITR. In one assay, HT1080 cells that stably express human or cynomolgus GITR were contacted with TM
format GITR ABPs or trimeric human GITRL. After 24 hours, the amount of IL-8 secreted by the cells was evaluated by an ELISA assay. Increased IL-8 secretion corresponds to an increase in GITR agonism. Results for N-terminal Fab TM format antibodies 1-8 are shown in FIG. 4. Shown are the IL-8 output based on antibody or ligand concentration for ABP1 (FIG. 4A), ABP2 (FIG. 4B), ABP3 (FIG. 4C), ABP4 (FIG. 4D), ABP5 (FIG.
4E), ABP6 (FIG. 4F), ABP7 (FIG. 4G), and ABP8 (FIG 4H). Antibodies shown as circles in the FIGs. and GITRL control is shown as squares. EC50 scores are compared to that of GITR ligand (GITRL).
[430] Table 8. Agonistic activity of TM Format antibodies on human and cynomolgus GITR on HT1080 cells % Maximum IL-Average EC50 % Maximum IL-Average EC50 in 8 Induction in human 8 Induction cynomolgus Relative to HT1080, Relative to ABP n HT1080, GITRL GITRL in n GITRL on GITRL in human on same plate cynomolgus same plate HT1080, GITRL
(PM) HT1080, GITRL
(PM) on same plate on same plate [431] The same assay was conducted using IgG1 N297A non-TM versions of ABPs 1-(see FIG. 4) and the data are summarized in Table 9.
Table 9. Activity of IgG1 N297A antibodies on human and cynomolgus GITR on HT1080 cells ABP Average ECso (Corresponding Average ECso in TM ABP) in human cynomolgus HT1080, HT1080, GITRL on 1 GITRL on 1 separate plate separate plate (nM) n (nM) 35(1) 0.88 1 2 1 36 (2) 0.58 1 8.8 1 37(3) 0.19 1 1.7 1 38 (4) 0.33 1 14.3 1 39 (6) 0.44 1 2.3 1 40(7) 0.34 1 1.1 1 41(8) 0.44 1 2 1 GITRL 0.43 2 0.17 2 [432] The assay was again used for testing the activity of additional N-terminal Fab and C-terminal Fab TM format antibodies as well the IgG1 N297A versions of those antibodies.
The data are summarized in Table 10 and Table 11 and shown in FIG. 5. FIG. 5A
shows ABP43 (squares), ABP23 (circles), ABP24 (triangles), and ABP29 (open circles), (open triangles), ABP31 (open circles), and ABP32 (open triangles), all in comparison to GITRL (+ sign). FIG. 5B shows ABP19 (N-terminal Fab, triangles) and ABP25 (C
terminal Fab, upside down triangles). GITRL is shown as plus signs. FIG. 5C
shows ABP21 (N-terminal Fab, triangles) and ABP27 (C terminal Fab, upside down triangles).
GITRL is shown as plus signs. FIG. 5D shows ABP20 (N-terminal Fab, triangles) and ABP26 (C terminal Fab, upside down triangles). GITRL is shown as plus signs.
FIG. 5E
shows ABP22 (N-terminal Fab, triangles) and ABP28 (C terminal Fab, upside down triangles). GITRL is shown as plus signs. As shown in the FIG., the N-terminal Fab format ABPs tended to induce more IL-8 than their C-terminal Fab counterparts.
[433] FIG. 10 shows an additional comparison of ABP43 (non-optimized IgG4 format) with two corresponding TM format ABPs where the IgG1 Fab counterpart of ABP43 is added to the N or C terminus of the ABP43. As can be seen in the Figure, the N-terminal Fab TM format ABP9 (squares) induced the most IL-8 (and had the best EC50) in comparison to the C-terminal Fab TM format ABP10 (circles) and the non-TM
format ABP43 (diamonds). Both TM format ABPs had better activity than the non-TM
format parental ABP as well as GITRL. IL-8 induction by GITRL (positive control) is shown as a single data point (star) IL-8 production is shown in pg/mL.
Table 10. Agonistic activity of N-terminal Fab and C-terminal Fab TM format antibodies on human GITR on HT1080 cells Average EC50 in Human ABP Format HT1080, GITRL on 1 n separate plate (nM) GITRL -- 0.37 1 9 N terminal Fab TM 0.18 1 19 N terminal Fab TM 0.25 1 20 N terminal Fab TM 0.63 1 21 N terminal Fab TM 0.18 1 22 N terminal Fab TM 0.30 1 23 N terminal Fab TM 0.30 1 24 N terminal Fab TM 0.17 1 25 C terminal Fab TM, linker = 15mer 0.46 26 C terminal Fab TM, linker = 15mer 0.63 1 27 C terminal Fab TM, linker = 15mer 0.35 1 28 C terminal Fab TM, linker = 15mer 0.63 1 29 C terminal Fab TM, linker = 15mer 0.27 1 30 C terminal Fab TM, linker = 15mer 0.31 1 31 C terminal Fab TM, linker = 5mer 0.18 1 32 C terminal Fab TM, linker = 5mer 0.30 1 Table 11. Agonistic activity of IgG1 N297A antibodies format antibodies on human GITR on HT1080 cells EC50 in human EC50 in cynomolgus HT1080, GITRL on HT1080, GITRL on ABP Format separate plate (nM), n separate plate (nM), n =2 =1 42 IgG1 N297A 17.8 no activity 44 IgG1 N297A 4.2 28.0 45 IgG1 N297A 10.5 15.1 46 IgG1 N297A 1.2 6.9 47 IgG1 N297A 4.1 11.8 48 IgG1 N297A 0.8 minimal activity 49 IgG1 N297A 2.7 65.8 [434] Additional IgG1 N297A versions of H1H2NH optimized antibodies are provided and shown below in Table 12 and their agonistic activity was determined in the HT1080 assay, as described above, is indicated. These antibodies are suitable to be made into TM format.
Table 12. Agonistic activity of IgG1 N297A antibodies format antibodies on human GITR on HT1080 cells EC50 in human EC50 in cynomolgus ABP Format HT1080, GITRL on HT1080, GITRL on separate plate (nM) separate plate (nM) 11 IgG1 N297A 3.9 21.6 12 IgG1 N297A 3.5 28.4 13 IgG1 N297A 7.8 15.0 14 IgG1 N297A 0.6 4.1 15 IgG1 N297A 0.6 4.5 16 IgG1 N297A 0.6 3.8 17 IgG1 N297A 5.3 8.4 18 IgG1 N297A 2.1 13.2 GITRL 0.4 0.2 [435] A
similar assay was performed in Jurkat cells, a T-cell based cell line, engineered to express human GITR and an NF-KB luciferase reporter (Promega0). Eight optimized, N-terminal Fab TM format antibodies, ABPs 1-8, were compared to GITRL for their ability to induce IL-8 in T cells. As shown in FIG. 7A-H (for ABPs 1-8) and Table 13, all eight ABPs were better than GITRL at inducing cytokine production.
Table 13. 8 Optimized TM format with N-terminal Fab are superior to GITRL
% Activity Compared to ABP EC50 (nM) GITRL
1 0.30 104 GITRL 0.90 2 0.21 114 GITRL 0.91 3 0.19 120 GITRL 0.85 4 0.22 117 GITRL 1.13 0.25 104 GITRL 1.01 6 0.29 121 GITRL 0.90 7 0.20 108 GITRL 0.81 8 0.30 114 GITRL 0.89 Agonistic activity of N-Terminal Fab TM-Format Antibodies in Primary Cells [436] In one embodiment, the GITR ABPs are further tested for their ability to deliver a co-stimulatory signal to CD4+CD25- effector T cells in conjunction with TCR
signaling via anti-CD3 antibody. Increased T cell activation is measured by quantifying cell proliferation, and/or measuring the increased production and secretion of cytokines including IFN-gamma using an ELISA assay.
[437] In another embodiment, the GITR ABPs are further analyzed to evaluate their ability to prevent the suppression of effector T cells by regulatory T cells. Human CD4+ T cells are isolated using a human CD4+ T cell isolation kit (Miltenyi #130-096).
Regulatory T
cells are further enriched using human CD25 MicroBeads0 II (Miltenyi #130-092-983) following the manufacturer's instructions. The CD25 depleted CD4+ T cells are used as effector T cells in the suppression assay. Beads conjugated to anti-human CD2, CD3, and CD28 antibodies are used to activate the effector T cells in the assay (Treg Suppression Inspector; a.k.a. T cell activation beads, Miltenyi #130-092-909). In a 96-well plate, 50,000 each of regulatory T cells and effector T cells are seeded in each well and incubated with an equal number of T cell activation beads. The mixtures of cells and beads are contacted with different concentrations of GITR ABP for five days.
Proliferation of effector T cells is measured by pulsing the cell cultures with tritiated thymidine during the last 16 hours of culture, washing, and measuring the amount of radioactivity incorporated into the cells.
Agonistic activity of N-Terminal Fab TM-Format Antibodies in T-blast Primary Cell Assay Pre-stimulated T cells (T-blasts) were used to assess the activity of eight N-Terminal Fab TM
format antibodies (ABPs 1-8).
To generate T-blasts, PBMCs are stimulated with PHA for 5-7 days in order to expand the cells and induce expression of GITR. Cells are washed and frozen prior to the setup of the functional assay.
To assess functional activity of ABPs 1-8, cells are stimulated by adding 1 mg/ml anti-CD3 +
2 mg/ml anti-CD28, 0.003 - 10 mg/ml ABPs 1-8, and 10 mg/ml GITRL as a positive control. Cells are incubated at 37 C and supernatants are collected after 48 hours. IL-2 production is measured by AlphaLISA0 (Perkin Elmer ). FIG. 8A shows the percentage of GITR+ CD4+ cells (left) and CD8+
cells (right) in cells from two human donors at various time points, +1-stimulation with PHA.
FIGs 8B-8M show results of treatment of T-blasts from 4 different donors treated with controls or ABPs and the resultant IL-2 production. In each FIG. the top row, from left to right is FACS measurement of ABO binding to CD4+ cells, IL-2 production in cells from Donor 1, IL-2 production in cells from Donor 2. In the bottom row, from left to right, is FACS measurement of ABP binding to CD8+ cells, IL-2 production in cells from Donor 3, IL-2 production in cells from Donor 4. Shown are data as follows: 8B: IgG4 isotype control; 8C: SEC4 antibody; 8D: IgG4 TM
format control; 8E: non-TM IgG4 non-optimized lineage parent of ABPs 1-8 (ABP9). 8F: ABP1; 8G:
ABP2; 8H: ABP3; 81: ABP4; 8J: ABP5; 8K: ABP6; 8L: ABP7; 8M:ABP8.
As shown in the FIG., T-blasts from different donors varied in their response to treatment with ABPs 1-8; however, treatment with all eight TM format ABPs had agonistic activity at most concentrations tested, as measured by production of IL-2 and as compared to control antibodies.
GITR Agonistic Activity Comparison of Optimized N-Terminal Fab TM Format ABPs and Non-TM Format IgG1 ABPs [438] The same eight optimized N-terminal Fab TM format ABPs (1-8) as in the above Examples were compared to the non-optimized parental controls in the same IL-8-induction assay described above and shown in FIG. 4. Each FIG. shows a comparison of the N-terminal Fab TM format ABPs 1-8 (IgG4 5228P with N-terminal IgG1 Fab, "IgG4 TM") and the corresponding non-TM format IgG1 (IgG1 N297, "IgGl") ABP, as well GITRL as a positive control and IgG4 negative control (GITRL and IgG4 run on a separate plate from the ABPs). The left panels show results from cells expressing hGITR
and the right panels show results from cells expressing cGITR. IL-8 induction as a function of ABP concentration is shown for ABP 1 (FIG. 9A), ABP 2 (FIG. 9B), ABP3 (FIG.
9C), ABP4 (FIG. 9D), ABP5 (FIG. 9E), ABP6 (FIG. 9F), ABP7 (FIG. 9G), and ABP8 (FIG.

9H). Induction of IL-8 by GITRL is shown as circles, by TM format antibodies as triangles, by parental IgG1 antibodies as diamonds, and by IgG4 control antibodies as squares. A table of EC50 values is shown on the bottom of each panel of each FIG.
[439] The results shown in Figure 9 demonstrate that the eight optimized ABPs are able to induce IL-8 production in cells expressing human or cynomolgus GITR to a much greater extent as N-terminal Fab TM format antibodies when compared to bivalent IgG1 N297A.
The N-terminal Fab TM format antibodies had smaller EC50 values and greater maximum production of IL-8 as compared to the bivalent IgG1 N297A format. In addition, all of the TM antibodies had greater affinity for GITR than the non-TM form of the parental antibody (compare Table 5 and 7 with Table 6).
Evaluation of GITRL Blockade [440] In another embodiment, GITR blockade was evaluated using a FORTEBIO
OCTET
instrument. The analysis was performed at 30 C using lx Kinetics Buffer (ForteBio, Inc.) as assay buffer. Anti-human IgG Fc Capture (AHC) biosensors (ForteBio, Inc.) are used to capture human GITR ABPs onto the sensors. Sensors are saturated in assay buffer for 300 seconds before the assay. ABPs were loaded onto sensors by dipping the sensors into ABP
supernatant solution for 300 seconds. Baseline was established by dipping the sensors into lx assay buffer for 200 seconds. Next, association of recombinant GITR was monitored for 180 seconds. The ability of recombinant GITRL to then associate with the ABP /GITR
complex was the determined by dipping the sensors in GITRL for 180 seconds.
[441] GITR blockade was evaluated according to the methods above using ABPs 1-8. All eight ABPs were capable of blocking GITRL binding.
[442] In one embodiment, to evaluate whether anti-human GITR ABPs block GITR
ligand (GITRL, R&D Systems #6987-GL-CF) binding to GITR, various concentrations of unlabeled GITR ABP are incubated with human pan T cells at 4 C in staining buffer (e.g., phosphate buffered saline with 0.5% bovine serum albumin) for 10 min. Without washing, 4 nM of HA-tagged human GITRL is added and incubated at 4 C for another 30 min. The cells are then washed twice with staining buffer, and incubated with anti-HA
PE antibody (Miltenyi #130-092-257) in staining buffer at 4 C for 30 min. The cells are then washed twice with staining buffer and fixed with 2% paraformaldehyde in PBS for flow cytometry analysis. A decrease in the amount of PE staining indicates that the ABP
blocks the GITR-GITRL interaction.
Example 3: Multispecific Antigen-Binding Proteins [443] One embodiment of multispecific GITR agonistic ABPs comprises a common light chain antibody. ABPs were identified that bind two distinct epitopes on GITR.
These two ABPs share the same light chain. ABP61 is an agonistic antibody and ABP59 has less agonistic activity but does not compete with ABP61 for binding to GITR.
Multivalent multispecific antibodies with common light chains were produced by transfecting a HEK-293 host cell with vectors encoding two heavy chains and the single common light chain.
The first exemplary ABP disclosed herein with a common light chain (SEQ ID
NO:125) is ABP33, which has an IgG4 heavy chain (ABP61) with N-terminal Fab (from ABP58 (IgG1 counterpart of ABP59)), and the full-length sequence SEQ ID NO:124 (HC) and SEQ ID NO:125 (LC). The second exemplary ABP disclosed herein with a common light chain is ABP34, which has a IgG4 heavy chain (ABP61) with C-terminal Fab (from ABP58 (IgG1 counterpart of ABP59), and the full-length sequence SEQ ID NO:136 (HC) and SEQ ID NO:125 (LC).
[444] Each multispecific ABP binds two distinct epitopes on GITR. The ABPs are characterized as described in the Examples above. Other multispecific ABPs described herein are produced and similarly characterized. FIG. 6 shows the results of determination for ABP33 and ABP34 in the HT1080 assay as described above in Example 2. ABP33 (tetravalent version combining the IgG4 ABP61 with the IgG1 Fab of [IgG1 counterpart of ABP591 on the N-terminus) and ABP34 (tetravalent version combining the IgG4 of ABP61 with the IgG1 Fab of ABP58 [IgG1 counterpart of on the C-terminus) were compared to bivalent ABPs 59 and 61 (IgG4 5228P). As shown in the FIG., the tetravalent antibodies both had superior EC50, as measured by induction, when compared to their bivalent counterparts.
Example 4: Comparison of TM-Format Antibodies to Benchmark anti-GITR
antibodies [445] The activity of N-terminal Fab TM-format antibodies was tested against two known anti-GITR antibodies, SEC4 and SEC9 in HT1080 cells that were engineered to stably express human GITR. Cultured cells were treated for six hours with a range of concentrations of two benchmark agonist antibodies SEC4 ("35E6" formatted to have mouse variable regions with human IgG4 S228P/kappa regions, orange diamonds) and SEC9 (humanized 6C8 N62Q IgG1 N297A). SEC4 is described, e.g., in U.S. Patent No.
8,709,424; variable regions are found in SEQ ID NOs 1 and 12. SEC9 is described, e.g., in U.S. Patent No. 7,812,135; full length sequences are set forth in SEQ ID
NOs 58 and 63.
A bivalent antibody dose of 1pg/m1 is equivalent to 6.67nM; a tetravalent antibody dose of 1 pg/m1 is equivalent to 4 nM.
[446] Induction of IL-8 was measured by ELISA and the EC50 was calculated.
FIG. 11A
shows a comparison of hGITRL to SEC4 (diamonds) and SEC9 (circles), as well as an IgG4 negative control (closed triangles), an IgG1 negative control (open triangles), and trimeric human GITR ligand ("hGITRL", squares) as a positive control. GITRL
had a better EC50 (inset) and max induction compared to both SEC4 and SEC9.
[447] Also shown are comparisons to GITRL with ABP1 (FIG. 11B), ABP2 (FIG.
11C), ABP3 (FIG. 11D), ABP4 (FIG. 11E), ABP5 (FIG. 11F), ABP6 (FIG. 11G), ABP7 (FIG.

11H), and ABP8 (FIG. 11I). As shown in the Figure, all eight N-Terminal Fab TM
format antibodies had a more favorable EC50 than did either SEC4 or SEC9. All eight N-Terminal Fab TM format antibodies also had a greater induction of IL-8 production than either SEC4 or SEC9.
[448] SEC4 was also tested as described above in the T-blast primary cell assay. As shown in FIG. 8, induction of IL-2 in primary cells by SEC4 was less for all four donors than that of the TM format antibodies.
Example 5: Anti-GITR ABPs increase production of cytokines in patient Tumor Infiltrating Lymphocytes and GITR+ T cells Materials and Methods [449] Dissociated human tumor samples were purchased from Conversant Bio.
Samples were NSCLC adenocarcinoma isolated from a 75-year-old male, a previous smoker, with Stage Ia disease, prior to any treatment. The sample was quickly thawed, then restimulated with several conditions, with and without immunotherapies as follows: cells were either unstimulated controls, or were stimulated with lug/mL aCD3 (Soluble) +2 ug/mL aCD28 (Soluble) + IL-2 (50ng/mL); cells either received no immunotherapy treatment (for assessment of checkpoint protein levels), pembrolizumab (10 g/mL), TM
format ABP control (2 g/mL), ABP1 (2 g/mL), or ABP1 + pembrolizumab. Cells were incubated for 48 hours before supernatants were collected and stained for expression of checkpoints. In some samples, brefeldin A (an inhibitor of cytokine secretion) was added to the last five hours of stimulation for detection of cytokines by intracellular cytokine staining.
Results [450] Cells were gated on GITR-positive T cells and the results are shown in Figure 12A
(TNF production) and Figure 12B (IFNy production). As shown in the Figures, anti-GITR
(ABP1) single agent treatment resulted in an increase in cytokine production.
There was not a significant increase in this assay of cytokine production in cells receiving the combination ABP1 + pembrolizumab treatment.
Example 6: Mutational analysis for epitope determination: Alanine Scanning [451] To identify the epitope for ABP1 binding to human GITR, single point mutations were made in the human GITR extra cellular domain to determine if APB1 binding was reduced. Either alanine substitutions or murine specific residues were used (ABP1 does not bind mouse GITR). Proteins were expressed in HEK-293 cells with an Fc tag, secreted as soluble protein, purified on MabSelectO Sure Lx resin, and characterized by SDS-PAGE. Binding was assessed by Bio-Layer Interferometry (BLI) using the Octet platform.
Wild type human GITR-Fc or GITR-Fc mutant was captured on anti-human Fc sensors, washed, and exposed to ABP1 Fab. Residues considered part of the binding epitope demonstrated reduced or no binding (e.g., a KD more than 3-fold poorer than that of binding to wild type human GITR). Alanine substitution at residues C58, R59, Y61, E64, C67 and an aspartic acid substitution at position C66 resulted in no binding, while alanine substitution at residues R56, D60, P62 or E65 resulted in reduced binding.
Example 7: In Vivo Evaluation of GITR Antigen-Binding Proteins [452] In vivo studies are performed to demonstrate the capability of the ABPs to decrease circulating regulatory T cell numbers in a humanized NSG mouse model. Neonate NSG
mice are transplanted with CD34+ human fetal liver cells by retro-orbital injection. Over 16 weeks, the animals develop a diverse human immune cell repertoire including CD4+
and CD8+ effector T cells, and regulatory T cells. A single intraperitoneal dose of 25 mg/kg anti-human GITR ABP or human isotype control is given to the mice and the percent of circulating human CD4+ T cells expressing the regulatory T cell marker FoxP3 is determined by flow cytometry on day 4 after dosing.
Example 8. Incubation of activated T cells with TM Format ABP1 or its conventional format parent ABP35 Preparation of activated T blasts [453] Activated T blasts were generated by stimulating freshly isolated PBMCs from two healthy donors for 7 days with PHA (final conc. 10 g/ml) and IL-2 (final conc. 4 ng/ml, added only during last 24h) at 37 C & 5% CO2.
Internalization of GITR after antibody binding [454] Activated CD4+/CD8+ T blasts were seeded at 2x105 per well in 96-well U bottom plates. Wells were treated with medium alone, recombinant GITR-Ligand (10 ug/ml, R&D
Systems, Cat# 6987-GL-025/CF), ABP1 (-250 kDa), hIgG4 TM Format isotype control, ABP35 (-150kDa), or hIgG1 standard format isotype control at nine doses each:

ug/mL, 2 ug/mL, 0.4 ug/mL, 80 ng/mL, 16 ng/mL, 3.2 ng/mL, 0.64 ng/mL, 0.13 ng/mL, and 0.026 ng/mL.
Internalization of GITR after antibody binding [455] Antibody-mediated clustering promotes endocytosis and signaling of TNF receptor superfamily members such as GITR. The ability of ABP1 and ABP35 (as well as the isotype controls) to mediate clustering and internalization was measured.
[456] The activated T blasts were first stained for FACS sorting. Fc receptors were blocked with human TruStain0 FcX for 10 minutes at room temperature. Cells were incubated with fluorescent-conjugated antibodies for 30 minutes at 4 C as in Table 14.
Cells were then washed 2X with FACS buffer, fixed in paraformaldehyde for 30 minutes in the dark, washed again, and resuspended in 200 ul FACS buffer and acquired on a BD
Fortessa instrument.
[457] GITR
internalization was measured in CD4+ cells (Figures 13A-E) and CD8+ cells (Figures 13F-J) from either Donor 1 (Figures 13A-B, 13F-G) or Donor 2 (Figures 13C-D, 13H-I). Cells were treated with either ABP1 TM format antibody or ABP35 standard bivalent antibody. As can be observed, incubation with either ABP1 or ABP35 inhibits the subsequent staining with ABP1Dylight650 (Figures 13A, 13C, 13F, 13H) but only incubation with ABP1 induces GITR internalization as measured by staining with non-competitive clone 108-17 (Figures 13B, 13D, 13G, 131). A determination of the EC50 of ABP1 on cells from both donors is shown in Figure 13E (CD4+ cells) and Figure (CD8+ cells).
Table 14. Fluorochrome labeling Antigen Clone Isotype control Fluorochrome CD3 UCHT-1 PE/Cy 7 GITR "ABP1" hIgG4 TM format Dylight-650 GITR 108-17 mIgG2a BV605 Cytokine production in activated T cells treated with ABP1 or ABP35 [458] Activated CD4+/CD8+ T blasts were seeded at 5x104 per well in 96-well U
bottom plates.
Wells were treated with medium alone, recombinant GITR-Ligand (10 ug/ml, R&D
Systems, Cat# 6987-GL-025/CF), ABP1, hIgG4 TM Format isotype control, ABP35, or hIgG1 standard format isotype control at nine doses each: 10 ug/mL, 2 ug/mL, 0.4 ug/mL, 80 ng/mL, 16 ng/mL, 3.2 ng/mL, 0.64 ng/mL, 0.13 ng/mL, and 0.026 ng/mL.
[459] Cells were stimulated by adding 1 ug/m1 anti-CD3 antibodies (mouse anti-human, clone UCHT-1), R&D Systems, Cat# MAB100) and 2 ug/m1 anti-CD28 (mouse anti-human, clone 37407), R&D Systems, Cat# MAB342) antibodies. Assays were incubated at 37 C & 5% CO2 for 48h. IL-2 production was measured by AlphaLISA0 (Perkin Elmer).
[460] Incubation of T blasts with the TM format antibody ABP1, but not the same antibody in standard bivalent format (ABP35) or either of the isotype controls, leads to internalization of GITR by activated CD4+ and CD8+ T cells (FIG. 13).
[461] In addition, superclustering of the GITR receptor by ABP1, but not binding by a conventional bivalent ABP, promotes IL-2 secretion by activated T blasts in a dose-dependent manner (FIG. 14). Together, these data show that T blasts that don't respond to conventional anti-GITR therapy will respond to the corresponding TM format antibody.
Example 9: Cytokine production in activated T cells treated with ABP1 in comparison with two benchmark antibodies, SEC4 and SEC9 [462] Activated T blasts were prepared as described in Example 8, and used to compare the activity of ABP1 with benchmark anti-GITR antibodies SEC4 and SEC9. Activated T blasts were generated by stimulating freshly isolated PBMCs from two healthy donors for 7 days with PHA
(final conc. 10 g/ml) and IL-2 (final conc. 4 ng/ml, added only during last 24h) at 37 C & 5%
CO2.
[463] Activated CD4+/CD8+ T blasts were seeded at 5x104 per well in 96-well U
bottom plates.
Wells were treated with medium alone, recombinant GITR-Ligand, ABP1, SEC4, SEC9, hIgG4 TM Format isotype control ("IsoTM"), hIgG1 standard format isotype control, and hIgG4 standard format isotype control, at nine doses each: 10 ug/mL, 2 ug/mL, 0.4 ug/mL, 80 ng/mL, 16 ng/mL, 3.2 ng/mL, 0.64 ng/mL, 0.13 ng/mL, and 0.026 ng/mL.
Cytokine production in activated T cells treated with ABP1, SEC4, and SEC9 [464] Cells were stimulated by adding 1 ug/m1 anti-CD3 antibodies and 2 ug/m1 anti-CD28 antibodies. Cells were incubated at 37 C & 5% CO2 for 48h. IL-2 production was measured by AlphaLISA0 (Perkin Elmer). As seen in Example 8, TM format ABP1 promotes IL-2 secretion by activated T blasts in a dose-dependent manner. IL-2 production from activated T cells is shown in Figure 15A (Donor 1) and 15B (Donor 2). The corresponding EC50 is shown in Figure 15C (Donor 1) and 15D (Donor 2).
[465] As can be seen in the Figures, SEC4 and SEC9 don't induce IL-2 efficiently in a dose dependent manner, ABP1 did induce IL-2 production to a greater extent than SEC4 and SEC9 in a clear dose dependent manner. Together, these data support that T blasts that don't respond to conventional anti-GITR therapy will respond to the corresponding TM format antibody.
EQUIVALENTS
[466] The disclosure set forth above may encompass multiple distinct inventions with independent utility. Although each of these inventions has been disclosed in its preferred form(s), the specific embodiments thereof as disclosed and illustrated herein are not to be considered in a limiting sense, because numerous variations are possible. The subject matter of the inventions includes all novel and nonobvious combinations and subcombinations of the various elements, features, functions, and/or properties disclosed herein. The following claims particularly point out certain combinations and subcombinations regarded as novel and nonobvious. Inventions embodied in other combinations and subcombinations of features, functions, elements, and/or properties may be claimed in this application, in applications claiming priority from this application, or in related applications. Such claims, whether directed to a different invention or to the same invention, and whether broader, narrower, equal, or different in scope in comparison to the original claims, also are regarded as included within the subject matter of the inventions of the present disclosure.

APPENDIX A: SEQUENCES
SEQ Molecule Description SEQUENCE
ID
NO
1 Human NP_004186.1 MAQHGAMGAFRALCGLALLCALSLGQRPTGGPGCGPGRLLL
GITR (ref seq) or GTGTDARCCRVHTTRCCRDYPGEECCSEWDCMCVQPEFHCG

(UniProt) GHCKPWTDCTQFGFLTVFPGNKTHNAVCVPGSPPAEPLGWL
TVVLLAVAACVLLLTSAQLGLHIWQLRSQCMWPRETQLLLE
VPPSTEDARSCQFPEEERGERSAEEKGRLGDLWV
2 Human MAQHGAMGAFRALCGLALLCALSLGQRPTGGPGCGPGRLLL
GITR GRGTDARCCRVHTTRCCRDYPGEECCSEWDCMCVQPEFHCG

SNP GHCKPWTDCTQFGFLTVFPGNKTHNAVCVPGSPPAEPLGWL
variant TVVLLAVAACVLLLTSAQLGLHIWQLRSQCMWPRETQLLLE
VPPSTEDARSCQFPEEERGERSAEEKGRLGDLWV
3 Cynomol XP_00554518 MCACGTLCCLALLCAASLGQRPTGGPGCGPGRLLLGTGKDA
gus 0.1 RCCRVHPTRCCRDYQSEECCSEWDCVCVQPEFHCGNPCCTTC
monkey QHHPCPSGQGVQPQGKFSFGFRCVDCALGTFSRGHDGHCKP
GITR WTDCTQFGFLTVFPGNKTHNAVCVPGSPPAEPPGWLTIVLLA
VAACVLLLTSAQLGLHIWQLGSQPTGPRETQLLLEVPPS lEDA
SSCQFPEEERGERLAEEKGRLGDLWV
4 Mouse MGAWAMLYGVSMLCVLDLGQPSVVEEPGCGPGKVQNGSGN
GITR NTRCCSLYAPGKEDCPKERCICVTPEYHCGDPQCKICKHYPC
QPGQRVESQGDIVFGFRCVACAMGTFSAGRDGHCRLWTNCS
QFGFLTMFPGNKTHNAVCIPEPLPTEQYGHLTVIFLVMAACIF
FLTTVQLGLHIWQLRRQHMCPRETQPFAEVQLSAEDACSFQF
PEEERGEQ lEEKCHLGGRWP
Linker 1 GGGGS
6 Linker 2 GGGGSGGGGSGGGGS
7 ABP1 Heavy Chain QVQLQESGPGLVKPSETLSLTCAVSGYSISSGLGWGWIRQPPG
Full, heavy KGLEWIGGIYESGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
variable 1 + AADTAVYYCAHERVRGYGDYGGHHAFDIWGQGTMVTVSSA
IgG1 CH1 + STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG
GGGGS + ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
heavy variable KPSNTKVDKRVEPKSCGGGGSQVQLQESGPGLVKPSETLSLT
1 + IgG4 CAVSGYSISSGLGWGWIRQPPGKGLEWIGGIYESGSTYYNPSL
5228P (with KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAHERVRGYGD
YGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSEST

or without C AALGCLVKDYFPEPVTVSWN S GALT S GVHTFPAVLQ SSGLYS
terminal Lys) L S SVVTVPS S SLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC
PP CPAPEFL GGP S VFLFPPKPKDTLMI SRTPEVTCVVVD VSQE
DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYTLP
PSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
PPVLD SD GSFFLYSRL TVDK SRWQEGNVF S C S VMHEALHNH
YTQKSL SL SLGK

Heavy Chain QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGAVVVSWIRQHP
Full, heavy GKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSS
variable 1 + VTAADTAVYYCADENVRGYGDYGGHHAFDIWGQGTMVTVS
IgG1 CH1 + SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
GGGGS + S GAL T
S GVHTFP AVLQ S SGLYSL S SVVTVPS S SL GTQTYICNV
heavy variable NHKP SNTKVDKRVEPK S C GGGG S QVQL QE S GP GLVKP SQTL S
1 + IgG4 LT CTVS GGS IS S GGAVVVSWIRQHPGKGLEWIGGIAYSGSTYY
S228P (with NP SLK SRVTI S VDT SKNQF SLKL S SVTAADTAVYYCADENVR
or without C GYGDYGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRST
terminal Lys) SESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS S
GLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY
GPPCPPCPAPEFL GGP S VFLFPPKPKD TLMI SRTPEVT CVVVD V
SQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVY
TLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLD SD GSFFLYSRL TVDK SRWQEGNVF S C S VMHEALH
NHYTQKSL SL SL GK

Heavy Chain QVQLQESGPGLVKPSETLSLTCAVSGYSISSGAGWGWIRQPPG
Full, heavy KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
variable 1 + AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSSA
IgG1 CH1 + STKGP S VFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSG
GGGGS + ALT S
GVHTFPAVL Q S SGLYSL S S VVTVP S S SL GTQTYICNVNH
heavy variable KPSNTKVDKRVEPKSCGGGGSQVQLQESGPGLVKPSETLSLT
1 + IgG4 CAVSGYSIS SGAGWGWIRQPPGKGLEWIGLIVHSGSTYYNPSL
S228P (with KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVLESVRGYGD
or without C YGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSEST
terminal Lys) AAL G CLVKDYFPEPVTVS WN S GALT S GVHTFPAVLQ S SGLYS
L S SVVTVPS S SLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC
PP CPAPEFL GGP S VFLFPPKPKDTLMI SRTPEVTCVVVD VSQE
DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYTLP
PSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT

PPVLD SD GSFFLYSRL TVDKSRWQEGNVF S C S VMHEALHNH
YTQKSL SL SLGK

Heavy Chain QVQLQES GP GLVKP SETL SLTCAVSGYSIS SGAGWGWIRQPPG
Full, heavy KGPEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
variable 1 + AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSSA
IgG1 CH1 + STKGP S VFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSG
GGGGS + ALT S
GVHTFPAVL Q S SGLYSL S S VVTVP S S SL GTQTYICNVNH
heavy variable KPSNTKVDKRVEPKSCGGGGSQVQLQESGPGLVKPSETLSLT
1 + IgG4 CAVSGYSIS SGAGWGWIRQPPGKGPEWIGLIVH SGSTYYNPSL
S228P (with KSRVTIS VDT SKNQF SLKL S S VTAADTAVYYCVLESVRGYGD
or without C YGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSEST
terminal Lys) AAL G CLVKDYFPEPVTVS WN S GALT S GVHTFPAVLQ S SGLYS
L S SVVTVPS S SLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC
PP CPAPEFL GGP S VFLFPPKPKDTLMI SRTPEVTCVVVD VSQE
DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYTLP
PSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
PPVLD SD GSFFLYSRL TVDKSRWQEGNVF S C S VMHEALHNH
YTQKSL SL SLGK

Heavy Chain QVQLQESGPGLVKPSETLSLTCAVSGYSISSGAGWGWIRQPPG
Full, heavy KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
variable 1 + AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSSA
IgG1 CH1 + STKGP S VFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSG
GGGGS + ALT S
GVHTFPAVL Q S SGLYSL S S VVTVP S S SL GTQTYICNVNH
heavy variable KPSNTKVDKRVEPKSCGGGGSQVQLQESGPGLVKPSETLSLT
1 + IgG4 CAVSGYSIS SGAGWGWIRQPPGKGLEWIGLIVHSGSTYYNPSL
S228P (with KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVLESVRGYGD
or without C YGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSEST
terminal Lys) AAL G CLVKDYFPEPVTVS WN S GALT S GVHTFPAVLQ S SGLYS
L S SVVTVPS S SLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC
PP CPAPEFL GGP S VFLFPPKPKDTLMI SRTPEVTCVVVD VSQE
DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYTLP
PSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
PPVLD SD GSFFLYSRL TVDKSRWQEGNVF S C S VMHEALHNH
YTQKSL SL SLGK

Heavy Chain QVQLQES GP GLVKP SETL SLTCAVSGYSIS SGAGWGWIRQPPG
Full, heavy KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
variable 1 + AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSSA
IgG1 CH1 + STKGP S VFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSG

GGGGS + ALT S GVHTFPAVL Q S SGLYSL S SVVTVP S S SL GTQTYICNVNH

heavy variable KPSNTKVDKRVEPKSCGGGGSQVQLQESGPGLVKPSETLSLT
1 + IgG4 CAVSGYSIS SGAGWGWIRQPPGKGLEWIGLIVHSGSTYYNPSL
S228P (with KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVLESVRGYGD
or without C YGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSEST
terminal Lys) AAL G CLVKDYFPEPVTVS WN S GALT S GVHTFPAVLQ S SGLYS
L S SVVTVPS S SLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC
PP CPAPEFL GGP S VFLFPPKPKDTLMI SRTPEVTCVVVD VSQE
DPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYTLP
PSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
PPVLD SD GSFFLYSRL TVDKSRWQEGNVF S C S VMHEALHNH
YTQKSL SL SLGK
42 ABP7 Heavy Chain QVQLQESGPGLVKPSETLSLTCAVSGYSISSEYMVVGWIRQPP
Full, heavy GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLSS
variable 1 + VTAADTAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVS
IgG1 CH1 + SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
GGGGS + S GAL TS GVH TFP AVLQ S SGLYSL S SVVTVPS S SL
GTQTYICNV
heavy variable NHKPSNTKVDKRVEPKSCGGGGSQVQLQESGPGLVKPSETLS
1 + IgG4 LTCAVSGYSIS SEYMWGWIRQPPGKGLEWIGLIYHSGKTYYN
S228P (with PSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREADRG
or without C YGDYGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTS
terminal Lys) ESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ S SG
LYSL S SVVTVPS S SL GTKTYTCNVDHKPSNTKVDKRVESKYG
PP CPP CPAPEFL GGP S VFLFPPKPKDTLMI SRTPEVTCVVVD VS
QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTV
LHQDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYT
LPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLD SD GSFFLYSRL TVDKSRWQEGNVF S C S VMHEALHN
HYTQKSLSLSLGK
51 ABP 8 Heavy Chain QVQLQES GP GLVKP SETL SLTCAVSGYSIS SEYMVVGWIRQPP
Full, heavy GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLSS
variable 1 + VTAADTAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVS
IgG1 CH1 + SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
GGGGS + S GAL TS GVH TFP AVLQ S SGLYSL S SVVTVPS S SL
GTQTYICNV
heavy variable NHKPSNTKVDKRVEPKSCGGGGSQVQLQESGPGLVKPSETLS
1 + IgG4 LTCAVSGYSIS SEYMWGWIRQPPGKGLEWIGLIYHSGKTYYN
S228P (with PSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREADRG
or without C YGDYGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTS
terminal Lys) ESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ S SG

LYSL S SVVTVPS S SL GTKTYTCNVDHKPSNTKVDKRVESKYG
PP CPP CPAPEFL GGP S VFLFPPKPKDTLMI SRTPEVTCVVVD VS
QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTV
LHQDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYT
LPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLD SD GSFFLYSRL TVDKSRWQEGNVF S C S VMHEALHN
HYTQKSLSLSLGK
57 ABP9 Heavy Chain QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYAWGWIRQPP
Full, heavy GKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSV
variable 1 + TAADTAVYYCARD SGRGYGDYGGHHAFDIWGQGTMVTVS S
IgG1 CH1 + ASTKGP S VFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNS
GGGGS + GALT S
GVHTFPAVL Q S SGLYSL S SVVTVPS S SL GTQTYICNVN
heavy variable HKPSNTKVDKRVEPKSCGGGGSQLQLQESGPGLVKPSETLSL
1 + IgG4 TCTVS
GGSIS S S SYAWGWIRQPPGKGLEWIGSIYYSGSTYYNP
S 228P (with SLK SRVTI S VD T SKNQF SLKL S SVTAADTAVYYCARD SGRGY
or without C GDYGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSE
terminal Lys) STAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
YSL S SVVTVPS S SL GTKTYTCNVDHKPSNTKVDKRVESKYGP
PCPPCPAPEFLGGPSVFLFPPKPKDTLM I SRTPEVTCVVVDVSQ
EDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYTL
PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLD SD GSFFLYSRLTVDKSRWQEGNVF S C S VMHEALHNH
YTQKSL SL SLGK
57 ABP10 Heavy Chain QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYAWGWIRQPP
Full, heavy GKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSV
variable 1 + TAADTAVYYCARD SGRGYGDYGGHHAFDIWGQGTMVTVS S
IgG1 CH1 + ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS
GGGGS + GALT S
GVHTFPAVL Q S SGLYSL S SVVTVPS S SL GTKTYTCNVD
heavy variable HKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKD
1 + IgG4 TLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTK
S228P (with PREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSI
or without C EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPS
terminal Lys) DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRW
QEGNVFSCSVMHEALHNHYTQKSL SL SL GKGGGGSQLQLQE
S GP GL VKP SETL SLT CTVS GG SI S S S SYAWGWIRQPPGKGLEW
IGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTA
VYYCARD SGRGYGDYGGHHAFDIWGQGTMVTVS S A S TKGP
S VFPL AP S SK S T S GGTAAL GCLVKDYFPEP VTVS WN S GALT S G

VHTFPAVLQS SGLYSLS SVVTVPS S SLGTQTYICNVNHKPSNT
KVDKRVEPKSC

Heavy Chain QVQLVQSGAEVKRPGS SVKVS CKASGGTFS SYYISWVRQVPG
Full (IgG1) QGLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELS
SLRSEDTAVYYCARAGGGYARGDHYYGMDVVVGQGTTVTVS
SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
S GAL TS GVH TFP AVLQ S SGLYSL S SVVTVPS S SLGTQTYICNV
NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYP SD IAVEWE SNGQPENNYKTTPPVLD SD GSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK

Heavy Chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYYISWVRQAPG
Full (IgG1) QRLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELS
SLRSEDTAVYYCARAGGGYARGDHYYGMDVVVGQGTTVTVS
SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
S GAL TS GVH TFP AVLQ S SGLYSL S SVVTVPS S SLGTQTYICNV
NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYP SD IAVEWE SNGQPENNYKTTPPVLD SD GSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK
173 ABP13 Heavy Chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRGAISWVRQAP
Full (IgG1) GQGLEWMGGIIPIEGTAYYAQKFQGRVTITADESTGTAYMEL
S SLR SED TAVYYCARQ SDYGLPRGMD VVVGQ GTTVTVS SAS T
KGPSVFPLAPS SKSTS GGTAAL GCLVKDYFPEPVTVSWNS GA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
PSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK
DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKT
KPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSL SLSPGK

Heavy Chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
Full (IgG1) QGLEWMGGIIPISGFTNYAQKFQGRVTITADESTSTAYMEL S S
LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVS SA STKGP
S VFPL AP S SK S T S GGTAAL GCLVKDYFPEP VTVS WNS GALT S G
VHTFPAVLQS SGLYSLS SVVTVPS S SLGTQTYICNVNHKPSNT

KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK

Heavy Chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
Full (IgG1) QRLEWMGGIIPISGFTNYAQKFQGRVTITADESTSTAYMELSS
LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK

Heavy Chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
Full (IgG1) QGLEWMGGIIPISGFTNYAQKFQGKVTITADESTSTAYMEL SS
LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK

Heavy Chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFVRYAISWVRQAP
Full (IgG1) GQGLEWMGGIIPIFGEAQYAQRFQGRVTITADESTSTAYMELS
SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVSSASTKGP
SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK

Heavy Chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFVRYAISWVRQAP
Full (IgG1) GQ
GLEWMGGIIP IF GEAQYAQKFRGRATITADE S T S TAYMEL S
SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVS SASTKGP
S VFPL AP S SK S T S GGTAAL GCLVKDYFPEP VTVS WN S GALT S G
VHTFPAVLQS SGLYSLS SVVTVPS S SL GTQTYI CNVNHKP S NT
KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
I SRTPEVTCVVVD VSHEDPEVKFNWYVD GVEVHNAKTKPRE
EQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTLPP SRDELTKNQVSL TCLVKGFYP SDI
AVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKSRWQ
QGNVFS CSVMHEALHNHYTQKSL SL SP GK

Heavy Chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYYISWVRQAPG
Full, heavy QGLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELS
variable 1 + SLRSEDTAVYYCARAGGGYARGDHYYGMDVVVGQGTTVTVS
IgG1 CH1 + SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
GGGGS + S GAL
TS GVH TFP AVLQ S SGLYSL S SVVTVPS S SL GTQTYICNV
heavy variable NHKPSNTKVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSV
1 + IgG4 KVSCKASGGTFS SYYISWVRQAPGQGLEWMGGIIPVPGTANY
S228P (with AQKFQGRVTITADESTSTAYMELS SLRSEDTAVYYCARAGGG
or without C YARGDHYYGMDVVVGQGTTVTVSSASTKGPSVFPLAPCSRST
terminal Lys) SESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS S
GLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY
GPPCPPCPAPEFL GGP S VFLFPPKPKD TLMI SRTPEVTCVVVD V
SQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVY
TLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLD SD GSFFLYSRL TVDKSRWQEGNVF S C S VMHEALH
NHYTQKSLSL SL G

Heavy Chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRGAISWVRQAP
Full, heavy GQGLEWMGGIIPIEGTAYYAQKFQGRVTITADESTSTAYMEL
variable 1 + S SLRSEDTAVYYCARQSDYGLPRGMDVVVGQGTTVTVS SAS T
IgG1 CH1 + KGPSVFPLAPS SKSTS GGTAAL GCLVKDYFPEPVTVSWNS GA
GGGGS +
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
heavy variable PSNTKVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVS
1 + IgG4 CKASGGTFSRGAISWVRQAPGQGLEWMGGIIPIEGTAYYAQK
S228P (with FQGRVTITADESTSTAYMEL S SLRSEDTAVYYCARQSDYGLP
or without C RGMDVVVGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALG
terminal Lys) CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSV
VT VP S S SL GTKTYTCNVDHKP SNTKVDKRVE SKYGPP CPP CP
APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEV

QFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYTLPPSQE
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
D SD GSFFLYSRL TVDK SRWQEGNVF S C S VMHEALHNHYTQK
SLSLSLG

Heavy Chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
Full, heavy QGLEWMGGIIPISGFANYAQKFQGRVTITADESTSTAYMELSS
variable 1 + LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
IgG1 CH1 + S VFPL AP S SKST S GGTAAL GCLVKDYFPEP VTVS WNS GALT S G
GGGGS +
VHTFPAVLQS SGLYSL S SVVTVPS S SL GTQTYI CNVNHKP S NT
heavy variable KVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVSCKAS
1 + IgG4 GGTF S
SYAISWVRQAPGQGLEWMGGIIPISGFANYAQKFQGR
S 228P (with VTITADESTSTAYMEL S SLR SED TAVYYCAREGGHYY S GWPY
or without C WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKD
terminal Lys) YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSS
SLGTKTYTCNVDHKP SNTKVDKRVESKYGPP CPP CP APEFL G
GP S VFLFPPKPKDTLMI SRTPEVT CVVVD VSQEDPEVQFNWY
VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKE
YKCKVSNKGLPS SIEKTISKAKGQPREPQVYTLPPSQEEMTKN
QVSLT CLVKGFYP SD IAVEWE SNGQPENNYKTTPPVLD SD GS
FFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSL SL SL
G

Heavy Chain QVQLVQ S GAEVKKP GS SVKVSCKASGGTFVRYAISWVRQAP
Full, heavy GQGLEWMGGIIPIFGEAQYAQKFQGRVTITADESTSTAYMELS
variable 1 + SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVSSASTKGP
IgG1 CH1 + S VFPL AP S SKST S GGTAAL GCLVKDYFPEP VTVS WNS GALT S G
GGGGS +
VHTFPAVLQS SGLYSL S SVVTVPS S SL GTQTYI CNVNHKP S NT
heavy variable KVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVSCKAS
1 + IgG4 GGTFVRYAISWVRQAPGQGLEWMGGIIPIFGEAQYAQKFQGR
S 228P (with VTITADESTSTAYMEL S SLR SED TAVYYCARE GYYYGALPYW
or without C GQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF
terminal Lys) PEP VTVS WNSGALTSGVHTFP AVLQ S SGLY SL SSVVTVPSSSL
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL GGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVD
GVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKC
KVSNKGLPS SIEKTISKAKGQPREPQVYTLPP SQEEMTKNQVS
LT CLVKGFYP SDIAVEWESNGQPENNYKTTPPVLD SD GSFFLY
SRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSL SL SLG

Heavy Chain QVQLQES GP GLVKP SETL SLTCAVSGYSIS SEYMVVGWIRQPP
Full, heavy GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLSS

variable 1 + VTAADTAVYYCARDSGRGYGDYGGHHAFDIWGQGTMVTVS
IgG1 CH1 + SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
GGGGS + S GAL
TS GVHTFP AVLQ S SGLYSL S SVVTVPS S SL GTQTYICNV
heavy variable NHKPSNTKVDKRVEPKSCGGGGSQVQLQESGPGLVKPSETLS
1 + IgG4 LTCAVSGYSIS SEYMWGWIRQPPGKGLEWIGLIYHSGKTYYN
S228P (with PSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDSGRG
or without C YGDYGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTS
terminal Lys) ESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SG
LYSL S SVVTVPS S SL GTKTYTCNVDHKPSNTKVDKRVESKYG
PP CPP CPAPEFL GGP S VFLFPPKPKDTLMI SRTPEVTCVVVD VS
QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTV
LHQDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYT
LPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLD SD GSFFLYSRL TVDKSRWQEGNVF S C S VMHEALHN
HYTQKSL SL SLG

Heavy Chain QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGAVVVSWIRQHP
Full, heavy GKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSS
variable 1 + VTAADTAVYYCARDSVRGYGDYGGHHAFDIWGQGTMVTVS
IgG1 CH1 + SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
GGGGS + S GAL
TS GVHTFP AVLQ S SGLYSL S SVVTVPS S SL GTQTYICNV
heavy variable NHKP SNTKVDKRVEPK S C GGGG S QVQL QE S GP GLVKP SQTL S
1 + IgG4 LTCTVS GGS IS S GGAVVVSWIRQHPGKGLEWIGGIAYSGSTYY
S228P (with NPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDSVR
or without C GYGDYGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRST
terminal Lys) SESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS S
GLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY
GPPCPPCPAPEFL GGP S VFLFPPKPKD TLMI SRTPEVTCVVVD V
SQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVY
TLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLD SD GSFFLYSRL TVDKSRWQEGNVF S C S VMHEALH
NHYTQKSL SL SL G

Heavy Chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYYISWVRQAPG
Full, heavy QGLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELS
variable 1 + SLRSEDTAVYYCARAGGGYARGDHYYGMDVVVGQGTTVTVS
IgG4 5228P SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN
(with or S GAL
TS GVHTFP AVLQ S SGLYSL S SVVTVPS S SL GTKTYTCNV
without C
DHKPSNTKVDKRVESKYGPPCPPCPAPEFL GGPSVFLFPPKPK
terminal Lys) DTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKT
+
KPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS

GGGGSGGG SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY
GS GGGGS + PSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLY SRL TVDK SR
heavy variable WQEGNVFSCSVMHEALHNHYTQKSLSLSLGGGGGSGGGGSG
1+ IgG1 CH1 GGGSQVQLVQSGAEVKKPGS SVKVSCKASGGTFS SYYISWVR
QAPGQGLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAY
MEL S SLR SED TAVYYCARAGGGYARGDHYYGMD VVVGQ GT
TVTVS SASTKGPSVFPLAPS SKSTSGGTAAL GCLVKDYFPEPV
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
YICNVNHKPSNTKVDKRVEPKS C
117 ABP26 Heavy Chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRGAISWVRQAP
Full, heavy GQGLEWMGGIIPIEGTAYYAQKFQGRVTITADESTSTAYMEL
variable 1 + S SLRSEDTAVYYCARQSDYGLPRGMDVVVGQGTTVTVS SAS T
IgG4 S228P KGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL
(with or TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKP
without C SNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLM
terminal Lys) ISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPRE
+ EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIEKT
GGGGSGGG ISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIA
GS GGGGS + VEWESNGQPENNYKTTPPVLD SD GSFFLY SRL TVDKSRWQEG
heavy variable NVFSCSVMHEALHNHYTQKSLSLSLGGGGGSGGGGSGGGGS
1 + IgG1 CH1 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRGAISWVRQAP
GQGLEWMGGIIPIEGTAYYAQKFQGRVTITADESTSTAYMEL
S SLR SED TAVYYCARQ SDYGLPRGMD VVVGQ GTTVTVS SAS T
KGPSVFPLAPS SKSTSGGTAAL GCLVKDYFPEPVTVSWNS GA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
PSNTKVDKRVEPKSC
118 ABP27 Heavy Chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
Full, heavy QGLEWMGGIIPISGFANYAQKFQGRVTITADESTSTAYMELSS
variable 1 + LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
IgG4 S228P SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSG
(with or VHTFPAVLQS SGLYSL S SVVTVPS S SLGTKTYTCNVDHKPSNT
without C KVDKRVE SKYGPP CPP CPAPEFL GGP S VFLFPPKPKDTLMI SR
terminal Lys) TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQF
+ NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIEKTISK
GGGGSGGG AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYP SDIAVE
GS GGGGS + WE SNGQPENNYKTTPPVLD SD GSFFLYSRLTVDKSRWQEGN
heavy variable VFSCSVMHEALHNHYTQKSLSLSLGGGGGSGGGGSGGGGSQ
1+ IgG1 CH1 VQLVQ S GAEVKKP GS SVKVS CKASGGTFS SYAISWVRQAPGQ
GLEWMGGIIPI S GFANYAQKFQ GRVTITADE ST STAYMEL S SL
RSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVS SASTKGPS

VFPL AP S SKST S GGTAAL GCLVKDYFPEPVTVSWNS GALT S G
VHTFPAVLQS SGLYSL S SVVTVPS S SL GTQTYI CNVNHKP S NT
KVDKRVEPKSC
119 ABP28 Heavy Chain QVQLVQSGAEVKKPGSSVKVSCKASGGTFVRYAISWVRQAP
Full, heavy GQGLEWMGGIIPIFGEAQYAQKFQGRVTITADESTSTAYMELS
variable 1 + SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVSSASTKGP
IgG4 S228P SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSG
(with or VHTFPAVLQS SGLYSL S SVVTVPS S SLGTKTYTCNVDHKPSNT
without C KVDKRVE SKYGPP CPP CPAPEFL GGP S VFLFPPKPKDTLMI SR
terminal Lys) TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQF
+ NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIEKTISK
GGGGSGGG AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYP SDIAVE
GS GGGGS + WE SNGQPENNYKTTPPVLD SD GSFFLYSRLTVDKSRWQEGN
heavy variable VFSCSVMHEALHNHYTQKSLSLSLGGGGGSGGGGSGGGGSQ
1+ IgG1 CH1 VQLVQSGAEVKKPGS SVKVS CKASGGTFVRYAISWVRQAPG
QGLEWMGGIIPIFGEAQYAQKFQGRVTITADESTSTAYMEL S S
LRSEDTAVYYCAREGYYYGALPYWGQGTLVTVS S ASTK GP S
VFPL AP S SKST S GGTAAL GCLVKDYFPEPVTVSWNS GALT S G
VHTFPAVLQS SGLYSL S SVVTVPS S SL GTQTYI CNVNHKP S NT
KVDKRVEPKSC
120 AB P29 Heavy Chain QVQLQE S GP GLVKP S ETL SL TCAVS GY S I S
SEYMVVGWIRQPP
Full, heavy GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLSS
variable 1 + VTAADTAVYYCARDSGRGYGDYGGHHAFDIWGQGTMVTVS
IgG4 S228P SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN
(with or S GAL T S GVH TFP AVLQ S SGLYSL S SVVTVPS S SL
GTKTYTCNV
without C DHKPSNTKVDKRVESKYGPPCPPCPAPEFL GGPSVFLFPPKPK
terminal Lys) DTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKT
+ KPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS
GGGGSGGG SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY
GS GGGGS + PSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLY SRL TVDK SR
heavy variable WQEGNVFSCSVMHEALHNHYTQKSLSLSLGGGGGSGGGGSG
1+ IgG1 CH1 GGGSQVQLQESGPGLVKP SETLSLTCAVSGYSIS SEYMVVGWI
RQPPGKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSL
KL S SVTAADTAVYYCARD SGRGYGDYGGHHAFDIWGQGTM
VTVS S A S TKGP S VFPL AP S SKSTSGGTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
ICNVNHKPSNTKVDKRVEPKSC
121 ABP30 Heavy Chain QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGAVVVSWIRQHP
Full, heavy GKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSS
variable 1 + VTAADTAVYYCARDSVRGYGDYGGHHAFDIWGQGTMVTVS

IgG4 S228P SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN
(with or S GAL T S GVH TFP AVLQ S SGLYSL S SVVTVPS S SL
GTKTYTCNV
without C DHKPSNTKVDKRVESKYGPPCPPCPAPEFL GGPSVFLFPPKPK
terminal Lys) DTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKT
+ KPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS
GGGGSGGG SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY
GS GGGGS + PSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLY SRL TVDK SR
heavy variable WQEGNVFSCSVMHEALHNHYTQKSLSLSLGGGGGSGGGGSG
1+ IgG1 CH1 GGGSQVQL QES GP GLVKP SQTL SLTCTVSGGSIS S GGAVVV SW
IRQHPGKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSL
KL S SVTAADTAVYYCARD SVRGYGDYGGHHAFDIWGQGTM
VTVS S A S TKGP S VFPL AP S SKSTSGGTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
ICNVNHKPSNTKVDKRVEPKSC
122 ABP31 Heavy Chain QVQLQES GP GLVKP SETL SL TCAVS GYSI S SEYMVVGWIRQPP
Full, heavy GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLSS
variable 1 + VTAADTAVYYCARDSGRGYGDYGGHHAFDIWGQGTMVTVS
IgG4 S228P SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN
(with or S GAL T S GVH TFP AVLQ S SGLYSL S SVVTVPS S SL
GTKTYTCNV
without C DHKPSNTKVDKRVESKYGPPCPPCPAPEFL GGPSVFLFPPKPK
terminal Lys) DTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKT
+ GGGGS + KPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS
heavy variable SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY
1 + IgG1 CH1 PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSR
WQEGNVFSCSVMHEALHNHYTQKSL SL SLGGGGGSQVQLQE
S GP GL VKP SETL SLT CAVS GY S I S SEYMWGWIRQPPGKGLEWI
GL IYH S GKTYYNP SLK SRVTI S VDT SKNQF SLKL S SVTAADTA
VYYCARD SGRGYGDYGGHHAFDIWGQGTMVTVS S A S TKGP
S VFPL AP S SK S T S GGTAAL GCLVKDYFPEP VTVS WN S GALT S G
VHTFPAVLQS SGLYSL S SVVTVPS S SL GTQTYI CNVNHKP S NT
KVDKRVEPKSC
123 ABP32 Heavy Chain QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGAVVVSWIRQHP
Full, heavy GKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSS
variable 1 + VTAADTAVYYCARDSVRGYGDYGGHHAFDIWGQGTMVTVS
IgG4 S228P SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN
(with or S GAL T S GVH TFP AVLQ S SGLYSL S SVVTVPS S SL
GTKTYTCNV
without C DHKPSNTKVDKRVESKYGPPCPPCPAPEFL GGPSVFLFPPKPK
terminal Lys) DTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKT
+ GGGGS + KPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS
SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY

heavy variable PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSR
1 + IgG1 CH1 WQEGNVFSCSVMHEALHNHYTQKSLSLSLGGGGGSQVQLQE
S GP GL VKP SQ TL SL TCTVS GG SI S SGGAVW SWIRQHPGKGLE
WIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAAD
TAVYYCARDSVRGYGDYGGHHAFDIWGQGTMVTVSSASTK
GP S VFPLAP S SK ST S GGTAAL GCL VKDYFPEPVTVS WNS GAL T
SGVHTFPAVLQS SGLYSL S SVVTVPS S SL GTQTYICNVNHKPS
NTKVDKRVEPKS C

Heavy Chain QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQA
Full, heavy PGQGLEWMGIINPSGGSTTYAQKFQGRVTMTRDTSTSTVYME
variable 1 + L S SLRSEDTAVYYCARGQYGYYGGRLDVWGQGTTVTVS SAS
IgG1 CH1 + TKGPSVFPLAPS SK ST S GGTAAL GCL VKDYFPEPVTVS WNS G
GGGGS + ALT S
GVHTFPAVL Q S SGLYSL S S VVTVP S S SL GTQTYICNVNH
heavy variable KPSNTKVDKRVEPKSCGGGGSQVQLVESGGGVVQPGRSLRL
2+ IgG4 S CAA S
GFTF S SYGMHWVRQAPGKGLEWVAVISYDGSNKYYA
S228P (with DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGLG
or without C YMAWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCL
terminal Lys) VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVT
VP S S SL GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAP
EFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQF
NWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN
GKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYTLPPSQEEM
TKNQVSLTCLVKGFYP SD IAVEWE SNGQPENNYKTTPPVLD S
DGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSL
SLSLGK

Heavy Chain QVQLVESGGGVVQPGRSLRL S CAA S GFTF S SYGMHWVRQ AP
Full, C GKGLEWVAVISYDGSNKYYAD SVKGRFTISRDNSKNTLYLQ
terminal Fab, MNSLRAEDTAVYYCARDGLGYMAWGQGTTVTVSSASTKGP
common light SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSG
chain VHTFPAVLQS SGLYSL S SVVTVPS S SLGTKTYTCNVDHKPSNT
bispecific: KVDKRVE SKYGPP CPP CPAPEFL GGP S VFLFPPKPKDTLMI SR
heavy variable TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQF
2+ IgG4 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIEKTISK
5228P (with AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVE
or without C WESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGN
terminal Lys) VFSCSVMHEALHNHYTQKSL SLSLGKGGGGSQVQLVQSGAE
+ GGGGS + VKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGII
heavy variable NPSGGSTTYAQKFQGRVTMTRDTSTSTVYMEL S SLRSEDTAV
1+ IgG1 CH1 YYCARGQYGYYGGRLDVWGQGTTVTVSSASTKGPSVFPLAP
S SK S T S GGTAAL GCL VKDYFPEPVTVSWNS GALT S GVHTFP A

VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV
EPKSC
N TERMINAL FAB TM = HEAVY VARIABLE 1+ IGG1 CH1 + GGGGS + HEAVY VARIABLE 1+
IGG4 S228P (WITH OR WITHOUT C l'ERMINAL LYS) Light Chain DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKA
Full PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKA
Full PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKA
Full PKLLIYAASSLKYGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIQMTQSPSSLSASVGDRVTITCRASKSIDSYLNWYQQKPGKA
Full PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIQMTQSPSSLSASVGDRVTITCRASKSIDSYLNWYQQKPGKA
Full PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKA
Full PKLLIYAADSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIQMTQSPSSLSASVGDRVTITCRASQSINSYLNWYQQKPGKA
Full PKLLIYAASSLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS

VVCLLNNFYPREAKVQWKVDNALQ S GNSQES VTEQD SKD ST
YSL SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIQMTQ SP S SL SASVGDRVTITCGASQSISTYLNWYQQKPGKA
Full PKLLIYSAS SLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
QQEYNTPPSFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV

SLSSTLTLSKADYEKHKVYACEVTHQGL SSPVTKSFNRGEC

Light Chain DIQMTQ SP S SL SASVGDRVTITCRASQSISSYLNWYQQKPGKA
Full PKLLIYAAS SLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQ S GNSQES VTEQD SKD ST
YSL SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIQMTQ SP S SL SASVGDRVTITCRASQSISSYLNWYQQKPGKA
Full PKLLIYAAS SLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQ S GNSQES VTEQD SKD ST
YSL SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIVMTQ SPL SLPVTPGEPAS IS CRS SQ SLLH SNGYNYLDWYLQ
Full KPGQ SPQLLIYLGSNRAS GVPDRF S GS GS GTDFTLKISRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QDSKDSTYSL SSTLTLSKADYEKHKVYACEVTHQGL SSPVTK
SFNRGEC

Light Chain DIVMTQ SPL SLPVTPGEPAS IS CRS SQ SLLH SNGYNYLDWYLQ
Full KPGQ SPQLLIYLGSNRAS GVPDRF S GS GS GTDFTLKISRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QDSKDSTYSL SSTLTLSKADYEKHKVYACEVTHQGL SSPVTK
SFNRGEC

Light Chain DIQLTQ SP S SVSASVGDRVTITCRASQGIS SWLAWYQQKPGK
Full APKLLIYGAS SLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATY
YCQQASLFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA
SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
TYSL SSTLTL SKADYEKHKVYACEVTHQGL SSPVTKSFNRGE
C

Light Chain EIVLTQSPATL SLSPGERATL SCRASQSVS SYLAWYQQKPGQA
Full PRLLIYDASNRATGIPARF S GS GS GTDFTLTIS SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQ S GNSQES VTEQD SKD ST
YSL SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain EIVLTQSPATL SLSPGERATL SCRASQSVS SYLAWYQQKPGQA
Full PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC

Light Chain EIVLTQSPATL SLSPGERATL SCRASQSVS SYLAWYQQKPGQA
Full PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC

Light Chain EIVLTQSPATL SLSPGERATL SCRASQSVS SYLAWYQQKPGQA
Full PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC

Light Chain EIVLTQSPATL SLSPGERATL SCRASQSVS SYLAWYQQKPGQA
Full PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC

Light Chain DIVMTQ SPL SLPVTPGEPAS IS CRS SQSLLH SNGYNYLDWYLQ
Full KPGQ SPQLLIYLGSNRAS GVPDRF S GS GS GTDFTLKI SRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QD SKD S TY SL S STLTLSKADYEKHKVYACEVTHQGL S SPVTK
SFNRGEC

Light Chain DIQLTQ SP S SVSASVGDRVTITCRASQGIS SWLAWYQQKPGK
Full APKLLIYGAS SLQ S GVP SRF S GS GS GTDF TLTIS SLQPEDFATY
YCQQASLFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA
SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD S
TY SL S STLTL SKADYEKHKVYACEVTHQGL S SPVTKSFNRGE
C

Light Chain EIVLTQSPATL SLSPGERATL SCRASQSVS SYLAWYQQKPGQA
Full PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC

Light Chain EIVLTQSPATL SLSPGERATL SCRASQSVS SYLAWYQQKPGQA
Full PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS

VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKA
Full PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKA
Full PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQ
Full KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK
SFNRGEC

Light Chain DIQLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGK
Full APKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATY
YCQQASLFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA
SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE
C

Light Chain EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQA
Full PRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQA
Full PRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKA
Full PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKA
Full PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKA
Full PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKA
Full PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Light Chain DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQ
Full KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQALQTPITFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK
SFNRGEC

Light Chain DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQ
Full KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQALQTPITFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK
SFNRGEC

KGLEWIGGIYESGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
AADTAVYYCAHERVRGYGDYGGHHAFDIWGQGTMVTVSS

GKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSS
VTAADTAVYYCADENVRGYGDYGGHHAFDIWGQGTMVTVS
S

KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSS

KGPEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSS

KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKL S S VT
AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS S

KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKL S S VT
AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS S

GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLS S
VTAADTAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVS
S

GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLS S
VTAADTAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVS
S

GKGLEWIGSIYYSGSTYYNP SLKSRVTISVDTSKNQFSLKLS SV
TAADTAVYYCARD SGRGYGDYGGHHAFDIWGQGTMVTVS S

GKGLEWIGSIYYSGSTYYNP SLKSRVTISVDTSKNQFSLKLS SV
TAADTAVYYCARD SGRGYGDYGGHHAFDIWGQGTMVTVS S

QGLEWMGGIIPVPGTANYAQKFQGRVTITADEST STAYNIEL S
SLRSEDTAVYYCARAGGGYARGDHYYGM DVWGQGTTVTVS
S

QRLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYNIELS
SLRSEDTAVYYCARAGGGYARGDHYYGM DVWGQGTTVTVS
S

GQGLEWMGGIIPIEGTAYYAQKFQGRVTITADESTGTAYNIEL
S SLR SED TAVYYCARQ SDYGLPRGMD VWGQ GTTVTVS S

QGLEWMGGIIPISGFTNYAQKFQGRVTITADESTSTAYNIEL S S
LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVS S

QRLEWMGGIIPI S GFTNYAQKFQGRVTITADES TS TAYNIEL S S
LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVS S

QGLEWMGGIIPISGFTNYAQKFQGKVTITADESTSTAYNIEL S S
LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVS S

GQGLEWMGGIIPIFGEAQYAQRFQGRVTITADESTSTAYIVIELS
SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVS S

GQGLEWNIGGIIPIF GEAQYAQKFRGRATITADE ST STAYIVIEL S
SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVS S

QGLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYIVIELS
SLRSEDTAVYYCARAGGGYARGDHYYGM DVWGQGTTVTVS
S

GQGLEWMGGIIPIEGTAYYAQKFQGRVTITADE STSTAYIVIEL
S SLR SED TAVYYCARQ SDYGLPRGMD VWGQ GTTVTVS S

QGLEWMGGIIPISGFANYAQKFQGRVTITADESTSTAYIVIELS S
LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVS S

GQGLEWMGGIIPIFGEAQYAQKFQGRVTITADESTSTAYIVIEL S
SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVS S

GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLS S
VTAADTAVYYCARD SGRGYGDYGGHHAFDIWGQGTMVTVS
S

GKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLS S
VTAADTAVYYCARD SVRGYGDYGGHHAFDIWGQGTMVTVS
S

QGLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYIVIELS
SLRSEDTAVYYCARAGGGYARGDHYYGM DVWGQGTTVTVS
S

GQGLEWMGGIIPIEGTAYYAQKFQGRVTITADE STSTAYIVIEL
S SLR SED TAVYYCARQ SDYGLPRGMD VWGQ GTTVTVS S

QGLEWMGGIIPISGFANYAQKFQGRVTITADESTSTAYIVIELS S
LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVS S

GQGLEWMGGIIPIFGEAQYAQKFQGRVTITADESTSTAYIVIEL S
SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVS S

GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLS S
VTAADTAVYYCARD SGRGYGDYGGHHAFDIWGQGTMVTVS

GKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLS S
VTAADTAVYYCARD SVRGYGDYGGHHAFDIWGQGTMVTVS

GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLS S
VTAADTAVYYCARD SGRGYGDYGGHHAFDIWGQGTMVTVS

GKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLS S
VTAADTAVYYCARD SVRGYGDYGGHHAFDIWGQGTMVTVS
126 ABP33 VH Variable 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQA
PGQGLEWMGIINPSGGSTTYAQKFQGRVTMTRDTSTSTVYME
LS SLRSEDTAVYYCARGQYGYYGGRLDVWGQGTTVTVS S
126 ABP34 VH Variable 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQA
PGQGLEWMGIINPSGGSTTYAQKFQGRVTMTRDTSTSTVYME
LS SLRSEDTAVYYCARGQYGYYGGRLDVWGQGTTVTVS S
127 ABP33 VH Variable 2 QVQLVESGGGVVQPGRSLRL S CAA S GFTF S SYGMHWVRQAP
GKGLEWVAVISYDGSNKYYAD SVKGRFTISRDNSKNTLYLQ
MNSLRAEDTAVYYCARDGLGYMAWGQGTTVTVS S
127 ABP34 VH Variable 2 QVQLVESGGGVVQPGRSLRL SCAASGFTFS SYGMHWVRQAP
GKGLEWVAVISYDGSNKYYAD SVKGRFTISRDNSKNTLYLQ
MNSLRAEDTAVYYCARDGLGYMAWGQGTTVTVS S

PKLLIYAAS SLQ S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYATPPTFGGGTKVEIK

PKLLIYAAS SLQ S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIK

PKLLIYAAS SLKYGVP SRF S GS GS GTDFTL TIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIK

SYLNWYQQKPGKA
PKLLIYAAS SLQ S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIK

SYLNWYQQKPGKA
PKLLIYAAS SLQ S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIK

PKLLIYAAD SLQSGVP SRF S GS GS GTDFTLTIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIK

PKLLIYAAS SLD S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIK

PKLLIYSAS SLE S GVP SRF S G S GS GTDFTL TIS SLQPEDFATYYC
QQEYNTPP SF GGGTKVEIK

PKLLIYAAS SLQ S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYATPPTFGGGTKVEIK

PKLLIYAAS SLQ S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYATPPTFGGGTKVEIK

KPGQ SPQLLIYLGSNRAS GVPDRF S GS GS GTDFTLKI SRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIK

KPGQ SPQLLIYLGSNRAS GVPDRF S GS GS GTDFTLKI SRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIK

APKLLIYGAS SLQ S GVP SRF S GS G S GTDF TLTIS SLQPEDFATY
YCQQASLFPPTFGGGTKVEIK

PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIK

PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIK

PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIK

PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIK

PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIK

KPGQ SPQLLIYLGSNRAS GVPDRF S GS GS GTDFTLKI SRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIK

APKLLIYGAS SLQ S GVP SRF S GS G S GTDF TLTIS SLQPEDFATY
YCQQASLFPPTFGGGTKVEIK

PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIK

PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIK

PKLLIYAAS SLQ S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYATPPTFGGGTKVEIK

PKLLIYAAS SLQ S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYATPPTFGGGTKVEIK

KPGQ SPQLLIYLGSNRAS GVPDRF S GS GS GTDFTLKI SRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIK

APKLLIYGAS SLQ S GVP SRF S GS G S GTDF TLTIS SLQPEDFATY
YCQQASLFPPTFGGGTKVEIK

PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIK

PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIK

PKLLIYAAS SLQ S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYATPPTFGGGTKVEIK

PKLLIYAAS SLQ S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYATPPTFGGGTKVEIK

PKLLIYAAS SLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIK

PKLLIYAAS SLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIK

KPGQ SPQLLIYLGSNRAS GVPDRF S GS GS GTDFTLKI SRVEAE
DVGVYYCMQALQTPITFGGGTKVEIK

KPGQ SPQLLIYLGSNRAS GVPDRF S GS GS GTDFTLKI SRVEAE
DVGVYYCMQALQTPITFGGGTKVEIK

131 ABP33 VH CDR3 vi ARGQYGYYGGRLDV
131 ABP34 VH CDR3 vi ARGQYGYYGGRLDV
134 ABP33 VH CDR3 v2 ARDGLGYMA
134 ABP34 VH CDR3 v2 ARDGLGYMA

60 ABP 9 VH CDR2 SIYYSGSTYYNPSLKS

130 ABP33 VH CDR2 vi IINPSGGSTTYAQKFQG
130 ABP34 VH CDR2 vi IINPSGGSTTYAQKFQG
133 ABP33 VH CDR2 v2 VI SYD G SNKYYAD SVKG
133 ABP34 VH CDR2 v2 VI SYD GSNKYYAD SVKG

129 ABP33 VH CDR1 vi YTFTSYYMH

129 ABP34 VH CDR1 vi YTFTSYYMH
132 ABP33 VH CDR1 v2 FTF S SYGMH
132 ABP34 VH CDR1 v2 FTF S SYGMH
16 ABP 1 VI, CDR3 QQEYATPPT
17 ABP2 VI, CDR3 QQEYNTPPT
17 ABP3 VI, CDR3 QQEYNTPPT
17 ABP4 VI, CDR3 QQEYNTPPT
17 ABP5 VI, CDR3 QQEYNTPPT
17 ABP6 VI, CDR3 QQEYNTPPT
17 ABP7 VI, CDR3 QQEYNTPPT
56 ABP 8 VI, CDR3 QQEYNTPPS
16 ABP9 VI, CDR3 QQEYATPPT
16 ABP10 VI, CDR3 QQEYATPPT
69 ABP11 VI, CDR3 MQKIGTPLT
69 ABP12 VI, CDR3 MQKIGTPLT
78 ABP13 VI, CDR3 QQASLFPPT
86 ABP14 VI, CDR3 QQRLVFPPT
86 ABP15 VI, CDR3 QQRLVFPPT
86 ABP16 VI, CDR3 QQRLVFPPT
94 ABP17 VI, CDR3 QQHSVFPPT
94 ABP18 VI, CDR3 QQHSVFPPT
69 ABP19 VI, CDR3 MQKIGTPLT
78 ABP20 VI, CDR3 QQASLFPPT
86 ABP21 VI, CDR3 QQRLVFPPT
94 ABP22 VI, CDR3 QQHSVFPPT
16 ABP23 VI, CDR3 QQEYATPPT
16 ABP24 VI, CDR3 QQEYATPPT
69 ABP25 VI, CDR3 MQKIGTPLT
78 ABP26 VI, CDR3 QQASLFPPT
86 ABP27 VI, CDR3 QQRLVFPPT
94 ABP28 VI, CDR3 QQHSVFPPT
16 ABP29 VI, CDR3 QQEYATPPT
16 ABP30 VI, CDR3 QQEYATPPT
16 ABP31 VI, CDR3 QQEYATPPT
16 ABP32 VI, CDR3 QQEYATPPT
135 ABP33 VI, CDR3 MQALQTPIT
135 ABP34 VI, CDR3 MQALQTPIT
15 ABP 1 VI, CDR2 AASSLQS
15 ABP2 VI, CDR2 AASSLQS

31 ABP3 VI, CDR2 AASSLKY
15 ABP4 VI, CDR2 AASSLQS
15 ABP5 VI, CDR2 AASSLQS
41 ABP6 VI, CDR2 AADSLQS
50 ABP7 VI, CDR2 AASSLDS
55 ABP8 VI, CDR2 SASSLES
15 ABP9 VI, CDR2 AASSLQS
15 ABP10 VI, CDR2 AASSLQS
68 ABP11 VI, CDR2 LGSNRAS
68 ABP12 VI, CDR2 LGSNRAS
77 ABP13 VI, CDR2 GASSLQS
85 ABP14 VI, CDR2 DASNRAT
85 ABP15 VI, CDR2 DASNRAT
85 ABP16 VI, CDR2 DASNRAT
85 ABP17 VI, CDR2 DASNRAT
85 ABP18 VI, CDR2 DASNRAT
68 ABP19 VI, CDR2 LGSNRAS
77 ABP20 VI, CDR2 GASSLQS
85 ABP21 VI, CDR2 DASNRAT
85 ABP22 VI, CDR2 DASNRAT
15 ABP23 VI, CDR2 AASSLQS
15 ABP24 VI, CDR2 AASSLQS
68 ABP25 VI, CDR2 LGSNRAS
77 ABP26 VI, CDR2 GASSLQS
85 ABP27 VI, CDR2 DASNRAT
85 ABP28 VI, CDR2 DASNRAT
15 ABP29 VI, CDR2 AASSLQS
15 ABP30 VI, CDR2 AASSLQS
15 ABP31 VI, CDR2 AASSLQS
15 ABP32 VI, CDR2 AASSLQS
68 ABP33 VI, CDR2 LGSNRAS
68 ABP34 VI, CDR2 LGSNRAS
14 ABP1 VI, CDR1 RASQSISSYLN
14 ABP2 VI, CDR1 RASQSISSYLN
14 ABP3 VI, CDR1 RASQSISSYLN
36 ABP4 VI, CDR1 RASKSIDSYLN
36 ABP5 VI, CDR1 RASKSIDSYLN
14 ABP6 VI, CDR1 RASQSISSYLN
49 ABP7 VI, CDR1 RASQSINSYLN

137 IgG1 Constant ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
CH1 Region GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN
HKPSNTKVDKRVEPKSC
138 IgG4 Constant ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS
S228P Region GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVD
HKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTK
PREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSI
EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRW
QEGNVFSCSVMHEALHNHYTQKSLSLSLGK

139 IgG4 Constant ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS
S228P no Region GALT S GVHTFPAVLQ S SGLYSLS SVVTVPS S SLGTKTYTCNVD
C HKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKD
terminal TLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTK
Lys PREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SI
EKTISKAKGQPREPQVYTLPP SQEEMTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLD SD GSFFLYSRLTVDKSRW
QEGNVFSCSVMHEALHNHYTQKSL SLSLG
140 Kappa Constant RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWK
Region VDNALQSGNSQESVTEQD SKD STYSLS STLTLSKADYEKHKV
YACEVTHQGLS SPVTKSFNRGEC
141 CDRH3 Generic X1X2X3X4X5RGYGDYGGHHAFDI, WHEREIN X1 IS A OR V, X2 Sequence 1 IS H, D, L, OR R, X3 IS E OR D, X4 IS R, N, S, OR A, AND X5 IS
V, D OR G
142 CDRH2 Generic X1lX2X3SGX4TYYNPSLKS, WHEREIN X1 IS G, L, OR S, X2 IS
Y, Sequence 1 A, OR V, X3 IS E, Y OR H, AND X4I5 S OR K
143 CDRH1 Generic X1SISSX2X3X4X5WX6, WHEREIN X1 IS Y OR G, X2 IS G, S, OR
Sequence 1 E, X3IS L, G, S, Y, OR A, X4I5 G, A, Y, M, OR G, X5 IS V, A, OR
IS ABSENT, AND X6 IS S OR G
144 CDRL 3 Generic QQEYX1TPPX2, WHEREIN X1 IS A OR N AND X2 IS T OR S
Sequence 1 145 CDRL2 Generic X1AX2SLX3X4, WHEREIN X1 IS A OR S, X2 IS D OR S, X3 IS
Q, Sequence 1 D, K, ORE, AND X4 IS S OR Y
146 CDRL1 Generic XiAS X25I X3X4YLN, WHEREIN X1 IS G OR R, X2 IS Q OR K, Sequence 1 X3 IS S, D, OR N, AND X4 IS S OR T
147 CDRH2 Generic GIIPIFGEAQYAQX1FX2G, WHEREIN X1 IS K OR R, AND X2 IS
Sequence 2 Q OR R
148 ABP35 Full Heavy, QVQLQES GP GLVKP SETL SL TCAVS GYSIS
SGLGWGWIRQPPG
IgG1 N297A KGLEWIGGIYESGSTYYNPSLKSRVTISVDTSKNQFSLKLS SVT
AADTAVYYCAHERVRGYGDYGGHHAFDIWGQGTMVTVS SA
STKGP SVFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSG
ALT S GVHTFPAVLQ S SGLYSLS SVVTVP S S SLGTQTYICNVNH
KPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF
YPSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK
149 ABP36 Full Heavy, QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGAVWSWIRQHP
IgG1 N297A GKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLS S

VTAADTAVYYCADENVRGYGDYGGHHAFDIWGQGTMVTVS
SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
S GAL TS GVH TFP AVLQ S SGLYSL S SVVTVPS S SL GTQTYICNV
NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYP SD IAVEWE SNGQPENNYKTTPPVLD SD GSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGK
150 ABP37 Full Heavy, QVQLQES
GP GLVKP SETL SL TCAVS GYSI S SGAGWGWIRQPPG
IgG1 N297A KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKL S SVT
AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS SA
STKGP SVFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSG
ALT S GVHTFPAVLQ S SGLYSLS SVVTVP S S SL GTQTYICNVNH
KPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF
YPSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK
151 ABP38 Full Heavy, QVQLQES
GP GLVKP SETL SL TCAVS GYSI S SGAGWGWIRQPPG
IgG1 N297A KGPEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLS SVT
AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS SA
STKGP SVFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSG
ALT S GVHTFPAVLQ S SGLYSLS SVVTVP S S SL GTQTYICNVNH
KPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF
YPSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK
152 ABP39 Full Heavy, QVQLQES
GP GLVKP SETL SL TCAVS GYSI S SGAGWGWIRQPPG
IgG1 N297A KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKL S SVT
AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS SA
STKGP SVFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSG
ALT S GVHTFPAVLQ S SGLYSLS SVVTVP S S SL GTQTYICNVNH
KPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF

YPSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKS
RWQQGNVFSCSVMHEALHNHYTQKSL SL SPGK
153 AB P40 Full Heavy, QVQLQE S GP GLVKP S ETL SL TCAVS GY S I S
SEYMVVGWIRQPP
IgG1 N297A GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKL S S
VTAADTAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVS
SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
S GAL TS GVH TFP AVLQ S SGLYSL S SVVTVPS S SL GTQTYICNV
NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYP SD IAVEWE SNGQPENNYKTTPPVLD SD GSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSL SL SPGK
154 ABP41 Full Heavy, QVQLQESGPGLVKPSETLSLTCAVSGYSIS SEYMVVGWIRQPP
IgG1 N297A GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKL S S
VTAADTAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVS
SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
S GAL TS GVH TFP AVLQ S SGLYSL S SVVTVPS S SL GTQTYICNV
NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYP SD IAVEWE SNGQPENNYKTTPPVLD SD GSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSL SL SPGK
155 AB P42 Full Heavy, QLQLQE S GP GL VKP SETL SLTCTVSGGSIS S S
SYAWGWIRQPP
IgG1 N297A GKGLEWIGSIYYSGSTYYNP SLKSRVTISVDTSKNQFSLKL S SV
TAAD TAVYY CARD SGRGYGDYGGHHAFDIWGQGTMVTVS S
ASTKGP SVFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNS
GALT S GVHTFPAVLQ S SGLYSL S SVVTVPS S SL GTQTYICNVN
HKPSNTKVDKKVEPKS CDKTHTCPPCPAPELL GGPSVFLFPPK
PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
KTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL
PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSL SL SPGK
156 ABP43 Full Heavy, QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYAWGWIRQPP
IgG4 S228P GKGLEWIGSIYYSGSTYYNP SLKSRVTISVDTSKNQFSLKL S SV
TAAD TAVYY CARD SGRGYGDYGGHHAFDIWGQGTMVTVS S
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNS
GALT S GVHTFPAVLQ S SGLYSL S SVVTVPS S SL GTKTYTCNVD

HKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTK
PREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SI
EKTISKAKGQPREPQVYTLPP SQEEMTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLD SD GSFFLYSRLTVDKSRW
QEGNVFSCSVMHEALHNHYTQKSL SL SL GK
157 ABP44 Full Heavy, QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYYISWVRQAPG
IgG1 N297A QGLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELS
SLRSEDTAVYYCARAGGGYARGDHYYGMDVVVGQGTTVTVS
SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
S GAL TS GVH TFP AVLQ S SGLYSL S SVVTVPS S SL GTQTYICNV
NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYP SD IAVEWE SNGQPENNYKTTPPVLD SD GSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSL SL SPGK
158 AB P45 Full Heavy, QVQLVQSGAEVKKPGS SVKVSCKASGGTFSRGAISWVRQAP
IgG1 N297A GQGLEWMGGIIPIEGTAYYAQKFQGRVTITADESTSTAYMEL
S SLR SED TAVYYCARQ SDYGLPRGMD VVVGQ GTTVTVS SAS T
KGPSVFPLAPS SKSTSGGTAAL GCLVKDYFPEPVTVSWNS GA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
PSNTKVDKKVEPKSCDKTHTCPPCPAPELL GGPSVFLFPPKPK
DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKT
KPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSL SL SPGK
159 ABP46 Full Heavy, QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
IgG1 N297A QGLEWMGGIIPISGFANYAQKFQGRVTITADESTSTAYMEL S S
LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVS SA STKGP
S VFPL AP S SK S T S GGTAAL GCLVKDYFPEP VTVS WN S GALT S G
VHTFPAVLQS SGLYSL S SVVTVPS S SL GTQTYI CNVNHKP S NT
KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
I SRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPRE
EQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTLPP SRDELTKNQVSL TCLVKGFYP SDI
AVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKSRWQ
QGNVFS CSVMHEALHNHYTQKSL SL SP GK

160 ABP47 Full Heavy, QVQLVQSGAEVKKPGSSVKVSCKASGGTFVRYAISWVRQAP
IgG1 N297A GQGLEWMGGIIPIFGEAQYAQKFQGRVTITADESTSTAYMELS
SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVSSASTKGP
SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK
161 ABP48 Full Heavy, QVQLQESGPGLVKPSETLSLTCAVSGYSISSEYMVVGWIRQPP
IgG1 N297A GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLSS
VTAADTAVYYCARDSGRGYGDYGGHHAFDIWGQGTMVTVS
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
162 ABP49 Full Heavy, QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGAVVVSWIRQHP
IgG1 N297A GKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSS
VTAADTAVYYCARDSVRGYGDYGGHHAFDIWGQGTMVTVS
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

Full Heavy, N QVQLVQSGAEVKRPGSSVKVSCKASGGTFSSYYISWVRQVPG
terminal Fab QGLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELS
TM (IgG1 SLRSEDTAVYYCARAGGGYARGDHYYGMDVVVGQGTTVTVS
Fab, IgG4 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
5228P) SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
NHKPSNTKVDKRVEPKSCGGGGSQVQLVQSGAEVKRPGSSV
KVSCKASGGTFSSYYISWVRQVPGQGLEWMGGIIPVPGTANY

AQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAGGG
YARGDHYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRST
SESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY
GPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
SQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVY
TLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALH
NHYTQKSLSLSLGK

Full Heavy, N QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYYISWVRQAPG
terminal Fab QRLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELS
TM (IgG1 SLRSEDTAVYYCARAGGGYARGDHYYGMDVWGQGTTVTVS
Fab, IgG4 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
S228P) SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
NHKPSNTKVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSV
KVSCKASGGTFSSYYISWVRQAPGQRLEWMGGIIPVPGTANY
AQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAGGG
YARGDHYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRST
SESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY
GPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
SQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVY
TLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALH
NHYTQKSLSLSLGK
165 ABP52 Full Heavy, N QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRGAISWVRQAP
terminal Fab GQGLEWMGGIIPIEGTAYYAQKFQGRVTITADESTGTAYMEL
TM (IgG1 SSLRSEDTAVYYCARQSDYGLPRGMDVWGQGTTVTVSSAST
Fab, IgG4 KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA
5228P) LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
PSNTKVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVS
CKASGGTFSRGAISWVRQAPGQGLEWMGGIIPIEGTAYYAQK
FQGRVTITADESTGTAYMELSSLRSEDTAVYYCARQSDYGLP
RGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALG
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCP
APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEV
QFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDW

LNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQE
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
DSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQK
SLSLSLGK

Full Heavy, N QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
terminal Fab QGLEWMGGIIPISGFTNYAQKFQGRVTITADESTSTAYMELSS
TM (IgG1 LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
Fab, IgG4 SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
S228P) VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVSCKAS
GGTFSSYAISWVRQAPGQGLEWMGGIIPISGFTNYAQKFQGR
VTITADESTSTAYMELSSLRSEDTAVYYCAREGGHYYSGWPY
WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKD
YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
SLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY
VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKE
YKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
FFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
GK

Full Heavy, N QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
terminal Fab QRLEWMGGIIPISGFTNYAQKFQGRVTITADESTSTAYMELSS
TM (IgG1 LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
Fab, IgG4 SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
S228P) VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVSCKAS
GGTFSSYAISWVRQAPGQRLEWMGGIIPISGFTNYAQKFQGR
VTITADESTSTAYMELSSLRSEDTAVYYCAREGGHYYSGWPY
WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKD
YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
SLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY
VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKE
YKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
FFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
GK
168 ABP55 Full Heavy, N QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
terminal Fab QGLEWMGGIIPISGFTNYAQKFQGKVTITADESTSTAYMELSS

TM (IgG1 LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
Fab, IgG4 SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
S228P) VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVSCKAS
GGTFSSYAISWVRQAPGQGLEWMGGIIPISGFTNYAQKFQGK
VTITADESTSTAYMELSSLRSEDTAVYYCAREGGHYYSGWPY
WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKD
YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
SLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY
VDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKE
YKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
FFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
GK

Full Heavy, N QVQLVQSGAEVKKPGSSVKVSCKASGGTFVRYAISWVRQAP
terminal Fab GQGLEWMGGIIPIFGEAQYAQRFQGRVTITADESTSTAYMELS
TM (IgG1 SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVSSASTKGP
Fab, IgG4 SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
S228P) VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVSCKAS
GGTFVRYAISWVRQAPGQGLEWMGGIIPIFGEAQYAQRFQGR
VTITADESTSTAYMELSSLRSEDTAVYYCAREGYYYGALPYW
GQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVD
GVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKC
KVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
SRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

Full Heavy, N QVQLVQSGAEVKKPGSSVKVSCKASGGTFVRYAISWVRQAP
terminal Fab GQGLEWMGGIIPIFGEAQYAQKFRGRATITADESTSTAYMELS
TM (IgG1 SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVSSASTKGP
Fab, IgG4 SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
S228P) VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVSCKAS
GGTFVRYAISWVRQAPGQGLEWMGGIIPIFGEAQYAQKFRGR
ATITADESTSTAYMELSSLRSEDTAVYYCAREGYYYGALPYW
GQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF

PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
GTKTYTCNVDHKP SNTKVDKRVESKYGPPCPPCPAPEFL GGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVD
GVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKC
KVSNKGLP S SIEKTISKAKGQPREPQVYTLPP SQEEMTKNQVS
LT CLVKGFYP SDIAVEWESNGQPENNYKTTPPVLD SD GSFFLY
SRLTVDKSRWQEGNVF SCSVMHEALHNHYTQK SL SL SLGK
179 AB P58 Full Heavy, QVQLVQ S GAEVKKP GA S VKV S CKA S GYTFT
SYYMHWVRQA
IgG1 N297A PGQGLEWMGIINPSGGSTTYAQKFQGRVTMTRDTSTSTVYME
L S SLRSEDTAVYYCARGQYGYYGGRLDVVVGQGTTVTVS SA S
TKGP SVFPLAP S SKST SGGTAALGCLVKDYFPEPVTVSWNSG
ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
KP SNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP S VFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF
YP SDIAVEWESNGQPENNYKTTPPVLD SD GSFFLY SKL TVDK S
RWQQGNVF SCSVMHEALHNHYTQKSL SL SP GK
180 AB P59 Full Heavy, QVQLVQ S GAEVKKP GA S VKV S CKA S GYTFT
SYYMHWVRQA
IgG4 S228P PGQGLEWMGIINP SGGSTTYAQKFQ GRVTMTRDT STSTVYME
L S SLRSEDTAVYYCARGQYGYYGGRLDVVVGQGTTVTVS SA S
TKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHK
P SNTKVDKRVESKYGPPCPPCPAPEFLGGP SVFLFPPKPKDTL
MISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPR
EEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLP S SIEK
TISKAKGQPREPQVYTLPP SQEEMTKNQVSLTCLVKGFYP SDI
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQE
GNVF SCSVMHEALHNHYTQKSL SL SL GK
181 AB P60 Full Heavy, QVQLVESGGGVVQPGRSLRL S CAA S GFTF S SYGMHWVRQ AP
IgG1 N297A GKGLEWVAVISYDGSNKYYAD SVKGRFTISRDNSKNTLYLQ
MNSLRAEDTAVYYCARDGLGYMAWGQGTTVTVSSASTKGP
S VFPL AP S SKST SGGTAALGCLVKDYFPEPVTVS WN S GALT S G
VHTFPAVLQ S SGLYSL S SVVTVP S S SLGTQTYICNVNHKP S NT
KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTLPP SRDELTKNQVSLTCLVKGFYP SDI
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVF S CSVMHEALHNHYTQKSL SL SP GK

182 ABP61 Full Heavy, QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAP
IgG4 S228P GKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQ
MNSLRAEDTAVYYCARDGLGYMAWGQGTTVTVSSASTKGP
SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNT
KVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQF
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK
AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVE
WESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGN
VFSCSVMHEALHNHYTQKSLSLSLGK

Full Heavy, N QVQLQESGPGLVKPSETLSLTCAVSGYSISSGLGWGWIRQPPG
terminal Fab KGLEWIGGIYESGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
TM (IgG1 AADTAVYYCAHERVRGYGDYGGHHAFDIWGQGTMVTVSSA
Fab, IgG1 STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG
(G1m(3))) ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
KPSNTKVDKRVEPKSCGGGGSQVQLQESGPGLVKPSETLSLT
CAVSGYSISSGLGWGWIRQPPGKGLEWIGGIYESGSTYYNPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAHERVRGYGD
YGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGT
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
NHYTQKSLSLSPGK

Full Heavy, N QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGAVWSWIRQHP
terminal Fab GKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSS
TM (IgG1 VTAADTAVYYCADENVRGYGDYGGHHAFDIWGQGTMVTVS
Fab, IgG1 SASTKGPSVFPLAPSS
(G1m(3))) KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP
KSCGGGGSQVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGAV
WSWIRQHPGKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKN
QFSLKLSSVTAADTAVYYCADENVRGYGDYGGHHAFDIWG
QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
GTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELL

GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK
EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTK
NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG
SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS
PGK

Full Heavy, N QVQLQESGPGLVKPSETLSLTCAVSGYSISSGAGWGWIRQPPG
terminal Fab KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
TM (IgG1 AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSSA
Fab, IgG1 STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG
(G1m(3))) ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
KPSNTKVDKRVEPKSCGGGGSQVQLQESGPGLVKPSETLSLT
CAVSGYSISSGAGWGWIRQPPGKGLEWIGLIVHSGSTYYNPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVLESVRGYGD
YGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGT
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
NHYTQKSLSLSPGK

Full Heavy, N QVQLQESGPGLVKPSETLSLTCAVSGYSISSGAGWGWIRQPPG
terminal Fab KGPEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
TM (IgG1 AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSSA
Fab, IgG1 STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG
(G1m(3))) ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
KPSNTKVDKRVEPKSCGGGGSQVQLQESGPGLVKPSETLSLT
CAVSGYSISSGAGWGWIRQPPGKGPEWIGLIVHSGSTYYNPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVLESVRGYGD
YGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGT
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
NHYTQKSLSLSPGK

Full Heavy, N QVQLQESGPGLVKPSETLSLTCAVSGYSISSGAGWGWIRQPPG
terminal Fab KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
TM (IgG1 AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS SA
Fab, IgG1 STKGP
SVFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSG
(G1m(3))) ALT S
GVHTFPAVLQ S SGLYSLS SVVTVP S S SLGTQTYICNVNH
KPSNTKVDKRVEPKS CGGGGSQVQLQESGPGLVKPSETLSLT
CAVSGYSIS SGAGWGWIRQPPGKGLEWIGLIVHSGSTYYNPSL
KSRVTISVDTSKNQFSLKLS SVTAADTAVYYCVLESVRGYGD
YGGHHAFDIWGQGTMVTVS SASTKGPSVFPLAPS SKS TS GGT
AAL G CLVKDYFPEPVTVS WN S GALT S GVHTFPAVLQ S SGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLD SD G SFFLY SKL TVDK SRWQQ GNVF SCSVMHEALH
NHYTQKSLSL SP GK

Full Heavy, N QVQLQESGPGLVKPSETLSLTCAVSGYSISSGAGWGWIRQPPG
terminal Fab KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
TM (IgG1 AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS SA
Fab, IgG1 STKGP
SVFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSG
(G1m(3))) ALT S
GVHTFPAVLQ S SGLYSLS SVVTVP S S SLGTQTYICNVNH
KPSNTKVDKRVEPKS CGGGGSQVQLQESGPGLVKPSETLSLT
CAVSGYSIS SGAGWGWIRQPPGKGLEWIGLIVHSGSTYYNPSL
KSRVTISVDTSKNQFSLKLS SVTAADTAVYYCVLESVRGYGD
YGGHHAFDIWGQGTMVTVS SASTKGPSVFPLAPS SKS TS GGT
AAL G CLVKDYFPEPVTVS WN S GALT S GVHTFPAVLQ S SGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLD SD G SFFLY SKL TVDK SRWQQ GNVF SCSVMHEALH
NHYTQKSLSL SP GK
189 ABP68 Full Heavy, N QVQLQESGPGLVKPSETLSLTCAVSGYSISSEYMVVGWIRQPP
terminal Fab GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLSS
TM (IgG1 VTAADTAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVS
Fab, IgG1 SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
(G1m(3))) S GAL
TS GVH TFP AVLQ S SGLYSL S SVVTVPS S SLGTQTYICNV
NHKPSNTKVDKRVEPKSCGGGGSQVQLQESGPGLVKPSETLS

LTCAVSGYSISSEYMWGWIRQPPGKGLEWIGLIYHSGKTYYN
PSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREADRG
YGDYGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTS
GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD
KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV
DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS
VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
EALHNHYTQKSLSLSPGK
190 ABP69 Full Heavy, N QVQLQESGPGLVKPSETLSLTCAVSGYSISSEYMVVGWIRQPP
terminal Fab GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLSS
TM (IgG1 VTAADTAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVS
Fab, IgG1 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
(G1m(3))) SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
NHKPSNTKVDKRVEPKSCGGGGSQVQLQESGPGLVKPSETLS
LTCAVSGYSISSEYMWGWIRQPPGKGLEWIGLIYHSGKTYYN
PSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREADRG
YGDYGGHHAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTS
GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD
KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV
DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS
VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
EALHNHYTQKSLSLSPGK

Full Heavy, C QVQLQESGPGLVKPSETLSLTCAVSGYSISSGLGWGWIRQPPG
terminal Fab KGLEWIGGIYESGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
TM, linker = AADTAVYYCAHERVRGYGDYGGHHAFDIWGQGTMVTVSSA
5mer (IgG1 STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG
(G1m(3)), ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
IgG1 Fab) KPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSQVQL
QESGPGLVKPSETLSLTCAVSGYSISSGLGWGWIRQPPGKGLE

WIGGIYESGSTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAAD
TAVYYCAHERVRGYGDYGGHHAFDIWGQGTMVTVS SASTK
GP SVFPLAP S SKSTS GGTAAL GCL VKDYFPEPVTVSWNS GAL T
SGVHTFPAVLQS SGLYSLS SVVTVPS S SLGTQTYICNVNHKPS
NTKVDKRVEPKS C

Full Heavy, C QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGAVVVSWIRQHP
terminal Fab GKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSS
TM, linker = VTAADTAVYYCADENVRGYGDYGGHHAFDIWGQGTMVTVS
5mer (IgG1 SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
(G1m(3)), S GAL
TS GVH TFP AVLQ S SGLYSL S SVVTVPS S SLGTQTYICNV
IgG1 Fab) NHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
KGFYP SD IAVEWE SNGQPENNYKTTPPVLD SD GSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGKGGGGSQ
VQLQE S GP GL VKP SQTL SLT CTVS GGS IS SGGAVWSWIRQHPG
KGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSV
TAADTAVYYCADENVRGYGDYGGHHAFDIWGQGTMVTVS S
ASTKGP SVFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNS
GALT S GVHTFPAVLQ S SGLYSLS SVVTVPS S SLGTQTYICNVN
HKPSNTKVDKRVEPKSC

Full Heavy, C QVQLQESGPGLVKPSETLSLTCAVSGYSISSGAGWGWIRQPPG
terminal Fab KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
TM, linker = AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSSA
5mer (IgG1 STKGP
SVFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSG
(G1m(3)), ALT S
GVHTFPAVLQ S SGLYSLS SVVTVP S S SLGTQTYICNVNH
IgG1 Fab) KPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
YPSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSL SPGKGGGGSQVQL
QESGPGLVKPSETLSLTCAVSGYSIS SGAGWGWIRQPPGKGLE
WI GLIVH S GS TYYNP SLK SRVTI S VD T SKNQF SLKL S SVTAAD
TAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS SA STK
GP SVFPLAP S SKSTS GGTAAL GCL VKDYFPEPVTVSWNS GAL T
SGVHTFPAVLQS SGLYSLS SVVTVPS S SLGTQTYICNVNHKPS
NTKVDKRVEPKS C

Full Heavy, C QVQLQESGPGLVKPSETLSLTCAVSGYSISSGAGWGWIRQPPG
terminal Fab KGPEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLS SVT
TM, linker = AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSSA
5mer (IgG1 STKGP
SVFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSG
(G1m(3)), ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
IgG1 Fab) KPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
YPSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSL SPGKGGGGSQVQL
QES GP GLVKP SETLSLTCAVSGYSIS SGAGWGWIRQPPGKGPE
WI GLIVH S GS TYYNP SLK SRVTI S VD T SKNQF SLKL S SVTAAD
TAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS SA STK
GP SVFPLAP S SKSTS GGTAAL GCL VKDYFPEPVTVSWNS GAL T
SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS
NTKVDKRVEPKS C

Full Heavy, C QVQLQESGPGLVKPSETLSLTCAVSGYSISSGAGWGWIRQPPG
terminal Fab KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
TM, linker = AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSSA
5mer (IgG1 STKGP
SVFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSG
(G1m(3)), ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
IgG1 Fab) KPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
YPSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSL SPGKGGGGSQVQL
QESGPGLVKPSETLSLTCAVSGYSIS SGAGWGWIRQPPGKGLE
WI GLIVH S GS TYYNP SLK SRVTI S VD T SKNQF SLKL S SVTAAD
TAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS SA STK
GP SVFPLAP S SKSTS GGTAAL GCL VKDYFPEPVTVSWNS GAL T
SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS
NTKVDKRVEPKS C

Full Heavy, C QVQLQESGPGLVKPSETLSLTCAVSGYSISSGAGWGWIRQPPG
terminal Fab KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
TM, linker = AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSSA
5mer (IgG1 STKGP
SVFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSG
(G1m(3)), ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
IgG1 Fab) KPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP

KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSQVQL
QESGPGLVKPSETLSLTCAVSGYSISSGAGWGWIRQPPGKGLE
WIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAAD
TAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSSASTK
GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT
SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS
NTKVDKRVEPKSC
197 ABP76 Full Heavy, C QVQLQESGPGLVKPSETLSLTCAVSGYSISSEYMWGWIRQPP
terminal Fab GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLSS
TM, linker = VTAADTAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVS
5mer (IgG1 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
(G1m(3)), SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
IgG1 Fab) NHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSQ
VQLQESGPGLVKPSETLSLTCAVSGYSISSEYMWGWIRQPPG
KGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLSSV
TAADTAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVSS
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN
HKPSNTKVDKRVEPKSC
198 ABP77 Full Heavy, C QVQLQESGPGLVKPSETLSLTCAVSGYSISSEYMWGWIRQPP
terminal Fab GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLSS
TM, linker = VTAADTAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVS
5mer (IgG1 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
(G1m(3)), SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
IgG1 Fab) NHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSQ
VQLQESGPGLVKPSETLSLTCAVSGYSISSEYMWGWIRQPPG

KGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLSSV
TAADTAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVSS
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN
HKPSNTKVDKRVEPKSC

Full Heavy, N QVQLVQSGAEVKRPGSSVKVSCKASGGTFSSYYISWVRQVPG
terminal Fab QGLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELS
TM (IgG1 SLRSEDTAVYYCARAGGGYARGDHYYGMDVWGQGTTVTVS
Fab, IgG1 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
(G1m(3))) SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
NHKPSNTKVDKRVEPKSCGGGGSQVQLVQSGAEVKRPGSSV
KVSCKASGGTFSSYYISWVRQVPGQGLEWMGGIIPVPGTANY
AQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAGGG
YARGDHYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKST
SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV
VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE
PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
HEALHNHYTQKSLSLSPGK

Full Heavy, N QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYYISWVRQAPG
terminal Fab QRLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELS
TM (IgG1 SLRSEDTAVYYCARAGGGYARGDHYYGMDVWGQGTTVTVS
Fab, IgG1 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
(G1m(3))) SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
NHKPSNTKVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSV
KVSCKASGGTFSSYYISWVRQAPGQRLEWMGGIIPVPGTANY
AQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAGGG
YARGDHYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKST
SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV
VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE
PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
HEALHNHYTQKSLSLSPGK

201 ABP80 Full Heavy, N QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRGAISWVRQAP
terminal Fab GQGLEWMGGIIPIEGTAYYAQKFQGRVTITADESTGTAYMEL
TM (IgG1 SSLRSEDTAVYYCARQSDYGLPRGMDVWGQGTTVTVSSAST
Fab, IgG1 KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA
(G1m(3))) LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
PSNTKVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVS
CKASGGTFSRGAISWVRQAPGQGLEWMGGIIPIEGTAYYAQK
FQGRVTITADESTGTAYMELSSLRSEDTAVYYCARQSDYGLP
RGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP
CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ
DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP
SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP
PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
TQKSLSLSPGK

Full Heavy, N QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
terminal Fab QGLEWMGGIIPISGFTNYAQKFQGRVTITADESTSTAYMELSS
TM (IgG1 LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
Fab, IgG1 SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
(G1m(3))) VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVSCKAS
GGTFSSYAISWVRQAPGQGLEWMGGIIPISGFTNYAQKFQGR
VTITADESTSTAYMELSSLRSEDTAVYYCAREGGHYYSGWPY
WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
SLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEL
LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SD
GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS
LSPGK

Full Heavy, N QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
terminal Fab QRLEWMGGIIPISGFTNYAQKFQGRVTITADESTSTAYMELSS
TM (IgG1 LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
Fab, IgG1 SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
(G1m(3))) VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVSCKAS

GGTFSSYAISWVRQAPGQRLEWMGGIIPISGFTNYAQKFQGR
VTITADESTSTAYMELSSLRSEDTAVYYCAREGGHYYSGWPY
WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
SLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEL
LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SD
GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS
LSPGK

Full Heavy, N QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
terminal Fab QGLEWMGGIIPISGFTNYAQKFQGKVTITADESTSTAYMEL SS
TM (IgG1 LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
Fab, IgG1 SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
(G1m(3))) VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVSCKAS
GGTFSSYAISWVRQAPGQGLEWMGGIIPISGFTNYAQKFQGK
VTITADESTSTAYMELSSLRSEDTAVYYCAREGGHYYSGWPY
WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD
YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
SLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEL
LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SD
GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS
LSPGK

Full Heavy, N QVQLVQSGAEVKKPGSSVKVSCKASGGTFVRYAISWVRQAP
terminal Fab GQGLEWMGGIIPIFGEAQYAQRFQGRVTITADESTSTAYMELS
TM (IgG1 SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVSSASTKGP
Fab, IgG1 SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
(G1m(3))) VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVSCKAS
GGTFVRYAISWVRQAPGQGLEWMGGIIPIFGEAQYAQRFQGR
VTITADESTSTAYMELSSLRSEDTAVYYCAREGYYYGALPYW
GQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
GTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELL
GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK
EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTK
NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG
SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS
PGK

Full Heavy, N QVQLVQSGAEVKKPGSSVKVSCKASGGTFVRYAISWVRQAP
terminal Fab GQGLEWMGGIIPIFGEAQYAQKFRGRATITADESTSTAYMELS
TM (IgG1 SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVSSASTKGP
Fab, IgG1 SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
(G1m(3))) VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
KVDKRVEPKSCGGGGSQVQLVQSGAEVKKPGSSVKVSCKAS
GGTFVRYAISWVRQAPGQGLEWMGGIIPIFGEAQYAQKFRGR
ATITADESTSTAYMELSSLRSEDTAVYYCAREGYYYGALPYW
GQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
GTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELL
GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK
EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTK
NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG
SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS
PGK

Full Heavy, C QVQLVQSGAEVKRPGSSVKVSCKASGGTFSSYYISWVRQVPG
terminal Fab QGLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELS
TM, linker = SLRSEDTAVYYCARAGGGYARGDHYYGMDVWGQGTTVTVS
5mer (IgG1 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
(G1m(3)), SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
IgG1 Fab) NHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSQ
VQLVQSGAEVKRPGSSVKVSCKASGGTFSSYYISWVRQVPGQ
GLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELSS
LRSEDTAVYYCARAGGGYARGDHYYGMDVWGQGTTVTVSS
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN
HKPSNTKVDKRVEPKSC

Full Heavy, C QVQLVQSGAEVKKPGS SVKVSCKASGGTFS SYYISWVRQAPG
terminal Fab QRLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELS
TM, linker = SLRSEDTAVYYCARAGGGYARGDHYYGMDVWGQGTTVTVS
5mer (IgG1 SASTKGPSVFPLAP S SKSTSGGTAALGCLVKDYFPEPVTVSWN
(G1m(3)), S GAL
TS GVH TFP AVLQ S SGLYSL S SVVTVPS S SLGTQTYICNV
IgG1 Fab) NHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV
KGFYP SD IAVEWE SNGQPENNYKTTPPVLD SD GSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSL SLSPGKGGGGSQ
VQLVQ SGAEVKKPGS SVKVS CKASGGTFS SYYISWVRQAPGQ
RLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELS S
LRSEDTAVYYCARAGGGYARGDHYYGMDVWGQGTTVTVS S
ASTKGP SVFPL AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNS
GALT S GVHTFPAVLQ S SGLYSLS SVVTVPS S SLGTQTYICNVN
HKPSNTKVDKRVEPKSC
209 ABP88 Full Heavy, C QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRGAISWVRQAP
terminal Fab GQGLEWMGGIIPIEGTAYYAQKFQGRVTITADESTGTAYMEL
TM, linker = S SLRSEDTAVYYCARQSDYGLPRGMDVWGQGTTVTVS SAS T
5mer (IgG1 KGPSVFPLAPS SKSTS GGTAAL GCLVKDYFPEPVTVSWNS GA
(G1m(3)), LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
IgG1 Fab) PSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK
DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKT
KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSQVQL
VQSGAEVKKPGS SVKVSCKASGGTFSRGAISWVRQAPGQGLE
WMGGIIPIEGTAYYAQKFQGRVTITADESTGTAYMELS SLRSE
DTAVYYCARQSDYGLPRGMDVWGQGTTVTVS SASTKGPSVF
PLAPS SKST S GGTAALGCLVKDYFPEPVTVS WNS GAL TS GVH
TFPAVLQS SGLYSL S SVVTVPS S SLGTQTYICNVNHKP SNTKV
DKRVEPKSC

Full Heavy, C QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
terminal Fab QGLEWMGGIIPISGFTNYAQKFQGRVTITADESTSTAYMEL S S
TM, linker = LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
5mer (IgG1 SVFPL
AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS G
(G1m(3)), VHTFPAVLQS SGLYSLS SVVTVPS S SL GTQTYI CNVNHKP S NT
IgG1 Fab) KVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM

I SRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTLPP SREEMTKNQVSL TCLVKGFYP SDI
AVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKSRWQ
QGNVFS CSVMHEALHNHYTQKSL SL SP GKGGGG S QVQLVQ S
GAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM
GGIIPISGFTNYAQKFQGRVTITADESTSTAYMEL S SLRSEDTA
VYYCAREGGHYYSGWPYWGQGTLVTVS SASTKGPSVFPLAP
S SKS TS GGTAAL GCL VKDYFPEPVTVSWNS GALTS GVHTFP A
VLQS SGLYSL S SVVTVPS S SL GTQTYICNVNHKPSNTKVDKRV
EPKSC

Full Heavy, C QVQLVQSGAEVKKPGS SVKVSCKASGGTFS SYAISWVRQAPG
terminal Fab QRLEWMGGIIPI S GFTNYAQKFQGRVTITADES TS TAYMEL S S
TM, linker = LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
5mer (IgG1 SVFPL
AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS G
(G1m(3)), VHTFPAVLQS SGLYSL S SVVTVPS S SL GTQTYI CNVNHKP S NT
IgG1 Fab) KVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
I SRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TI SKAKGQPREPQVYTLPP SREEMTKNQVSL TCLVKGFYP SDI
AVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKSRWQ
QGNVFS CSVMHEALHNHYTQKSL SL SP GKGGGG S QVQLVQ S
GAEVKKPGS SVKVSCKASGGTFS SYAISWVRQAPGQRLEWM
GGIIPISGFTNYAQKFQGRVTITADESTSTAYMEL S SLRSEDTA
VYYCAREGGHYYSGWPYWGQGTLVTVS SASTKGPSVFPLAP
S SKS TS GGTAAL GCL VKDYFPEPVTVSWNS GALTS GVHTFP A
VLQS SGLYSL S SVVTVPS S SL GTQTYICNVNHKPSNTKVDKRV
EPKSC

Full Heavy, C QVQLVQSGAEVKKPGS SVKVSCKASGGTFS SYAISWVRQAPG
terminal Fab QGLEWMGGIIPISGFTNYAQKFQGKVTITADESTSTAYMEL S S
TM, linker = LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
5mer (IgG1 SVFPL
AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS G
(G1m(3)), VHTFPAVLQS SGLYSL S SVVTVPS S SL GTQTYI CNVNHKP S NT
IgG1 Fab) KVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
I SRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TI SKAKGQPREPQVYTLPP SREEMTKNQVSL TCLVKGFYP SDI
AVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKSRWQ
QGNVFS CSVMHEALHNHYTQKSL SL SP GKGGGG S QVQLVQ S
GAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWM

GGIIPISGFTNYAQKFQGKVTITADESTSTAYMEL S SLRSEDTA
VYYCAREGGHYYSGWPYWGQGTLVTVS SASTKGPSVFPLAP
S SKS TS GGTAAL GCL VKDYFPEPVTVSWNS GALTS GVHTFP A
VLQS SGLYSL S SVVTVPS S SL GTQTYICNVNHKPSNTKVDKRV
EPKSC

Full Heavy, C QVQLVQSGAEVKKPGSSVKVSCKASGGTFVRYAISWVRQAP
terminal Fab GQGLEWMGGIIPIFGEAQYAQRFQGRVTITADESTSTAYMEL S
TM, linker = SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVSSASTKGP
5mer (IgG1 SVFPL
AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS G
(G1m(3)), VHTFPAVLQS SGLYSL S SVVTVPS S SL GTQTYI CNVNHKP S NT
IgG1 Fab) KVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
I SRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TI SKAKGQPREPQVYTLPP SREEMTKNQVSL TCLVKGFYP SDI
AVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKSRWQ
QGNVFS CSVMHEALHNHYTQKSL SL SP GKGGGG S QVQLVQ S
GAEVKKPGS SVKVS CKASGGTFVRYAISWVRQAPGQGLEWM
GGIIPIFGEAQYAQRFQGRVTITADESTSTAYMEL S SLRSEDTA
VYYCAREGYYYGALPYWGQGTLVTVS S A S TKGP S VFPL AP S S
KST S GGTAAL GCLVKDYFPEPVTVSWNS GAL TS GVHTFPAVL
QS SGLYSL S SVVTVP S S SLGTQTYICNVNHKPSNTKVDKRVEP
KSC

Full Heavy, C QVQLVQSGAEVKKPGSSVKVSCKASGGTFVRYAISWVRQAP
terminal Fab GQGLEWMGGIIPIF GEAQYAQKFRGRATITADE ST STAYMEL S
TM, linker = SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVSSASTKGP
5mer (IgG1 SVFPL
AP S SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS G
(G1m(3)), VHTFPAVLQS SGLYSL S SVVTVPS S SL GTQTYI CNVNHKP S NT
IgG1 Fab) KVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
I SRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TI SKAKGQPREPQVYTLPP SREEMTKNQVSL TCLVKGFYP SDI
AVEWESNGQPENNYKTTPPVLD SD GSFFLYSKL TVDKSRWQ
QGNVFS CSVMHEALHNHYTQKSL SL SP GKGGGG S QVQLVQ S
GAEVKKPGS SVKVS CKASGGTFVRYAISWVRQAPGQGLEWM
GGIIPIFGEAQYAQKFRGRATITADESTSTAYMEL S SLR SED TA
VYYCAREGYYYGALPYWGQGTLVTVS S A S TKGP S VFPL AP S S
KST S GGTAAL GCLVKDYFPEPVTVSWNS GAL TS GVHTFPAVL
QS SGLYSL S SVVTVP S S SLGTQTYICNVNHKPSNTKVDKRVEP
KSC

8 ABP35 Full Light D IQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
18 ABP36 Full Light D IQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
25 ABP37 Full Light D IQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAAS SLKYGVP SRF S GS GS GTDFTL TIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
33 ABP38 Full Light D IQMTQ
SP S SL S A S VGDRVTITCRA SK SID SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
39 ABP39 Full Light D IQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAAD SLQSGVP SRF S GS GS GTDFTLTIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
43 ABP40 Full Light D IQMTQ
SP S SL S A S VGDRVTITCRA S Q SINSYLNWYQQKP GKA
PKLLIYAASSLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
52 ABP41 Full Light D IQMTQ
SP S SL SASVGDRVTITCGASQSISTYLNWYQQKPGKA
PKLLIYSASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
QQEYNTPPSFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV

SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
8 ABP42 Full Light D IQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

8 ABP43 Full Light D IQMTQ SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
107 ABP44 Full Light D IVMTQ SPL SLPVTP GEPASIS CRS SQSLLH SNGYNYLDWYLQ
KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QD SKD S TY SL S STLTLSKADYEKHKVYACEVTHQGL S SPVTK
SFNRGEC
109 ABP45 Full Light D IQL TQ SP S S VS A S VGDRVTIT CRA S Q GI S
SWLAWYQQKPGK
APKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATY
YCQQASLFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA
SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD S
TY SL S STLTL SKADYEKHKVYACEVTHQGL S SPVTKSFNRGE
C
111 ABP46 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
113 ABP47 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
8 ABP48 Full Light D IQMTQ SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
8 ABP49 Full Light D IQMTQ SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
107 ABP50 Full Light D IVMTQ SPL SLPVTP GEPASIS CRS SQSLLH SNGYNYLDWYLQ
KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ

LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QD SKD S TY SL S STLTLSKADYEKHKVYACEVTHQGL S SPVTK
SFNRGEC
107 ABP51 Full Light D IVMTQ SPL SLPVTP GEPASIS CRS SQSLLH SNGYNYLDWYLQ
KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QD SKD S TY SL S STLTLSKADYEKHKVYACEVTHQGL S SPVTK
SFNRGEC
109 ABP52 Full Light D IQL TQ SP S S VS A S VGDRVTIT CRA S Q GI S
SWLAWYQQKPGK
APKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATY
YCQQASLFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA
SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD S
TY SL S STLTL SKADYEKHKVYACEVTHQGL S SPVTKSFNRGE
C
111 ABP53 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
111 ABP54 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
111 ABP55 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
113 ABP56 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
113 ABP57 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

107 ABP58 Full Light D IVMTQ
SPL SLPVTP GEPASIS CRS SQSLLH SNGYNYLDWYLQ
KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQALQTPITFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QD SKD S TY SL S STLTLSKADYEKHKVYACEVTHQGL S SPVTK
SFNRGEC
107 ABP59 Full Light D IVMTQ
SPL SLPVTP GEPASIS CRS SQSLLH SNGYNYLDWYLQ
KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQALQTPITFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QD SKD S TY SL S STLTLSKADYEKHKVYACEVTHQGL S SPVTK
SFNRGEC
109 ABP60 Full Light D IVMTQ
SPL SLPVTP GEPASIS CRS SQSLLH SNGYNYLDWYLQ
KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQALQTPITFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QD SKD S TY SL S STLTLSKADYEKHKVYACEVTHQGL S SPVTK
SFNRGEC
111 ABP61 Full Light D IVMTQ
SPL SLPVTP GEPASIS CRS SQSLLH SNGYNYLDWYLQ
KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQALQTPITFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QD SKD S TY SL S STLTLSKADYEKHKVYACEVTHQGL S SPVTK
SFNRGEC
8 ABP62 Full Light D IQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAAS SLQ S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
18 ABP63 Full Light D IQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAAS SLQ S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
25 ABP64 Full Light D IQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAAS SLKYGVP SRF S GS GS GTDFTL TIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

33 ABP65 Full Light D IQMTQ
SP S SL S A S VGDRVTITCRA SK SID SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
33 ABP66 Full Light D IQMTQ
SP S SL S A S VGDRVTITCRA SK SID SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
39 ABP67 Full Light D IQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAAD SLQSGVP SRF S GS GS GTDFTLTIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
43 ABP68 Full Light D IQMTQ
SP S SL S A S VGDRVTITCRA S Q SINSYLNWYQQKP GKA
PKLLIYAASSLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
52 ABP69 Full Light D IQMTQ
SP S SL SASVGDRVTITCGASQSISTYLNWYQQKPGKA
PKLLIYSASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
QQEYNTPPSFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV

SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
8 ABP70 Full Light D IQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
18 ABP71 Full Light D IQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
25 ABP72 Full Light D IQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAAS SLKYGVP SRF S GS GS GTDFTL TIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

33 ABP73 Full Light D IQMTQ SP S SL S A S VGDRVTITCRA SK SID
SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
33 ABP74 Full Light D IQMTQ SP S SL S A S VGDRVTITCRA SK SID
SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
39 ABP75 Full Light D IQMTQ SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAAD SLQSGVP SRF S GS GS GTDFTLTIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
43 ABP76 Full Light D IQMTQ SP S SL S A S VGDRVTITCRA S Q SINSYLNWYQQKP
GKA
PKLLIYAASSLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
52 ABP77 Full Light D IQMTQ SP S SL SASVGDRVTITCGASQSISTYLNWYQQKPGKA
PKLLIYSASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
QQEYNTPPSFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV

SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
107 ABP78 Full Light D IVMTQ SPL SLPVTP GEPASIS CRS SQSLLH SNGYNYLDWYLQ
KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QD SKD S TY SL S STLTLSKADYEKHKVYACEVTHQGL S SPVTK
SFNRGEC
107 ABP79 Full Light D IVMTQ SPL SLPVTP GEPASIS CRS SQSLLH SNGYNYLDWYLQ
KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QD SKD S TY SL S STLTLSKADYEKHKVYACEVTHQGL S SPVTK
SFNRGEC
109 ABP80 Full Light D IQL TQ SP S S VS A S VGDRVTIT CRA S Q GI S
SWLAWYQQKPGK
APKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATY
YCQQASLFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA

SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD S
TY SL S STLTL SKADYEKHKVYACEVTHQGL S SPVTKSFNRGE
C
111 ABP81 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
111 ABP82 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
111 ABP83 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
113 ABP84 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
113 ABP85 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
107 ABP86 Full Light D IVMTQ
SPL SLPVTP GEPASIS CRS SQSLLH SNGYNYLDWYLQ
KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QD SKD S TY SL S STLTLSKADYEKHKVYACEVTHQGL S SPVTK
SFNRGEC
107 ABP87 Full Light D IVMTQ
SPL SLPVTP GEPASIS CRS SQSLLH SNGYNYLDWYLQ
KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QD SKD S TY SL S STLTLSKADYEKHKVYACEVTHQGL S SPVTK
SFNRGEC

109 ABP88 Full Light D IQL TQ SP S S VS A S VGDRVTIT CRA S Q GI S
SWLAWYQQKPGK
APKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATY
YCQQASLFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA
SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD S
TY SL S STLTL SKADYEKHKVYACEVTHQGL S SPVTKSFNRGE
C
111 ABP89 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
111 ABP90 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
111 ABP91 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
113 ABP92 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
113 ABP93 Full Light EIVLTQSPATLSLSPGERATL SCRASQSVS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
114 ABP94 Full Heavy QVQLQESGPGLVKPSETLSLTCAVSGYSISSGLGWGWIRQPPG
KGLEWIGGIYESGSTYYNPSLKSRVTISVDTSKNQFSLKLS SVT
AADTAVYYCAHERVRGYGDYGGHHAFDIWGQGTMVTVS SA
STKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG
ALT S GVHTFPAVLQ S SGLYSLS SVVTVP S S SLGTKTYTCNVDH
KPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDT
LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIE
KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPS

DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRW
QEGNVFSCSVMHEALHNHYTQKSL SLSLGKGGGGSQVQLQE
S GP GL VKP SETL SLTCAVSGYSIS SGLGWGWIRQPPGKGLEWI
GGIYESGSTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTA
VYYCAHERVRGYGDYGGHHAFDIWGQGTMVTVSSASTKGP
S VFPL AP S SK S T S GGTAAL GCLVKDYFPEP VTVS WNS GALT S G
VHTFPAVLQS SGLYSLS SVVTVPS S SLGTQTYICNVNHKPSNT
KVDKRVEPKSC
115 ABP95 Full Heavy QVQLQESGPGLVKPSQTLSLTCTVSGGSIS SGGAVVVSWIRQHP
GKGLEWIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLS S
VTAADTAVYYCADENVRGYGDYGGHHAFDIWGQGTMVTVS
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV
DHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPK
DTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKT
KPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS
SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSR
WQEGNVFSCSVMHEALHNHYTQKSLSLSLGKGGGGSQVQLQ
ESGPGLVKPSQTLSLTCTVSGGSISSGGAVVVSWIRQHPGKGLE
WIGGIAYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAAD
TAVYYCADENVRGYGDYGGHHAFDIWGQGTMVTVSSASTK
GP SVFPLAP S SKSTS GGTAAL GCLVKDYFPEPVTVSWNS GAL T
SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS
NTKVDKRVEPKSC
116 ABP96 Full Heavy QVQLQESGPGLVKPSETLSLTCAVSGYSISSGAGWGWIRQPPG
KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSSA
STKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG
ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDH
KPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDT
LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE
KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRW
QEGNVFSCSVMHEALHNHYTQKSL SLSLGKGGGGSQVQLQE
S GP GL VKP SETL SLTCAVSGYSIS SGAGWGWIRQPPGKGLEWI
GLIVH S G STYYNP SLKSRVTIS VDT SKNQF SLKL S SVTAADTA
VYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG

VHTFPAVLQS SGLYSLS SVVTVPS S SLGTQTYICNVNHKPSNT
KVDKRVEPKSC
117 ABP97 Full Heavy QVQLQESGPGLVKPSETLSLTCAVSGYSISSGAGWGWIRQPPG
KGPEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLS SVT
AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS SA
STKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG
ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDH
KPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDT
LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIE
KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRW
QEGNVFSCSVMHEALHNHYTQKSL SLSLGKGGGGSQVQLQE
S GP GL VKP SETL SLTCAVSGYSIS SGAGWGWIRQPPGKGPEWI
GLIVH S G STYYNP SLKSRVTIS VDT SKNQF SLKL S SVTAADTA
VYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS SASTKGPS
VFPL AP S SKST S GGTAALGCLVKDYFPEPVTVSWNS GALT S G
VHTFPAVLQS SGLYSLS SVVTVPS S SLGTQTYICNVNHKPSNT
KVDKRVEPKSC
118 ABP98 Full Heavy QVQLQESGPGLVKPSETLSLTCAVSGYSIS SGAGWGWIRQPPG
KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS SA
STKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG
ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDH
KPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDT
LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIE
KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRW
QEGNVFSCSVMHEALHNHYTQKSL SLSLGKGGGGSQVQLQE
S GP GL VKP SETL SLTCAVSGYSIS SGAGWGWIRQPPGKGLEWI
GLIVH S G STYYNP SLKSRVTIS VDT SKNQF SLKL S SVTAADTA
VYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS SASTKGPS
VFPL AP S SKST S GGTAALGCLVKDYFPEPVTVSWNS GALT S G
VHTFPAVLQS SGLYSLS SVVTVPS S SLGTQTYICNVNHKPSNT
KVDKRVEPKSC
119 ABP99 Full Heavy QVQLQESGPGLVKPSETLSLTCAVSGYSIS SGAGWGWIRQPPG
KGLEWIGLIVHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVT
AADTAVYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVS SA
STKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDH
KPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDT
LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE
KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPS
DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRW
QEGNVFSCSVMHEALHNHYTQKSL SLSL GKGGGGSQVQLQE
S GP GL VKP SETL SLTCAVSGYSIS SGAGWGWIRQPPGKGLEWI
GLIVH S G STYYNP SLKSRVTIS VDT SKNQF SLKL S SVTAADTA
VYYCVLESVRGYGDYGGHHAFDIWGQGTMVTVSSASTKGPS
VFPL AP S SKST S GGTAALGCLVKDYFPEPVTVSWNS GALT S G
VHTFPAVLQS SGLYSLS SVVTVPS S SLGTQTYICNVNHKPSNT
KVDKRVEPKSC
120 ABP100 Full Heavy QVQLQESGPGLVKPSETLSLTCAVSGYSIS SEYMWG
WIRQPPGKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQF
SLKLSSVTAADTAVYYCAREADRGYGDYGGHHAFDIWGQG
TMVTVS SASTKGPSVFPLAPCSRSTSESTAAL GCLVKDYFPEP
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTK
TYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL GGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVE
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVS
NKGLPS SIEKTISKAKGQPREPQVYTLPP SQEEMTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
TVDKSRWQEGNVFSCSVMHEALHNHYTQKSL SLSL GKGGGG
SQVQLQES GP GLVKP SETL SL TCAVS GY SI S SEYMVVGWIRQPP
GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLS S
VTAADTAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVS
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
NHKPSNTKVDKRVEPKSC
121 ABP 101 Full Heavy QVQLQE S
GP GLVKP SETL SLT CAVS GY SI S SEYMWGWIRQPP
GKGLEWIGLIYHSGKTYYNPSLKSRVTISVDTSKNQFSLKLS S
VTAADTAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVS
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV
DHKPSNTKVDKRVESKYGPPCPPCPAPEFL GGPSVFLFPPKPK
DTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKT
KPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS
SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLD SD GSFFLY SRL TVDK SR

WQEGNVFSCSVMHEALHNHYTQKSLSLSLGKGGGGSQVQLQ
ES GP GLVKP S ETL SLTCAVS GY SI S SEYMWGWIRQPPGKGLE
WIGLIYH S GKTYYNP SLK SRVTI S VD T SKNQF SLKL S SVTAAD
TAVYYCAREADRGYGDYGGHHAFDIWGQGTMVTVSSASTK
GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT
SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS
NTKVDKRVEPKSC
122 ABP102 Full Heavy QVQLVQSGAEVKRPGSSVKVSCKASGGTFSSYYISWVRQVPG
QGLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELS
SLRSEDTAVYYCARAGGGYARGDHYYGMDVVVGQGTTVTVS
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV
DHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPK
DTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKT
KPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS
SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSR
WQEGNVFSCSVMHEALHNHYTQKSLSLSLGKGGGGSQVQLV
QSGAEVKRPGSSVKVSCKASGGTFSSYYISWVRQVPGQGLE
WMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELSSLRSE
DTAVYYCARAGGGYARGDHYYGMDVVVGQGTTVTVSSAST
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
PSNTKVDKRVEPKSC
123 ABP103 Full Heavy QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYYISWVRQAPG
QRLEWMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELS
SLRSEDTAVYYCARAGGGYARGDHYYGMDVVVGQGTTVTVS
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV
DHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPK
DTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKT
KPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS
SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSR
WQEGNVFSCSVMHEALHNHYTQKSLSLSLGKGGGGSQVQLV
QSGAEVKKPGSSVKVSCKASGGTFSSYYISWVRQAPGQRLE
WMGGIIPVPGTANYAQKFQGRVTITADESTSTAYMELSSLRSE
DTAVYYCARAGGGYARGDHYYGMDVVVGQGTTVTVSSAST
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
PSNTKVDKRVEPKSC
124 ABP104 Full Heavy QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRGAISWVRQAP
GQGLEWMGGIIPIEGTAYYAQKFQGRVTITADESTGTAYMEL
S SLR SED TAVYYCARQ SDYGLPRGMD VVVGQ GTTVTVS SAS T
KGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL
TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKP
SNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLM
ISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPRE
EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT
ISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEG
NVFSCSVMHEALHNHYTQKSLSL SLGKGGGGSQVQLVQ S GA
EVKKPGS SVKVS CKASGGTFSRGAISWVRQAPGQGLEWMGG
IIPIEGTAYYAQKFQGRVTITADESTGTAYMELS SLRSEDTAV
YYCARQSDYGLPRGMDVVVGQGTTVTVSSASTKGPSVFPLAP
SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA
VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV
EPKSC
125 ABP105 Full Heavy QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
QGLEWMGGIIPISGFTNYAQKFQGRVTITADESTSTAYMEL SS
LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQS SGLYSLS SVVTVPS S SLGTKTYTCNVDHKPSNT
KVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQF
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK
AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVE
WESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGN
VFSCSVMHEALHNHYTQKSL SLSLGKGGGGSQVQLVQSGAE
VKKPGS SVKVSCKASGGTFS SYAISWVRQAPGQGLEWMGGII
PI S GFTNYAQKFQ GRVTITADE STS TAYMEL S SLRSEDTAVYY
CAREGGHYYSGWPYWGQGTLVTVS SASTKGP SVFPL AP S SKS
TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLS SVVTVPS S SLGTQTYICNVNHKPSNTKVDKRVEPKS
C
126 ABP106 Full Heavy QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPG
QRLEWMGGIIPI S GFTNYAQKFQGRVTITADES TS TAYMEL S S
LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVSSASTKGP
SVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSG

VHTFPAVLQS SGLYSLS SVVTVPS S SLGTKTYTCNVDHKPSNT
KVDKRVE SKYGPPCPP CPAPEFLGGP SVFLFPPKPKDTLMI SR
TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQF
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIEKTISK
AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYP SDIAVE
WE SNGQPENNYKTTPPVLD SD GSFFLYSRLTVDKSRWQEGN
VFSCSVMHEALHNHYTQKSL SLSLGKGGGGSQVQLVQSGAE
VKKPGS SVKVSCKASGGTFS SYAISWVRQAPGQRLEWMGGII
PI S GFTNYAQKFQ GRVTITADE STS TAYMEL S SLRSEDTAVYY
CAREGGHYYSGWPYWGQGTLVTVS SASTKGP SVFPL AP S SKS
TS GGTAAL GCLVKDYFPEPVTVSWNS GALT S GVHTFPAVLQ S
SGLYSLS SVVTVPS S SLGTQTYICNVNHKPSNTKVDKRVEPKS
C
127 ABP107 Full Heavy QVQLVQSGAEVKKPGS SVKVSCKASGGTFS SYAISWVRQAPG
QGLEWMGGIIPISGFTNYAQKFQGKVTITADESTSTAYMEL S S
LRSEDTAVYYCAREGGHYYSGWPYWGQGTLVTVS SA STKGP
SVFPL APC SRSTSE STAALGCLVKDYFPEPVTVSWNS GAL TS G
VHTFPAVLQS SGLYSLS SVVTVPS S SLGTKTYTCNVDHKPSNT
KVDKRVE SKYGPPCPP CPAPEFLGGP SVFLFPPKPKDTLMI SR
TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQF
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIEKTISK
AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYP SDIAVE
WE SNGQPENNYKTTPPVLD SD GSFFLYSRLTVDKSRWQEGN
VFSCSVMHEALHNHYTQKSL SLSLGKGGGGSQVQLVQSGAE
VKKPGS SVKVSCKASGGTFS SYAISWVRQAPGQGLEWMGGII
PI S GFTNYAQKFQ GKVTITADEST STAYMEL S SLRSEDTAVYY
CAREGGHYYSGWPYWGQGTLVTVS SASTKGP SVFPL AP S SKS
TS GGTAAL GCLVKDYFPEPVTVSWNS GALT S GVHTFPAVLQ S
SGLYSLS SVVTVPS S SLGTQTYICNVNHKPSNTKVDKRVEPKS
C
128 ABP108 Full Heavy QVQLVQS
GAEVKKP GS SVKVSCKASGGTFVRYAISWVRQAP
GQGLEWMGGIIPIFGEAQYAQRFQGRVTITADESTSTAYMELS
SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVS SASTKGP
SVFPL APC SRSTSE STAALGCLVKDYFPEPVTVSWNS GAL TS G
VHTFPAVLQS SGLYSLS SVVTVPS S SLGTKTYTCNVDHKPSNT
KVDKRVE SKYGPPCPP CPAPEFLGGP SVFLFPPKPKDTLMI SR
TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQF
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIEKTISK
AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYP SDIAVE
WE SNGQPENNYKTTPPVLD SD GSFFLYSRLTVDKSRWQEGN

VFSCSVMHEALHNHYTQKSL SLSLGKGGGGSQVQLVQSGAE
VKKPGS SVKVSCKASGGTFVRYAISWVRQAPGQGLEWMGGI
IPIFGEAQYAQRFQGRVTITADESTSTAYMELS SLRSEDTAVY
YCAREGYYYGALPYWGQGTLVTVS SASTK GP SVFPL AP S SKS
TS GGTAAL GCLVKDYFPEPVTVSWNS GALT S GVHTFPAVLQ S
SGLYSLS SVVTVPS S SLGTQTYICNVNHKPSNTKVDKRVEPKS
C
129 ABP109 Full Heavy QVQLVQS
GAEVKKP GS SVKVSCKASGGTFVRYAISWVRQAP
GQGLEWMGGIIPIF GEAQYAQKFRGRATITADE ST STAYMEL S
SLRSEDTAVYYCAREGYYYGALPYWGQGTLVTVS SASTKGP
SVFPL APC SRSTSE STAALGCLVKDYFPEPVTVSWNS GAL TS G
VHTFPAVLQS SGLYSLS SVVTVPS S SLGTKTYTCNVDHKPSNT
KVDKRVE SKYGPPCPP CPAPEFLGGP SVFLFPPKPKDTLMI SR
TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQF
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIEKTISK
AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYP SDIAVE
WE SNGQPENNYKTTPPVLD SD GSFFLYSRLTVDKSRWQEGN
VFSCSVMHEALHNHYTQKSL SLSLGKGGGGSQVQLVQSGAE
VKKPGS SVKVSCKASGGTFVRYAISWVRQAPGQGLEWMGGI
IPIFGEAQYAQKFRGRATITADESTSTAYMELS SLRSEDTAVY
YCAREGYYYGALPYWGQGTLVTVS SASTK GP SVFPL AP S SKS
TS GGTAAL GCLVKDYFPEPVTVSWNS GALT S GVHTFPAVLQ S
SGLYSLS SVVTVPS S SLGTQTYICNVNHKPSNTKVDKRVEPKS
C
8 ABP94 Full Light DIQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAAS SLQ S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYATPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC
18 ABP95 Full Light DIQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAAS SLQ S GVP SRF S GS G S GTDFTLTIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC
25 ABP96 Full Light DIQMTQ
SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAAS SLKYGVP SRF S GS GS GTDFTL TIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC

33 ABP97 Full Light D IQMTQ SP S SL S A S VGDRVTITCRA SK SID
SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
33 ABP98 Full Light D IQMTQ SP S SL S A S VGDRVTITCRA SK SID
SYLNWYQQKPGKA
PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
39 ABP99 Full Light D IQMTQ SP S SL SASVGDRVTITCRASQSIS SYLNWYQQKPGKA
PKLLIYAAD SLQSGVP SRF S GS GS GTDFTLTIS SLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
43 ABP100 Full Light DIQMTQ SP S SL SA SVGDRVTITCRASQ S INSYLNWYQQKPGKA
PKLLIYAASSLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY
CQQEYNTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
52 ABP101 Full Light D IQMTQ SP S SL SAS VGDRVTITC GASQ SISTYLNWYQQKP
GKA
PKLLIYSASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
QQEYNTPPSFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV

SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
107 ABP102 Full Light D IVMTQ SPL SLPVTP GEPASIS CRS SQSLLH SNGYNYLDWYLQ
KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QD SKD S TY SL S STLTLSKADYEKHKVYACEVTHQGL S SPVTK
SFNRGEC
107 ABP103 Full Light D IVMTQ SPL SLPVTP GEPASIS CRS SQSLLH SNGYNYLDWYLQ
KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAE
DVGVYYCMQKIGTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QD SKD S TY SL S STLTLSKADYEKHKVYACEVTHQGL S SPVTK
SFNRGEC
109 ABP104 Full Light DIQLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGK
APKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATY
YCQQASLFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA

SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD S
TY SL S STLTL SKADYEKHKVYACEVTHQGL S SPVTKSFNRGE
C
111 ABP105 Full Light EIVLTQSPATLSL SP GERATL S CRA S Q S VS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC
111 ABP106 Full Light EIVLTQSPATLSL SP GERATL S CRA S Q S VS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC
111 ABP107 Full Light EIVLTQSPATLSL SP GERATL S CRA S Q S VS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQRLVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC
113 ABP108 Full Light EIVLTQSPATLSL SP GERATL S CRA S Q S VS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC
113 ABP109 Full Light EIVLTQSPATLSL SP GERATL S CRA S Q S VS SYLAWYQQKPGQA
PRLLIYDASNRATGIPARF S GS GS GTDFTLTI S SLEPEDFAVYY
CQQHSVFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKD ST
YSL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC

Claims

WHAT IS CLAIMED IS:

1. An isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), comprising the following six CDR sequences:
a. a CDR-H3 having the sequence X1X2X3X4X5RGYGDYGGHHAFDI, wherein X1 is A or V, X2 is H, D, L, or R, X3 is E or D, X4 is R, N, S, or A, and X5 iS
V, D or G (SEQ ID NO:141);
b. a CDR-H2 having the sequence X1IX 2X3 SGX 4 TYYNPSLKS, wherein X1 is G, L, or S, X2 is Y, A, or V, X3 is E, Y or H, and X4 is S or K (SEQ ID
NO:142);
c. a CDR-H1 having the sequence X1SISSX 2 X3X4X5 WX 6, wherein X1 is Y or G, X2 is G, S, or E, X3 is L, G, S, Y, or A, X4 is G, A, Y, M, or G, X5 iS V, A, or is absent, and X6 is S or G (SEQ ID NO:143);
d. a CDR-L3 having the sequence QQEYX 1 TPPX 2, wherein X1 is A or N and X2 is T or S (SEQ ID NO:144);
e. a CDR-L2 having the sequence X1AX 2 SLX 3X4, wherein X1 is A or S, X2 is D
or S, X3 is Q, D, K, or E, and X4 is S or Y (SEQ ID NO:145); and f. a CDR-L1 having the sequence X1AS X25I X3X4 YLN, wherein X1 is G or R, X2 is Q or K, X3 is S, D, or N, and X4 is S or T (SEQ ID NO:146).

2. The ABP of claim 1, wherein the ABP comprises:
a. a CDR-H3 of SEQ ID NO:13, a CDR-H2 of SEQ ID NO:12, a CDR-H1 of SEQ ID NO:11, a CDR-L3 of SEQ ID NO:16, a CDR-L2 of SEQ ID NO:15, and a CDR-L1 of SEQ ID NO:14;
b. a CDR-H3 of SEQ ID NO:23, a CDR-H2 of SEQ ID NO:22, a CDR-H1 of SEQ ID NO:21, a CDR-L3 of SEQ ID NO:17, a CDR-L2 of SEQ ID NO:15, and a CDR-L1 of SEQ ID NO:14;
c. a CDR-H3 of SEQ ID NO:30, a CDR-H2 of SEQ ID NO:29, a CDR-H1 of SEQ ID NO:28, a CDR-L3 of SEQ ID NO:17, a CDR-L2 of SEQ ID NO:31, and a CDR-L1 of SEQ ID NO:14;
d. a CDR-H3 of SEQ ID NO:30, a CDR-H2 of SEQ ID NO:29, a CDR-H1 of SEQ ID NO:28, a CDR-L3 of SEQ ID NO:17, a CDR-L2 of SEQ ID NO:15, and a CDR-L1 of SEQ ID NO:36;

e. a CDR-H3 of SEQ ID NO:30, a CDR-H2 of SEQ ID NO:29, a CDR-H1 of SEQ ID NO:28, a CDR-L3 of SEQ ID NO:17, a CDR-L2 of SEQ ID NO:41, and a CDR-L1 of SEQ ID NO:14;
f. a CDR-H3 of SEQ ID NO:48, a CDR-H2 of SEQ ID NO:47, a CDR-H1 of SEQ ID NO:46, a CDR-L3 of SEQ ID NO:17, a CDR-L2 of SEQ ID NO:50, and a CDR-L1 of SEQ ID NO:49;
g. a CDR-H3 of SEQ ID NO:48, a CDR-H2 of SEQ ID NO:47, a CDR-H1 of SEQ ID NO:46, a CDR-L3 of SEQ ID NO:56, a CDR-L2 of SEQ ID NO:55, and a CDR-L1 of SEQ ID NO:54;
h. a CDR-H3 of SEQ ID NO:61, a CDR-H2 of SEQ ID NO:60, a CDR-H1 of SEQ ID NO:59, a CDR-L3 of SEQ ID NO:16, a CDR-L2 of SEQ ID NO:15, and a CDR-L1 of SEQ ID NO:14;
i. a CDR-H3 of SEQ ID NO:61, a CDR-H2 of SEQ ID NO:47, a CDR-H1 of SEQ ID NO:46, a CDR-L3 of SEQ ID NO:16, a CDR-L2 of SEQ ID NO:15, and a CDR-L1 of SEQ ID NO:14; or j. a CDR-H3 of SEQ ID NO:103, a CDR-H2 of SEQ ID NO:22, a CDR-H1 of SEQ ID NO:21, a CDR-L3 of SEQ ID NO:16, a CDR-L2 of SEQ ID NO:15, and a CDR-L1 of SEQ ID NO:14.

3. The ABP of claim 2, wherein:
a. the ABP of claim 2.a comprises a VH sequence of SEQ ID NO:9 and a VL
sequence of SEQ ID NO:10;
b. the ABP of claim 2.b comprises a VH sequence of SEQ ID NO:19 and a VL
sequence of SEQ ID NO:20;
c. the ABP of claim 2.c comprises a VH sequence of SEQ ID NO:26 and a VL
sequence of SEQ ID NO:27;
d. the ABP of claim 2.d comprises a VII sequence of SEQ ID NO:26 or SEQ ID
NO:34 and a VL sequence of SEQ ID NO:35;
e. the ABP of claim 2.e comprises a VII sequence of SEQ ID NO:26 and a VL
sequence of SEQ ID NO:40;
f. the ABP of claim 2.f comprises a VII sequence of SEQ ID NO:44 and a VL
sequence of SEQ ID NO:45;
g. the ABP of claim 2.g comprises a VII sequence of SEQ ID NO:44 and a VL
sequence of SEQ ID NO:53;

h. the ABP of claim 2.h comprises a VII sequence of SEQ ID NO:58 and a VL
sequence of SEQ ID NO:10;
i. the ABP of claim 2.i comprises a VII sequence of SEQ ID NO:104 and a VL
sequence of SEQ ID NO:10; and j. the ABP of claim 2.j comprises a VH sequence of SEQ ID NO:105 and a VL
sequence of SEQ ID NO:10.

4. The ABP of claim 3, wherein:
a. the ABP of claim 3.a comprises a heavy chain of SEQ ID NO:7 and a light chain of SEQ ID NO:8;
b. the ABP of claim 3.b comprises a heavy chain of SEQ ID NO:17 and a light chain of SEQ ID NO:18;
c. the ABP of claim 3.c comprises a heavy chain of SEQ ID NO:24 and a light chain of SEQ ID NO:25;
d. the ABP of claim 3.d comprises (i) a heavy chain of SEQ ID NO:32 and a light chain of SEQ ID NO:33, or (ii) a heavy chain of SEQ ID NO:37 and a light chain of SEQ ID NO:33;
e. the ABP of claim 3.e comprises (i) a heavy chain of SEQ ID NO:38 and a light chain of SEQ ID NO:39;
f. the ABP of claim 3.f comprises (i) a heavy chain of SEQ ID NO:42 and a light chain of SEQ ID NO:43;
g. the ABP of claim 3.g comprises (i) a heavy chain of SEQ ID NO:51 and a light chain of SEQ ID NO:52;
h. the ABP of claim 3.h comprises (i) a heavy chain of SEQ ID NO:57 and a light chain of SEQ ID NO:8;
i. the ABP of claim 3.i comprises (i) a heavy chain of SEQ ID NO:114 and a light chain of SEQ ID NO:8, or (ii) a heavy chain of SEQ ID NO:120 and a light chain of SEQ ID NO:8; or (iii) a heavy chain of SEQ ID NO:122 and a light chain of SEQ ID NO:8; or j. the ABP of claim 3.j comprises (i) a heavy chain of SEQ ID NO:115 and a light chain of SEQ ID NO:8, or (ii) a heavy chain of SEQ ID NO:121 and a light chain of SEQ ID NO:8; or (iii) a heavy chain of SEQ ID NO:123 and a light chain of SEQ ID NO:8.

5. An isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), comprising the following six CDR sequences:
a. a CDR-H3 having the sequence set forth in SEQ ID NO:66;
b. a CDR-H2 having the sequence set forth in SEQ ID NO:65;
c. a CDR-H1 having the sequence set forth in SEQ ID NO:64;
d. a CDR-L3 having the sequence set forth in SEQ ID NO:69;
e. a CDR-L2 having the sequence set forth in SEQ ID NO:68; and f. a CDR-L1 having the sequence set forth in SEQ ID NO:67.

6. The ABP of claim 5, wherein:
a. the ABP comprises a V H sequence of SEQ ID NO:62 and a V L sequence of SEQ ID NO:63;
b. the ABP comprises a V H sequence of SEQ ID NO:70 and a V L sequence of SEQ ID NO:63; or c. the ABP comprises a V H sequence of SEQ ID NO:97 and a V L sequence of SEQ ID NO:63.

7. The ABP of claim 6, wherein:
a. the ABP of claim 6.a comprises (i) a heavy chain of SEQ ID NO:171 and a light chain of SEQ ID NO:172;
b. the ABP of claim 6.b comprises a heavy chain of SEQ ID NO:173 and a light chain of SEQ ID NO:174;
c. the ABP of claim 6.c comprises (i) a heavy chain sequence of SEQ ID
NO:106 and a light chain sequence of SEQ ID NO:107; or (ii) a heavy chain sequence of SEQ ID NO:116 and a light chain sequence of SEQ ID NO:107.

8. An isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), comprising the following six CDR sequences:
a. a CDR-H3 having the sequence set forth in SEQ ID NO:75;
b. a CDR-H2 having the sequence set forth in SEQ ID NO:74;
c. a CDR-H1 having the sequence set forth in SEQ ID NO:73;
d. a CDR-L3 having the sequence set forth in SEQ ID NO:78;
e. a CDR-L2 having the sequence set forth in SEQ ID NO:77; and f. a CDR-L1 having the sequence set forth in SEQ ID NO:75.

9. An ABP of claim 8, wherein:
a. the ABP comprises a VH sequence of SEQ ID NO:71 and a VL sequence of SEQ ID NO:72; or b. the ABP comprises a VH sequence of SEQ ID NO:98 and a VL sequence of SEQ ID NO:72.

10. An ABP of claim 9, wherein:
a. the ABP of claim 9.a comprises a heavy chain of SEQ ID NO:173 and a light chain of SEQ ID NO:109; or b. the ABP of claim 9.b comprises (i) a heavy chain of SEQ ID NO:108 and a light chain of SEQ ID NO:109; or (ii) a heavy chain of SEQ ID NO:117 and a light chain of SEQ ID NO:109.

11. An isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), comprising the following six CDR sequences:
a. a CDR-H3 having the sequence set forth in SEQ ID NO:83;
b. a CDR-H2 having the sequence set forth in (i) SEQ ID NO:82, or (ii) SEQ
ID
NO:100;
c. a CDR-H1 having the sequence set forth in SEQ ID NO:81;
d. a CDR-L3 having the sequence set forth in SEQ ID NO:86;
e. a CDR-L2 having the sequence set forth in SEQ ID NO:85; and f. a CDR-L1 having the sequence set forth in SEQ ID NO:84.

12. An ABP of claim 11, wherein:
a. the ABP comprises the CDR-H2 sequence of claim 11.b(i) and a VH sequence of SEQ ID NO:79 and a VL sequence of SEQ ID NO:80;
b. the ABP comprises the CDR-H2 sequence of claim 11.b(i) and a VH sequence of SEQ ID NO:87 and a VL sequence of SEQ ID NO:80;
c. the ABP comprises the CDR-H2 sequence of claim 11.b(i) and a VH sequence of SEQ ID NO:88 and a VL sequence of SEQ ID NO:80;
d. the ABP comprises the CDR-H2 sequence of claim 11.b(ii) a VH sequence of SEQ ID NO:99 and a VL sequence of SEQ ID NO:80.

13. An ABP of claim 12, wherein:

a. the ABP of claim 12.a comprises a heavy chain of SEQ ID NO:174 and a light chain of SEQ ID NO:111;
b. the ABP of claim 12.b comprises a heavy chain of SEQ ID NO:175 and a light chain of SEQ ID NO:111;
c. the ABP of claim 12.c comprises a heavy chain of SEQ ID NO:176 and a light chain of SEQ ID NO:111;
d. the ABP of claim 12.d comprises (i) a heavy chain of SEQ ID NO:110 and a light chain of SEQ ID NO:111; or (ii) a heavy chain of SEQ ID NO:118 and a light chain of SEQ ID NO:111.

14. An isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), comprising the following six CDR sequences:
a. a CDR-H3 having the sequence set forth in SEQ ID NO:93;
b. a CDR-H2 having the sequence GIIPIFGEAQYAQX 1 FX 2 G, wherein X1 is K
or R, and X2 is Q or R (SEQ ID NO:215);
c. a CDR-H1 having the sequence set forth in SEQ ID NO:91;
d. a CDR-L3 having the sequence set forth in SEQ ID NO:94;
e. a CDR-L2 having the sequence set forth in SEQ ID NO:85; and f. a CDR-L1 having the sequence set forth in SEQ ID NO:84.

15. An ABP of claim 14, wherein the ABP comprises:
a. a CDR-H2 of SEQ ID NO:92;
b. a CDR-H2 of SEQ ID NO:96; or c. a CDR-H2 of SEQ ID NO:102.

16. An ABP of claim 15, wherein:
a. the ABP of claim 15.a comprises a VH sequence of SEQ ID NO:89 and a VL
sequence of SEQ ID NO:90;
b. the ABP of claim 15.b comprises a VH sequence of SEQ ID NO:95 and a VL
sequence of SEQ ID NO:90; and c. the ABP of claim 15.c comprises a VH sequence of SEQ ID NO:101 and a VL
sequence of SEQ ID NO:90.

17. An ABP of claim 16, wherein:

a. the ABP of claim 16.a comprises a heavy chain of SEQ ID NO:177 and a light chain of SEQ ID NO:113;
b. the ABP of claim 16.b comprises a heavy chain of SEQ ID NO:178 and a light chain of SEQ ID NO:113;
c. the ABP of claim 16.c comprises (i) a heavy chain of SEQ ID NO:112 and a light chain of SEQ ID NO:113; or (ii) a heavy chain of SEQ ID NO:119 and a light chain of SEQ ID NO:113.

18. An isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), comprising the following six CDR sequences:
a. a CDR-H3 having the sequence set forth in SEQ ID NO:134;
b. a CDR-H2 having the sequence set forth in SEQ ID NO:133;
c. a CDR-H1 having the sequence set forth in SEQ ID NO:132;
d. a CDR-L3 having the sequence set forth in SEQ ID NO:135;
e. a CDR-L2 having the sequence set forth in SEQ ID NO:68; and f. a CDR-L1 having the sequence set forth in SEQ ID NO:67.

19. The ABP of claim 18, wherein the ABP comprises (i) a VH sequence of SEQ
ID
NO:126 and a VL sequence of SEQ ID NO:128; or (ii) a VH sequence of SEQ ID
NO:127 and a VL sequence of SEQ ID NO:128.

20. The ABP of claim 18 or claim 19, wherein the ABP comprises (i) a heavy chain of SEQ ID NO:124 and a light chain of SEQ ID NO:125; or (ii) a heavy chain of SEQ
ID
NO:136 and a light chain of SEQ ID NO:125.

21. An isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), comprising:
a. a CDR-H3 having at least about 80% identity to a CDR-H3 of a VH region selected from SEQ ID NOs: 9, 19, 26, 34, 44, 58, 62, 70, 71, 79, 87, 88, 89, 95, 97, 98, 99, 101, 104, 105, 126, and 127;
b. a CDR-H2 having at least about 80% identity to a CDR-H2 of a VH region selected from SEQ ID NOs: 9, 19, 26, 34, 44, 58, 62, 70, 71, 79, 87, 88, 89, 95, 97, 98, 99, 101, 104, 105, 126, and 127;
c. a CDR-H1 having at least about 80% identity to a CDR-H1 of a VH region selected from SEQ ID NOs: 9, 19, 26, 34, 44, 58, 62, 70, 71, 79, 87, 88, 89, 95, 97, 98, 99, 101, 104, 105, 126, and 127;

d. a CDR-L3 having at least about 80% identity to a CDR-L3 of a VL region selected from SEQ ID NOs: 10, 20, 27, 35, 40, 45, 53, 63, 72, 80, 90, and 128;
e. a CDR-L2 having at least about 80% identity to a CDR-L2 of a VL region selected from SEQ ID NOs: 10, 20, 27, 35, 40, 45, 53, 63, 72, 80, 90, and 128;
and f. a CDR-L1 having at least about 80% identity to a CDR-L1 of a VL region selected from SEQ ID NOs: 10, 20, 27, 35, 40, 45, 53, 63, 72, 80, 90, and 128.

22. The ABP of claim 21, wherein the CDR-H3, CDR-H2, CDR-H1, CDR-L3, CDR-L2, and CDR-L1 are each identified according to a numbering scheme selected from the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT numbering scheme.

23. The ABP of any one of claims 21 or 22, wherein the CDR-H1 is identified as defined by both the Chothia and Kabat numbering schemes, inclusive of the boundaries of both numbering schemes.

24. The ABP of any one of claims 21-23, wherein:
a. the CDR-H3 comprises a CDR-H3 selected from SEQ ID NOs: 13, 23, 30, 48, 61, 66, 75, 83, 93, 103, 131, or a variant thereof having 1, 2, or 3 amino acid substitutions;
b. the CDR-H2 comprises a CDR-H3 selected from SEQ ID NOs: 12, 22, 29, 47, 60, 65, 74, 82, 92, 96, 100, 102, 130, and 133, or a variant thereof having 1, 2, or 3 amino acid substitutions;
c. the CDR-H1 comprises a CDR-H1 selected from SEQ ID NOs: 11, 21, 28, 46, 59, 64, 73, 81, 91, 129, 132, or a variant thereof having 1 or 2 amino acid substitutions;
d. the CDR-L3 comprises a CDR-L3 selected from SEQ ID NOs: 16, 17, 56, 69, 78, 86, 94, 135, or a variant thereof having 1 or 2 amino acid substitutions;
e. the CDR-L2 comprises a CDR-L2 selected from SEQ ID NOs: 15, 31, 41, 50, 55, 68, 77, and 85, or a variant thereof having 1 amino acid substitution; and f. the CDR-L1 comprises a CDR-L1 selected from SEQ ID NOs: 14, 36, 49, 54, 67, 76, and 84, or a variant thereof having 1 or 2 amino acid substitutions.

25. The ABP of any one of claims 1-24, wherein the amino acid substitutions are conservative amino acid substitutions.

26. The ABP of any one of claims 1-25, wherein the ABP:

a. competes for binding to GITR with an antibody selected from ABP1, ABP2, ABP3, ABP4, ABP5, ABP6, ABP7, ABP8, ABP9, ABP10, ABP11, ABP12, ABP13, ABP14, ABP15, ABP16, ABP17, ABP18, ABP19, ABP20, ABP21, ABP22, ABP23, ABP24, ABP25, ABP26, ABP27, ABP28, ABP29, ABP30, ABP31, ABP32, ABP33, and ABP34, each as provided in Appendix A of this disclosure;
b. has at least three antigen-binding domains that specifically bind an epitope on GITR;
c. has at least three antigen-binding domains that specifically bind a single epitope on GITR;
d. has at least four antigen-binding domains that specifically bind an epitope on GITR;
e. at least four antigen-binding domains that specifically bind a single epitope on GITR;
f. agonizes GITR expressed on the surface of a target cell;
g. blocks the binding of GITRL to GITR;
h. co-stimulates an effector T cell in combination with antigen presentation from an antigen-presenting cell;
i. inhibits the suppression of an effector T cell by a regulatory T cell;
j. reduces the number of regulatory T cells in a tissue or in systemic circulation;
k. is capable of binding to one or more of GITR (SEQ ID NO:1) residues from the group consisting of R56, C58, R59, D60, Y61, P62, E64, E65, C66, and C67;
or 1. is capable of any combination of (a) - (k).

27. The ABP of any one of claims 1-26, wherein the GITR is selected from hGITR (SEQ
ID NO: 1), hGITR-T43R (SEQ ID NO: 2), cGITR (SEQ ID NO: 3), mGITR (SEQ ID NO:
4), and combinations thereof.

28. The ABP of any one of claims 1-26, wherein the ABP (a) specifically binds cynomolgus monkey GITR (cGITR; SEQ ID NO: 3); (b) binds murine GITR (mGITR;
SEQ ID NO: 4) with an affinity lower (as indicated by higher KD) than the affinity of the ABP for hGITR, or does not bind mGITR; or (c) is capable of any combination of (a) - (b).

29. The ABP of any one of claims 1-26 wherein the ABP: (a) specifically binds cGITR
(SEQ ID NO: 3); (b) binds mGITR (SEQ ID NO: 4) with an affinity lower (as indicated by higher KD) than the affinity of the ABP for hGITR and cGITR; and (c) enhances binding of GITRL to GITR.

30. An ABP that competes for binding to GITR with an ABP of any one of claims 1-26, wherein the ABP: (a) specifically binds cGITR (SEQ ID NO: 3); (b) binds mGITR
(SEQ ID

NO: 4) with an affinity lower (as indicated by higher KD) than the affinity of the ABP for hGITR and cGITR; and (c) enhances binding of GITRL to GITR.

31. The ABP of any one of claims 1-30, wherein the ABP comprises an antibody.

32. The ABP of claim 31, wherein the antibody is a monoclonal antibody.

33. The ABP of claim 31 or claim 32, wherein the antibody is selected from a human antibody, a humanized antibody or a chimeric antibody.

34. The ABP of any one of claims 1-33, wherein the ABP is multivalent.

35. The ABP of any one of claims 1-30, wherein the ABP comprises an antibody fragment.

36. The ABP of any one of claims 1-30, wherein the ABP comprises an alternative scaffold.

37. The ABP of any one of claims 1-30, wherein the ABP comprises an immunoglobulin constant region.

38. The ABP claim 37, wherein the ABP comprises a heavy chain constant region of a class selected from IgA, IgD, IgE, IgG, or IgM.

39. The ABP of claim 38, wherein the ABP comprises a heavy chain constant region of the class IgG and a subclass selected from IgG4, IgG1, IgG2, or IgG3.

40. The ABP of any one of claims 1-39, wherein at least one Fab is fused to a C-terminus of an Fc domain of an IgG.

41. The ABP of any one of claims 1-39, further comprising at least one linker.

42. The ABP of claim 39, wherein the IgG is an IgG4.

43. The ABP of claim 39, wherein the IgG is an IgG1.

44. The ABP of any one of claims 1-43, wherein at least one Fab is fused to an N-terminus of an Fc domain of an IgG.

45. The ABP of claim 44, wherein the at least one Fab is at least two Fabs.

46. The ABP of claim 44, wherein the at least one Fab is at least three Fabs.

47. The ABP of claim 44, wherein the at least one Fab is at least four Fabs.

48. The ABP of any one of claims 45-47, wherein two Fabs are independently fused to an N-terminus of the IgG.

49. The ABP of any one of claims 45-47, wherein two Fabs are independently fused to a C-terminus of the IgG.

50. The ABP of claim 48, wherein a Fab is attached to each N-terminus of the IgG, a linker is attached to each said Fab, and a Fab is attached to each linker.

51. The ABP of claim 49, wherein a Fab is attached to each C-terminus of the IgG, a linker is attached to each said Fab, and a Fab is attached to each linker.

52. The ABP of claim 50 or claim 51, wherein each linker comprises SEQ ID
NO:5.

53. The ABP of claim 50 or claim 51, wherein each linker comprises SEQ ID
NO:6.

54. The ABP of any one of claims 1-53, wherein the ABP comprises a common light chain antibody, an antibody with a knobs-into-holes modification, an scFv attached to an IgG, a Fab attached to an IgG, a diabody, a tetravalent bispecific antibody, a DVD-Ig.TM., a DART.TM., a DuoBody®, a CovX-Body, an Fcab antibody, a TandAb®, a tandem Fab, a Zybody.TM., or combinations thereof.

55. The ABP of claim 34, wherein the ABP binds more than one GITR molecule.

56. The ABP of claim 26.f, wherein agonism of GITR by the ABP is independent of GITRL binding.

57. The ABP of claim 26.f, wherein the ABP enhances binding of GITRL to GITR by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%.

58. The ABP of claim 57, wherein the ABP enhances binding of GITRL to GITR
by at least about 50%.

59. The ABP of claim 26.f wherein the target cell is selected from an effector T cell, a regulatory T cell, a natural killer (NK) cell, a natural killer T (NKT) cell, a dendritic cell, and a B cell.

60. The ABP of claim 26.f, wherein the target cell is an effector T cell selected from a helper (CD4+) T cell, a cytotoxic (CD8+) T cell, and combinations thereof

61. The ABP of claim 26.f, wherein the target cell is a regulatory T cell selected from a CD4+CD25+Foxp3+ regulatory T cell, a CD8+CD25+ regulatory T cell, and combinations thereof

62. The ABP of claim 26.j, wherein the tissue is a tumor.

63. The ABP of any one of claims 1-62, wherein the KD of the first antigen-binding domain for hGITR (SEQ ID NO: 1) or hGITR-T43R (SEQ ID NO: 2) is less than about 20 nM.

64. The ABP of any one of claims 1-62, wherein the KD of the first antigen-binding domain for cGITR (SEQ ID NO: 3) is less than about 200 nM.

65. The ABP of any one of claims 1-62, wherein the KD of the second antigen-binding domain for hGITR (SEQ ID NO: 1) or hGITR-T43R (SEQ ID NO: 2) is less than about 100 nM.

66. The ABP of any one of claims 1-62, wherein the KD of the second antigen-binding domain for cGITR (SEQ ID NO: 3) is less than about 1 µM.

67. The ABP of any one of claims 1-66, wherein the ABP comprises an Fc domain with reduced effector function when compared to an IgG1 Fc domain.

68. The ABP of any one of claims 1-67, wherein the ABP comprises an aglycosylated Fc domain.

69. The ABP of any one of claims 1-67, wherein the ABP comprises an IgG1 Fc domain with an alanine at one or more of positions 234, 235, 265, and 297.

70. The ABP of any one of claims 1-69, wherein the GITR is expressed on the surface of a target cell.

71. The ABP of any one of claims 1-70, wherein the ABP multimerizes GITR
expressed on the surface of a target cell.

72. The ABP of claim 71, wherein the ABP multimerizes 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 GITR molecules.

73. The ABP of any one of claims 1-72, wherein the ABP comprises an immunoglobulin comprising at least two different heavy chain variable regions each paired with a common light chain variable region.

74. The ABP of claim 73, wherein the common light chain variable region forms a distinct antigen-binding domain with each of the two different heavy chain variable regions.

75. The ABP of claim 73 or claim 74, wherein the ABP comprises a first VH
variable domain having SEQ ID NO:189, a second VH variable domain having SEQ ID NO:215, and a common variable light chain having SEQ ID NO:190.

76. The ABP of claim 73 or claim 74, wherein the ABP comprises a first VH
variable domain having SEQ ID NO:199, a second VH variable domain having SEQ ID NO:216, and a common variable light chain having SEQ ID NO:200.

77. A kit comprising an ABP of any one of claims 1-76, and instructions for use of the ABP.

78. The kit of claim 77, wherein the ABP is lyophilized.

79. The kit of claim 78, further comprising a fluid for reconstitution of the lyophilized ABP.

80. The ABP of any one of claims 1-76, wherein the ABP comprises a polypeptide sequence having a pyroglutamate (pE) residue at its N-terminus.

81. The ABP of any one of claims 1-76, wherein the ABP comprises a VH
sequence in which an N-terminal Q is substituted with pE.

82. The ABP of any one of claims 1-76, wherein the ABP comprises a VL
sequence in which an N-terminal E is substituted with pE.

83. The ABP of any one of claims 1-76, wherein the ABP comprises a heavy chain sequence in which an N-terminal Q is substituted with pE.

84. The ABP of any one of claims 1-76, wherein the ABP comprises a light chain sequence in which an N-terminal E is substituted with pE.

85. The ABP of any one of claims 1-76, for use as a medicament.

86. The ABP of any one of claims 1-76, for use in the treatment of a cancer or viral infection.

87. The ABP of claim 85 for use in the treatment of a cancer, wherein the cancer is selected from a solid tumor and a hematological tumor.

88. An isolated polynucleotide encoding an ABP of any one of claims 1-76, a VH thereof, a VL thereof, a light chain thereof, a heavy chain thereof or an antigen-binding portion thereof.

89. A vector comprising the polynucleotide of claim 88.

90. A host cell comprising the polynucleotide of claim 88 or the vector of claim 89.

91. The host cell of claim 90, wherein the host cell is selected from a bacterial cell, a fungal cell, and a mammalian cell.

92. The host cell of claim 90, wherein the host cell is selected from an E.
coli cell, a Saccharomyces cerevisiae cell, and a CHO cell.

93. A cell-free expression reaction comprising the polynucleotide of claim 88 or vector of claim 89.

94. A method of producing an ABP of any one of claims 1-76, comprising expressing the ABP in the host cell of claim 90 and isolating the expressed ABP.

95. A pharmaceutical composition comprising an ABP of any one of claims 1-76 and a pharmaceutically acceptable excipient.

96. The pharmaceutical composition of claim 95, wherein the amount of the ABP in the pharmaceutical composition is sufficient to (a) reduce the suppression of effector T cells by regulatory T cells; (b) activate effector T cells; (c) reduce the number of regulatory T cells in a tissue or systemically; (d) induce or enhance proliferation of effector T
cells; (e) inhibit the rate of tumor growth; (f) induce tumor regression; or (g) combinations thereof, in a subject.

97. The pharmaceutical composition of claim 95 or claim 96 for use as a medicament.

98. The pharmaceutical composition of any one of claims 95-97 for use in the treatment of a cancer or a viral infection.

99. The pharmaceutical composition of claim 98 for use in the treatment of a cancer, wherein the cancer is selected from a solid tumor and a hematological tumor.

100. A pharmaceutical composition comprising the ABP of any one of claims 1-76 and a pharmaceutically acceptable excipient.

101. The pharmaceutical composition of claim 100, wherein the amount of the ABP in the pharmaceutical composition is sufficient to (a) reduce the suppression of effector T cells by regulatory T cells; (b) activate effector T cells; (c) reduce the number of regulatory T cells in a tissue or systemically; (d) induce or enhance proliferation of effector T
cells; (e) inhibit the rate of tumor growth; (f) induce tumor regression; or (g) combinations thereof, in a subject.

102. A method of treating or preventing a disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of an ABP of any one of claims 1-76, or a pharmaceutical composition of any one of claims 100 and 101.

103. A method of increasing activation of immune cells in a subject, comprising administering to the subject an effective amount of an ABP of any one of claims 1-76, or a pharmaceutical composition of any one of claims 100 and 101.

104. The method of claim 102 or 103, wherein the disease or condition is a cancer.

105. The method of any one of claims 102-103, wherein the method induces or enhances an immune response to a cancer-associated antigen.

106. The method of any one of claims 102-105, wherein the ABP is administered in an amount sufficient to (a) reduce the suppression of effector T cells by regulatory T cells; (b) activate effector T cells; (c) reduce the number of regulatory T cells in a tissue or systemically; (d) induce or enhance proliferation of effector T cells; (e) inhibit the rate of tumor growth; (f) induce tumor regression; or (g) combinations thereof.

107. The method of any one of claims 104-106, wherein the cancer is a solid cancer.

108. The method of any one of claims 104-106, wherein the cancer is a hematological cancer.

109. The method of any one of claims 102-108, further comprising administering one or more additional therapeutic agents.

110. The method of claim 109, wherein the additional therapeutic agent is selected from radiation, a cytotoxic agent, a chemotherapeutic agent, a cytostatic agent, an anti-hormonal agent, an EGFR inhibitor, an immunostimulatory agent, an anti-angiogenic agent, and combinations thereof.

111. The method of claim 109, wherein the additional therapeutic agent is an immunostimulatory agent.

112. The method of claim 111, wherein the immunostimulatory agent comprises an agent that blocks signaling of an inhibitory receptor expressed by an immune cell or a ligand thereof.

113. The method of claim 112, wherein the inhibitory receptor expressed by an immune cell or ligand thereof is selected from CTLA-4, PD-1, PD-L1, NRP-1, LAG-3, Tim3, TIGIT, neuritin, BTLA, KIR, and combinations thereof.

114. The method of claim 111, wherein the immunostimulatory agent comprises an agonist to a stimulatory receptor expressed by an immune cell.

115. The method of claim 113, wherein the stimulatory receptor expressed by an immune cell is selected from OX40, ICOS, CD27, CD28, 4-1BB, CD40, and combinations thereof.

116. The method of claim 111, wherein the immunostimulatory agent comprises a cytokine.

117. The method of claim 116, wherein the cytokine is selected from IL-2, IL-5, IL-7, IL-12, IL-15, IL-21, and combinations thereof.

118. The method of claim 115, wherein the immunostimulatory agent comprises an oncolytic virus.

119. The method of claim 118, wherein the oncolytic virus is selected from herpes simplex virus, vesicular stomatitis virus, adenovirus, Newcastle disease virus, vaccinia virus, a maraba virus, and combinations thereof.

120. The method of claim 111, wherein the immunostimulatory agent comprises a T cell expressing a chimeric antigen receptor.

121. The method of claim 111, wherein the immunostimulatory agent comprises a bi- or multi-specific T cell directed antibody.

122. The method of claim 111, wherein the immunostimulatory agent comprises an anti-TGF-.beta. antibody, a TGF-.beta. trap, or a combination thereof

123. The method of claim 111, wherein the immunostimulatory agent comprises a vaccine to a cancer-associated antigen.

124. A method of modulating an immune response in a subject in need thereof, comprising administering to the subject an effective amount of an ABP of any one of claims 1-76 or a pharmaceutical composition of any one of claims 99-105.

125. The method of any one of claims 106-128, further comprising administering one or more additional therapeutic agents to the subject.

126. The method of claim 129, wherein the additional therapeutic agent is an agonist to a stimulatory receptor of an immune cell, and the stimulatory receptor of an immune cell is selected from OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), 4-1BB (CD137), CD28, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, CD83 ligand, and combinations thereof.

127. The method of claim 129 wherein the additional therapeutic agent is a cytokine selected from IL-2, IL-5, IL-7, IL-12, IL-15, IL-21, and combinations thereof

128. The method of claim 129, wherein the additional therapeutic agent is an oncolytic virus selected from herpes simplex virus, vesicular stomatitis virus, adenovirus, Newcastle disease virus, vaccinia virus, a maraba virus, and combinations thereof

129. The method of any one of claims 125-128, wherein the additional therapeutic agent is formulated in the same pharmaceutical composition as the ABP.

130. The method of any one of claims 125-128, wherein the additional therapeutic agent is formulated in a different pharmaceutical composition from the ABP.

131. The method of any one of claims 125-128 or 130, wherein the additional therapeutic agent is administered prior to administering the ABP.

132. The method of any one of claims 125-128 or 130, wherein the additional therapeutic agent is administered after administering the ABP.

133. The method of any one of claims 125-132, wherein the additional therapeutic agent is administered contemporaneously with the ABP.

134. The ABP of any one of claims 1-76, wherein the ABP specifically binds an epitope of human GITR (hGITR; SEQ ID NO:1) and is capable of binding one or more residues from the group consisting of R56, C58, R59, D60, Y61, P62, E64, E65, C66, and C67.

135. An isolated multivalent antigen binding protein (ABP) that specifically binds human GITR (hGITR; SEQ ID NO: 1), wherein the ABP competes for binding with one or more of ABP1, ABP2, ABP3, ABP4, ABP5, ABP6, ABP7, ABP8, ABP9, ABP10, ABP11, ABP12, ABP13, ABP14, ABP15, ABP16, ABP17, ABP18, ABP19, ABP20, ABP21, ABP22, ABP23, ABP24, ABP25, ABP26, ABP27, ABP28, ABP29, ABP30, ABP31, ABP32, ABP33, and ABP34, ABP50, ABP51, ABP52, ABP53, ABP54, ABP55, ABP56, ABP57, ABP62, ABP63, ABP64, ABP65, ABP66, ABP67, ABP68, ABP67, ABP68, ABP69, ABP70, ABP71, ABP72, ABP73, ABP74, ABP75, ABP76, ABP77, ABP78, ABP79, ABP80, ABP812, ABP82, ABP83, ABP84, ABP85, ABP86, ABP87, ABP88, ABP89, ABP90, ABP91, ABP92, ABP93, ABP94, ABP95, ABP96, ABP97, ABP98, ABP99, ABP100, ABP102, ABP103, ABP104, ABP105, ABP106, ABP107, ABP108, and ABP109, each as provided in Appendix A of this disclosure.

136. An anti-human GITR antibody or an antigen-binding fragment thereof comprising four heavy chain variable regions and four light chain variable regions, wherein the heavy chain variable regions comprise a CDR-H3 consisting of SEQ
ID NO:13, a CDR-H2 consisting of SEQ ID NO:12 and a CDR-H1 consisting of SEQ ID NO:11;
and the light chain variable regions comprise a CDR-L3 consisting of SEQ ID
NO:16, a CDR-L2 consisting of SEQ ID NO:15, and a CDR-L1 consisting of SEQ ID NO:14;
and wherein one heavy chain variable region and one light chain variable region constitute one antigen-binding site, and wherein the anti-human GITR antibody or the antigen-binding fragment comprises a total of four antigen-binding sites.

137. The anti-human GITR antibody or the antigen-binding fragment thereof according to claim 136, selected from (1) or (2):
(1) an anti-human GITR antibody or an antigen-binding fragment thereof, comprising four heavy chain variable regions and four light chain variable regions, in which the heavy chain variable region consists of SEQ ID NO: 9, the light chain variable region consists of SEQ ID NO: 10, and the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody or the antigen-binding fragment comprises four antigen-binding sites; and (2) an anti-human GITR antibody or an antigen-binding fragment thereof comprising four heavy chain variable regions and four light chain variable regions, in which each heavy chain variable region consists of SEQ ID NO: 9, wherein Q at position 1 of the sequence is modified to pyroglutamate, the light chain variable region consists of SEQ ID NO: 10, and the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody or the antigen-binding fragment comprises four antigen-binding sites.

138. The anti-human GITR antibody of claim 136, wherein the antibody comprises two heavy chains and four light chains; each heavy chain comprising a first heavy chain variable region and a second heavy chain variable region, each comprising a CDR-H3 consisting of SEQ ID NO:13, a CDR-H2 consisting of SEQ ID NO:12 and a CDR-H1 consisting of SEQ
ID NO:11; a first CH1 region, a linker, a second CH1 region, a CH2 region, and a CH3 region; and each light chain comprises a light chain variable region comprising a CDR-L3 consisting of SEQ ID NO:16, a CDR-L2 consisting of SEQ ID NO:15, and a CDR-L1 consisting of SEQ ID NO:14.

139. The anti-human GITR antibody of claim 136, selected from (1) or (2) (1) an anti-human GITR antibody comprising two heavy chains and four light chains, in which each heavy chain comprises two structures consisting of a heavy chain variable region of SEQ ID NO: 9 and a CH1 region, a CH2 region, and a CH3 region, and the C
terminus of one of the structures is linked to the N terminus of the other structure through a linker; and each light chain comprises a light chain variable region of SEQ ID NO: 10, and a light chain constant region; and (2) an anti-human GITR antibody comprising two heavy chains and four light chains, in which each heavy chain comprises two structures consisting of a heavy chain variable region of SEQ ID NO: 9 and a CH1 region, a CH2 region, and a CH3 region, and the C
terminus of one of the structures is linked to the N terminus of the other structure through a linker, wherein Q at position 1 of the sequence is modified to pyroglutamate; and each light chain comprises a light chain variable region of SEQ ID NO: 10, and a light chain constant region.

140. The anti-human GITR antibody of claim 136, selected from (1) to (4):
(1) An anti-human GITR antibody comprises two heavy chains consisting of SEQ
ID NO: 7 and four light chains consisting of SEQ ID NO: 8.
(2) An anti-human GITR antibody comprises two heavy chains consisting of SEQ
ID NO:
7, wherein Q at position 1 is modified to pyroglutamate and four light chains consisting of SEQ ID NO: 8.

(3) An anti-human GITR antibody comprises two heavy chains consisting of the amino acid sequence ranging from Q at position 1 to G at position 686 of SEQ ID NO: 7 and four light chains consisting of SEQ ID NO: 8.
(4) An anti-human GITR antibody comprises two heavy chains consisting of the amino acid sequence ranging from Q at position 1 to G at position 686 of SEQ ID NO: 7, wherein the Q at position 1 is modified to pyroglutamate and four light chains consisting of SEQ
ID NO: 8.

141. A polynucleotide selected from the group consisting of (a) and (b):
(a) a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof of claim 137(1);
and (b) a polynucleotide comprising a base sequence encoding the light chain variable region of the anti-human GTIR antibody or the antigen-binding fragment thereof of claim 137(1).

142. A polynucleotide selected from the group consisting of (a) and (b):
(a) a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR antibody of claim 140(1); and (b) a polynucleotide comprising a base sequence encoding the light chain of the anti-human GTIR antibody of claim 140(1).

143. An expression vector comprising:
(a) a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof of claim 137(1), and/or (b) a polynucleotide comprising a base sequence encoding the light chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof of claim 137(1).

144. An expression vector comprising:
(a) a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR antibody of claim 140(1), and/or (b) a polynucleotide comprising a base sequence encoding the light chain of the anti-human GITR antibody of claim 140(1).

145. A host cell transformed with an expression vector selected from the group consisting of (a) to (d):

(a) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof of claim 137(1), and a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody or the antigen-binding fragment thereof;
(b) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR antibody or the antigen-biding fragment thereof according to claim 137(1) and an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody or the antigen-binding fragment thereof;
(c) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof according to claim 137(1); and (d) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof according to claim 137(1).

146. A host cell transformed with an expression vector selected from the group consisting of (a) to (d):
(a) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR
antibody of claim 140(1) and a polynucleotide comprising a base sequence encoding the light chain of the antibody;
(b) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR
antibody of claim 140(1) and an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain of the antibody;
(c) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR
antibody of claim 140(1); and (d) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain of the anti-human GITR
antibody of claim 140(1).

147. A method for producing an anti-human GITR antibody or an antigen-binding fragment thereof, comprising culturing host cell(s) selected from the group consisting of (a) to (c) below to express a tetravalent anti-human GITR antibody or an antigen-binding fragment thereof:
(a) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof of 137(1) and a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody or the antigen-binding fragment thereof;
(b) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof of claim 137(1) and an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody or the antigen-binding fragment thereof, and (c) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human GITR antibody or the antigen-binding fragment thereof of claim 137(1) and a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody or the antigen-binding fragment thereof

148. A method for producing an anti-human GITR antibody, comprising culturing host cell(s) selected from the group consisting of (a) to (c) below to express an anti-human GITR
antibody:
(a) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR
antibody of 140(1) and a polynucleotide comprising a base sequence encoding the light chain of the antibody;
(b) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR
antibody of claim 140(1) and an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain of the antibody; and (c) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain of the anti-human GITR
antibody of claim 140(1) and a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain of the antibody.

149. A pharmaceutical composition comprising the anti-human GITR antibody of claim 140 and a pharmaceutically acceptable excipient.

150. A pharmaceutical composition comprising the anti-human GITR antibody of claim 140(1) and the anti-human GITR antibody of claim 140(4) and a pharmaceutically acceptable excipient.

151. The pharmaceutical composition of any one of claims 149 and 150, which is a pharmaceutical composition for preventing or treating cancer.

152. The pharmaceutical composition of any one of claims 149 and 150, wherein the composition is administered in combination with radiation, a cytotoxic agent, a chemotherapeutic agent, a cytostatic agent, an anti-hormonal agent, an EGFR
inhibitor, an immunostimulatory agent, an anti-angiogenic agent, and combinations thereof

153. The anti-human GITR antibody of claim 140, for preventing or treating cancer.

154. Use of the anti-human GITR antibody of claim 140 for manufacture of a pharmaceutical composition for preventing or treating cancer.

155. A method for preventing or treating cancer, comprising administering a therapeutically effective amount of the anti-human GITR antibody of claim 140.

156. The method of claim 155, further comprising administering one or more additional therapeutic agents.

157. The method of claim 156, wherein the additional therapeutic agent is selected from the group consisting of radiation, a cytotoxic agent, a chemotherapeutic agent, a cytostatic agent, an anti-hormonal agent, an EGFR inhibitor, an immunostimulatory agent, an anti-angiogenic agent, and combinations thereof